,AID,AID Version,AID Revision,Panel Member ID,SID,CID,Bioactivity Outcome,Target GI,Target GeneID,Activity Value [uM],Activity Name,Assay Name,Bioassay Type,PubMed ID,RNAi
0,410,1,5,,11114094,30323,Active,73915100.0,1544.0,,,p450-cyp1a2,Confirmatory,,
1,411,2,1,,11114094,30323,Inactive,160794.0,,,Potency,qHTS Assay for Inhibitors of Firefly Luciferase,Confirmatory,,
2,445,3,1,,11114094,30323,Inconclusive,10092619.0,4792.0,,,IkB Signaling,Confirmatory,,
3,447,1,1,,11114094,30323,Inconclusive,,,,,O-Glc NAc Transferase (sOGT),Confirmatory,,
4,448,1,2,,11114094,30323,Inactive,4325211.0,,,,Schistosoma Mansoni Peroxiredoxins (Prx2),Confirmatory,,
5,450,1,2,,11114094,30323,Inactive,66528677.0,2908.0,,,GR-GFP Redistribution,Confirmatory,,
6,451,1,2,,11114094,30323,Inactive,66528677.0,2908.0,,,GR-EFC Redistribution,Confirmatory,,
7,526,1,1,,11114094,30323,Inactive,,,,,Ubiquitin-GFP Assay,Confirmatory,,
8,530,1,1,,11114094,30323,Inconclusive,2499604.0,26414.0,,,JNK3 AlphaScreen Assay,Confirmatory,,
9,584,1,3,,11114094,30323,Inactive,119389684.0,,,,Promiscuous and Specific Inhibitors of AmpC Beta-Lactamase (assay with detergent),Confirmatory,,
10,585,1,4,,11114094,30323,Inactive,119389684.0,,,,Promiscuous and Specific Inhibitors of AmpC Beta-Lactamase (assay without detergent),Confirmatory,,
11,595,1,3,,11114094,30323,Inconclusive,,,,,qHTS Assay for Disrupters of an Hsp90 Co-Chaperone Interaction,Confirmatory,,
12,596,1,2,,11114094,30323,Active,92096784.0,4137.0,,,qHTS Assay for Tau Filament Binding,Confirmatory,,
13,597,1,3,,11114094,30323,Inactive,,,,,qHTS Assay for Epigenetic Modulators,Confirmatory,,
14,603,1,2,,11114094,30323,Active,,,,,qHTS Assay for Inhibitors of DNA Polymerase III Holoenzyme System,Confirmatory,,
15,605,1,2,,11114094,30323,Inactive,84028058.0,,,,qHTS Assay for Inhibitors of YjeE,Confirmatory,,
16,607,1,3,,11114094,30323,Inactive,82799486.0,5142.0,,,qHTS Assay for Inhibitors of PDE-IV,Confirmatory,,
17,662,1,1,,11114094,30323,Inconclusive,,,,,Cell signaling CRE-BLA (Fsk stim),Confirmatory,,
18,875,1,2,,11114094,30323,Inactive,159162802.0,,,Potency,qHTS Assay for Inhibitors of BRCT-Phosphoprotein Interaction (Green Fluorophore),Confirmatory,,
19,880,2,1,,11114094,30323,Active,3290016.0,6002.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
20,880,2,1,,11114094,30323,Active,33946324.0,2770.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
21,880,2,1,,29215022,30323,Active,3290016.0,6002.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
22,880,2,1,,29215022,30323,Active,33946324.0,2770.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
23,881,2,2,,11114094,30323,Inactive,317373425.0,247.0,12.5893,Potency,qHTS Assay for Inhibitors of 15-hLO-2 (15-human lipoxygenase 2),Confirmatory,,
24,881,2,2,,29215022,30323,Inactive,317373425.0,247.0,17.7828,Potency,qHTS Assay for Inhibitors of 15-hLO-2 (15-human lipoxygenase 2),Confirmatory,,
25,883,1,3,,11114094,30323,Inactive,13699818.0,1559.0,,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 2C9,Confirmatory,,
26,884,1,2,,11114094,30323,Inconclusive,13435386.0,1576.0,31.6228,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 3A4,Confirmatory,,
27,885,1,2,,11114094,30323,Inactive,13435386.0,1576.0,31.6228,Potency,qHTS Assay for Activators of Cytochrome P450 3A4,Confirmatory,,
28,886,1,2,,11114094,30323,Inactive,122921310.0,,,Potency,"qHTS Assay for Inhibitors of HADH2 (Hydroxyacyl-Coenzyme A Dehydrogenase, Type II)",Confirmatory,,
29,886,1,2,,11114094,30323,Inactive,122921311.0,,,Potency,"qHTS Assay for Inhibitors of HADH2 (Hydroxyacyl-Coenzyme A Dehydrogenase, Type II)",Confirmatory,,
30,887,1,2,,11114094,30323,Inactive,1832253.0,246.0,,Potency,qHTS Assay for Inhibitors of 15-hLO (15-human lipoxygenase),Confirmatory,,
31,889,1,3,,11114094,30323,Inactive,1730092.0,840.0,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-7,Confirmatory,,
32,891,1,2,,11114094,30323,Inactive,40805836.0,1565.0,,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 2D6,Confirmatory,,
33,892,1,2,,11114094,30323,Inconclusive,159162802.0,,12.5893,Potency,qHTS Assay for Inhibitors of BRCT-Phosphoprotein Interaction (Red Fluorophore),Confirmatory,,
34,893,1,2,,11114094,30323,Inconclusive,122921310.0,,31.6228,Potency,"qHTS Assay for Inhibitors of HSD17B4, hydroxysteroid (17-beta) dehydrogenase 4",Confirmatory,,
35,893,1,2,,11114094,30323,Inconclusive,122921311.0,,31.6228,Potency,"qHTS Assay for Inhibitors of HSD17B4, hydroxysteroid (17-beta) dehydrogenase 4",Confirmatory,,
36,894,2,1,,11114094,30323,Inactive,31542939.0,3248.0,,Potency,qHTS Assay for Inhibitors of HPGD (15-Hydroxyprostaglandin Dehydrogenase),Confirmatory,,
37,894,2,1,,29215022,30323,Inactive,31542939.0,3248.0,,Potency,qHTS Assay for Inhibitors of HPGD (15-Hydroxyprostaglandin Dehydrogenase),Confirmatory,,
38,899,1,2,,11114094,30323,Inactive,4503219.0,1557.0,,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 2C19,Confirmatory,,
39,900,1,3,,11114094,30323,Inactive,15431328.0,834.0,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-1,Confirmatory,,
40,901,1,2,,11114094,30323,Inactive,44888968.0,83523.0,,Potency,qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors,Confirmatory,,
41,902,1,2,,11114094,30323,Inconclusive,120407068.0,7157.0,31.6228,Potency,qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature,Confirmatory,,
42,912,1,2,,11114094,30323,Inconclusive,21392848.0,,31.6228,Potency,qHTS Assay for Anthrax Lethal Toxin Internalization,Confirmatory,,
43,923,1,2,,11114094,30323,Inactive,,,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-1: Spectroscopic Profiling in AFC Spectral Region,Confirmatory,,
44,924,1,2,,11114094,30323,Inconclusive,120407068.0,7157.0,15.8489,Potency,qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature,Confirmatory,,
45,926,1,2,,11114094,30323,Inactive,38016895.0,7253.0,,Potency,qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor,Confirmatory,,
46,938,1,2,,11114094,30323,Inactive,38016895.0,7253.0,,Potency,qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor: Activators of Intracellular cAMP Concentrations in Parental HEK 293,Confirmatory,,
47,995,1,2,,11114094,30323,Inconclusive,66932916.0,5594.0,31.6228,Potency,qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay,Confirmatory,,
48,1030,2,1,,11114094,30323,Inconclusive,30582681.0,216.0,39.8107,Potency,qHTS Assay for Inhibitors of Aldehyde Dehydrogenase 1 (ALDH1A1),Confirmatory,,
49,1030,2,1,,29215022,30323,Inactive,30582681.0,216.0,,Potency,qHTS Assay for Inhibitors of Aldehyde Dehydrogenase 1 (ALDH1A1),Confirmatory,,
50,1195,1,2,,48415843,30323,Active,,,,,DSSTox (FDAMDD) FDA Maximum (Recommended) Daily Dose Database,Other,,
51,1332,1,1,,49699346,30323,Active,,,,,High Throughput Screen to Identify Inhibitors of Mycobacterium tuberculosis H37Rv,Confirmatory,,
52,1379,1,2,,11114094,30323,Inactive,1669525.0,,,Potency,Counterscreen for Luciferase (Kinase-Glo TM) Inhibition,Confirmatory,,
53,1379,1,2,,29215022,30323,Inactive,1669525.0,,,Potency,Counterscreen for Luciferase (Kinase-Glo TM) Inhibition,Confirmatory,,
54,1452,1,1,,11114094,30323,Inactive,154426292.0,239.0,,Potency,qHTS Assay for Inhibitors of 12-hLO (12-human lipoxygenase),Confirmatory,,
55,1452,1,1,,29215022,30323,Inactive,154426292.0,239.0,,Potency,qHTS Assay for Inhibitors of 12-hLO (12-human lipoxygenase),Confirmatory,,
56,1454,1,1,,11114094,30323,Inactive,66932916.0,5594.0,,Potency,qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay; Stimulation with EGF,Confirmatory,,
57,1457,1,1,,11114094,30323,Inactive,44888968.0,83523.0,12.5893,Potency,qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors: Potentiation with Lithium,Confirmatory,,
58,1457,1,1,,29215022,30323,Inactive,44888968.0,83523.0,,Potency,qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors: Potentiation with Lithium,Confirmatory,,
59,1460,1,3,,11114094,30323,Active,92096784.0,4137.0,4.4668,Potency,"qHTS for Inhibitors of Tau Fibril Formation, Thioflavin T Binding",Confirmatory,,
60,1460,1,3,,29215022,30323,Active,92096784.0,4137.0,5.0119,Potency,"qHTS for Inhibitors of Tau Fibril Formation, Thioflavin T Binding",Confirmatory,,
61,1463,1,1,,11114094,30323,Inactive,,,,Potency,"Counterscreen qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization",Confirmatory,,
62,1463,1,1,,29215022,30323,Inactive,,,,Potency,"Counterscreen qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization",Confirmatory,,
63,1467,1,3,,11114094,30323,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors of Human alpha-Galactosidase at pH 4.5.,Confirmatory,,
64,1467,1,3,,29215022,30323,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors of Human alpha-Galactosidase at pH 4.5.,Confirmatory,,
65,1468,1,1,,11114094,30323,Active,92096784.0,4137.0,25.1189,Potency,"qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization",Confirmatory,,
66,1468,1,1,,29215022,30323,Active,92096784.0,4137.0,25.1189,Potency,"qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization",Confirmatory,,
67,1469,1,1,,11114094,30323,Active,189491771.0,7068.0,11.2202,Potency,qHTS for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
68,1469,1,1,,29215022,30323,Active,189491771.0,7068.0,22.3872,Potency,qHTS for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
69,1471,2,1,,11114094,30323,Inactive,90903231.0,3064.0,,,qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Cytoprotection (ATP),Confirmatory,,
70,1471,2,1,,29215022,30323,Inactive,90903231.0,3064.0,,,qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Cytoprotection (ATP),Confirmatory,,
71,1476,2,1,,11114094,30323,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (without detergent),Confirmatory,,
72,1476,2,1,,29215022,30323,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (without detergent),Confirmatory,,
73,1477,1,1,,11114094,30323,Inactive,,,,Potency,qHTS Assay for Compounds Blocking the Interaction Between CBF-beta and RUNX1 for the Treatment of Acute Myeloid Leukemia,Confirmatory,,
74,1477,1,1,,29215022,30323,Inconclusive,,,3.9811,Potency,qHTS Assay for Compounds Blocking the Interaction Between CBF-beta and RUNX1 for the Treatment of Acute Myeloid Leukemia,Confirmatory,,
75,1478,2,1,,11114094,30323,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (with detergent),Confirmatory,,
76,1478,2,1,,29215022,30323,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (with detergent),Confirmatory,,
77,1479,1,2,,11114094,30323,Active,189491771.0,7068.0,31.6228,Potency,Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
78,1479,1,2,,29215022,30323,Active,189491771.0,7068.0,44.6684,Potency,Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
79,1487,1,1,,29215022,30323,Inconclusive,27436948.0,4000.0,,Potency,qHTS Assay for Modulators of Lamin A Splicing,Confirmatory,,
80,1490,2,1,,11114094,30323,Inconclusive,10954339.0,,3.1623,Potency,qHTS Assay for Inhibitors of Bacillus subtilis Sfp phosphopantetheinyl transferase (PPTase),Confirmatory,,
81,1490,2,1,,29215022,30323,Inactive,10954339.0,,,Potency,qHTS Assay for Inhibitors of Bacillus subtilis Sfp phosphopantetheinyl transferase (PPTase),Confirmatory,,
82,1519,1,3,,11114094,30323,Inconclusive,,,,Potency,qHTS Assay for Lipid Storage Modulators,Confirmatory,,
83,1688,1,1,,29215022,30323,Active,90903231.0,3064.0,2.2387,Potency,qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Aggregate Formation (GFP),Confirmatory,,
84,1766,1,1,,11114094,30323,Inconclusive,18860839.0,4221.0,14.1254,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
85,1766,1,1,,11114094,30323,Inconclusive,56550039.0,4297.0,14.1254,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
86,1766,1,1,,29215022,30323,Inconclusive,18860839.0,4221.0,2.8184,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
87,1766,1,1,,29215022,30323,Inconclusive,56550039.0,4297.0,2.8184,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
88,1768,1,1,,11114094,30323,Inconclusive,18860839.0,4221.0,12.5893,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
89,1768,1,1,,11114094,30323,Inconclusive,56550039.0,4297.0,12.5893,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
90,1768,1,1,,29215022,30323,Inconclusive,18860839.0,4221.0,15.8489,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
91,1768,1,1,,29215022,30323,Inconclusive,56550039.0,4297.0,15.8489,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
92,1851,1,2,,11114094,30323,Unspecified,,,,,Cytochrome panel assay with activity outcomes,Other,,
93,1851,1,2,1.0,11114094,30323,Inactive,4503219.0,1557.0,,,Cytochrome panel assay with activity outcomes,Other,,
94,1851,1,2,2.0,11114094,30323,Inactive,68509921.0,1565.0,,,Cytochrome panel assay with activity outcomes,Other,,
95,1851,1,2,3.0,11114094,30323,Inconclusive,13435386.0,1576.0,,,Cytochrome panel assay with activity outcomes,Other,,
96,1851,1,2,4.0,11114094,30323,Inconclusive,73915100.0,1544.0,,,Cytochrome panel assay with activity outcomes,Other,,
97,1851,1,2,5.0,11114094,30323,Inactive,13699818.0,1559.0,,,Cytochrome panel assay with activity outcomes,Other,,
98,1865,1,1,,11114094,30323,Inactive,,,,Potency,Quantitative High-Throughput Screen for Regulators of Epigenetic Control,Confirmatory,,
99,1865,1,1,,29215022,30323,Inactive,,,,Potency,Quantitative High-Throughput Screen for Regulators of Epigenetic Control,Confirmatory,,
100,1948,1,1,,11114094,30323,Inactive,,,1.0,Potency,qHTS Assay for Compounds that Induce Erasure of Genomic Imprints,Confirmatory,,
101,1948,1,1,,29215022,30323,Inactive,,,0.3981,Potency,qHTS Assay for Compounds that Induce Erasure of Genomic Imprints,Confirmatory,,
102,2101,1,1,,11114094,30323,Inactive,496369.0,2629.0,,Potency,qHTS Assay for Inhibitors and Activators of N370S glucocerebrosidase as a Potential Chaperone Treatment of Gaucher Disease,Confirmatory,,
103,2101,1,1,,29215022,30323,Inactive,496369.0,2629.0,,Potency,qHTS Assay for Inhibitors and Activators of N370S glucocerebrosidase as a Potential Chaperone Treatment of Gaucher Disease,Confirmatory,,
104,2107,1,1,,11114094,30323,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Galactosidase From Spleen Homogenate,Confirmatory,,
105,2107,1,1,,29215022,30323,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Galactosidase From Spleen Homogenate,Confirmatory,,
106,2112,1,1,,11114094,30323,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase From Spleen Homogenate,Confirmatory,,
107,2112,1,1,,29215022,30323,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase From Spleen Homogenate,Confirmatory,,
108,2147,1,1,,11114094,30323,Active,221046486.0,,35.4813,Potency,qHTS Assay for Inhibitors of  Human Jumonji Domain Containing 2E (JMJD2E),Confirmatory,,
109,2240,1,1,,85788867,30323,Inactive,38156699.0,4286.0,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of MITF,Screening,,
110,2241,1,1,,85788867,30323,Active,167013344.0,,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of A1,Screening,,
111,2275,1,1,,85788867,30323,Active,,,,,Luminescence Cell-Based Primary HTS to Measure Viability of BJeLR cells,Screening,,
112,2313,1,1,,85788867,30323,Active,,,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of the Sonic Hedgehog Signaling Pathway,Screening,,
113,2314,1,2,,29215022,30323,Inactive,32400299.0,,,,Cycloheximide Counterscreen for Small Molecule Inhibitors of Shiga Toxin,Screening,,
114,2314,1,2,,29215022,30323,Inactive,32400300.0,,,,Cycloheximide Counterscreen for Small Molecule Inhibitors of Shiga Toxin,Screening,,
115,2315,1,2,,29215022,30323,Active,32400299.0,,,,A qHTS for Small Molecule Inhibitors of Shiga Toxin,Screening,,
116,2315,1,2,,29215022,30323,Active,32400300.0,,,,A qHTS for Small Molecule Inhibitors of Shiga Toxin,Screening,,
117,2322,1,1,,85788867,30323,Inactive,,,,,Luminescence Homogenous Primary HTS to Identify Inhibitors of STK33 Activity,Screening,,
118,2330,1,1,,85788867,30323,Active,12830367.0,65975.0,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of STK33,Screening,,
119,2451,1,2,,11114094,30323,Inconclusive,122920737.0,,22.3342,Potency,"qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia",Confirmatory,,
120,2451,1,2,,29215022,30323,Inconclusive,122920737.0,,14.0919,Potency,"qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia",Confirmatory,,
121,2472,1,2,,11114094,30323,Inactive,7669492.0,2597.0,,,"qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia: Coupling assay counterscreen",Screening,,
122,2472,1,2,,29215022,30323,Inactive,7669492.0,2597.0,,,"qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia: Coupling assay counterscreen",Screening,,
123,2517,2,1,,11114094,30323,Active,6980812.0,,14.1254,Potency,qHTS Assay for Inhibitors of the Human Apurinic/apyrimidinic Endonuclease 1 (APE1),Confirmatory,,
124,2517,2,1,,144204447,30323,Active,6980812.0,,14.1254,Potency,qHTS Assay for Inhibitors of the Human Apurinic/apyrimidinic Endonuclease 1 (APE1),Confirmatory,,
125,2528,1,2,,11114094,30323,Active,4557365.0,641.0,14.1254,Potency,qHTS Assay for Inhibitors of Bloom's syndrome helicase (BLM),Confirmatory,,
126,2528,1,2,,29215022,30323,Active,4557365.0,641.0,28.1838,Potency,qHTS Assay for Inhibitors of Bloom's syndrome helicase (BLM),Confirmatory,,
127,2546,1,1,,11114094,30323,Active,188536040.0,19885.0,0.0631,Potency,VP16 counterscreen qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
128,2546,1,1,,29215022,30323,Active,188536040.0,19885.0,6.3096,Potency,VP16 counterscreen qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
129,2549,1,1,,11114094,30323,Active,282403581.0,,31.6228,Potency,qHTS Assay for Inhibitors of RecQ-Like Dna Helicase 1 (RECQ1),Confirmatory,,
130,2549,1,1,,29215022,30323,Active,282403581.0,,28.1838,Potency,qHTS Assay for Inhibitors of RecQ-Like Dna Helicase 1 (RECQ1),Confirmatory,,
131,2551,1,1,,11114094,30323,Active,188536040.0,19885.0,7.9433,Potency,qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
132,2551,1,1,,29215022,30323,Active,188536040.0,19885.0,2.8184,Potency,qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
133,2564,1,1,,29215022,30323,Inactive,,,,Potency,Counterscreen for APE1 Inhibitors: Fluorescent Dye Displacement Assay,Confirmatory,,
134,2565,1,1,,29215022,30323,Inactive,405898.0,,,Potency,Counterscreen for APE1 Inhibitors: qHTS Assay for Inhibitors of Endonuclease IV,Confirmatory,,
135,2572,1,1,,29215022,30323,Active,6980812.0,,10.0,Potency,Confirmation qHTS Assay for Inhibitors of the Human Apurinic/apyrimidinic Endonuclease 1 (APE1),Confirmatory,,
136,2573,1,1,,29215022,30323,Active,6980812.0,,1.9953,Potency,qHTS FP-Based Assay for Inhibitors of the Human Apurinic/apyrimidinic Endonuclease 1 (APE1),Confirmatory,,
137,2585,1,1,,11114094,30323,Active,4557365.0,641.0,16.2313,Potency,qHTS Confirmation Assay for Inhibitors of Bloom's syndrome helicase (BLM),Confirmatory,,
138,2662,2,1,,29215022,30323,Inconclusive,56550039.0,4297.0,28.1838,Potency,qHTS Fluorescence Polarization Assay for Inhibitors of MLL CXXC domain - DNA interaction,Confirmatory,,
139,2708,1,1,,29215022,30323,Active,282403581.0,,,Potency,Confirmation qHTS Assay for Inhibitors of RecQ-Like Dna Helicase 1 (RECQ1),Confirmatory,,
140,2711,1,1,,29215022,30323,Active,,,0.631,Potency,Counterscreen for RECQ1 Inhibitors: ADP Fluorescence Polarization Displacement Assay,Confirmatory,,
141,2712,1,1,,29215022,30323,Active,,,0.631,Potency,Counterscreen for BLMA Inhibitors: ADP Fluorescence Polarization Displacement Assay,Confirmatory,,
142,8261,4,1,,103477782,30323,Unspecified,,,,,Cytotoxicity against A 498 tumor cell line,Other,10602713.0,
143,19006,4,3,,103477782,30323,Unspecified,,,,,Calculated membrane partition coefficient (Kmemb),Other,15027870.0,
144,21036,3,3,,103477782,30323,Unspecified,,,,,Tested for the partition coefficient between water and n-octanol.,Other,2296017.0,
145,21848,3,4,,103477782,30323,Unspecified,,,,,Compound was evaluated for the change in Tm of isolated helical DNA in solution.,Other,3761325.0,
146,23271,4,4,,103477782,30323,Unspecified,,,,,Partition coefficient (logD7.4),Other,2362268.0,
147,23436,3,5,,103477782,30323,Unspecified,,,,,Partition coefficient in octanol-phosphate buffer at pH 7.4,Other,3761325.0,
148,23702,3,3,,103477782,30323,Unspecified,,,,,Partition coefficient (logP),Other,6699880.0,
149,26756,3,4,,103477782,30323,Unspecified,,,,,DNA binding dissociation constant as KD,Other,6708048.0,
150,31432,5,1,,103477782,30323,Unspecified,,,,,Cytotoxic activity against D100 daunorubicin (100 nM) resistant AML-2 cell line was determined,Other,14643344.0,
151,31433,5,1,,103477782,30323,Unspecified,,,,,Cytotoxic activity against DX-100: doxorubicin (100 ng/mL) resistant AML-2 cell line was determined,Other,14643344.0,
152,31434,5,1,,103477782,30323,Unspecified,,,,,Cytotoxic activity against wild type AML-2 leukemia cell line was determined,Other,14643344.0,
153,39111,4,5,,103477782,30323,Active,,,0.0092,IC50,In vitro antiproliferative activity against B16 cell lines,Confirmatory,,
154,39867,6,2,,103477782,30323,Active,,,0.16,EC50,Cytotoxicity that caused a 50% reduction in absorbance at 490 nm in B16 mouse melanoma cells using MTS assay.,Confirmatory,11020285.0,
155,40219,6,2,,103477782,30323,Unspecified,,,,,Compound was tested for antibacterial activity against Bacillus cereus WSU-60,Other,3018245.0,
156,40501,3,4,,103477782,30323,Active,,,,,Compound was tested for its lambda-phage induction activity against Bacillus subtilis in a disk plate assay at concentration of dose of 0.8 ug/mL; Active,Other,6779008.0,
157,40767,6,2,,103477782,30323,Unspecified,,,,,Compound was tested for antibacterial activity against Bacillus subtilis ATCC E6051,Other,3018245.0,
158,43843,8,1,,103477782,30323,Active,,,0.04,ID50,In vitro growth inhibitory activity against CCRF-CEM (human lymphoblastic leukemic) cells.,Confirmatory,6951049.0,
159,44040,8,1,,103477782,30323,Active,,,0.04,ID50,Inhibitory activity against CCRF-CEM(human leukemic lymphoblastic) cells in culture.,Confirmatory,7057426.0,
160,44202,3,4,,103477782,30323,Unspecified,,,,,Effect on cross resistance of CCRF-CEM cells resistant to vincristine.,Other,2362268.0,
161,45400,3,4,,103477782,30323,Unspecified,,,,,Effect on cross resistance of CHO cells resistant to colchicine (CHRC5),Other,2362268.0,
162,46154,3,4,,103477782,30323,Unspecified,,,,,Thermal denaturation temperature (Tm) of isolated calf thymus helical DNA was measured,Other,7086816.0,
163,50756,4,1,,103477782,30323,Unspecified,,,,,Tested for the cytotoxicity(1 hour incubation) against human colon tumor cell lines colon 4).,Other,2296017.0,
164,50757,4,1,,103477782,30323,Unspecified,,,,,Tested for the cytotoxicity (continuous incubation) against human colon tumor cell lines (colon 4)determined by clonogenic assay.,Other,2296017.0,
165,51924,3,3,,103477782,30323,Unspecified,,,,,Effect on cross resistance of chinese hamster cells resistant to Actinomycin D.,Other,2362268.0,
166,52346,9,2,,103477782,30323,Active,,,1.9,IC50,Inhibitory concentration against Clostridium histolyticum Collagenase,Confirmatory,1322986.0,
167,54144,6,2,,103477782,30323,Unspecified,,,,,Compound was tested for antibacterial activity against Corynebacterium diphtheria WSU,Other,3018245.0,
168,54463,3,3,,103477782,30323,Active,,,,,Tested for the binding affinity for DNA by intercalation between adjacent base pairs of the helix.,Other,2296017.0,
169,55168,4,1,,103477782,30323,Unspecified,,,,,Tested for binding affinity per DNA base pair in rat,Other,3018245.0,
170,57470,4,6,,103477782,30323,Unspecified,,,,,Inhibitory activity against dihydrofolate reductase (DHFR) isolated from murine L5178Y tumor cells resistant and sensitive to methotrexate,Other,6699880.0,
171,63723,6,3,,103477782,30323,Active,,,2.0,IC50,The compound was evaluated for the growth inhibition of Dx5 cell lines using MTT assay.,Confirmatory,10698449.0,
172,63724,6,3,,103477782,30323,Active,,,0.013999999999999999,IC50,The compound was evaluated for the growth inhibition of Dx5 w/PSC cell lines using MTT assay.,Confirmatory,10698449.0,
173,68285,4,1,,103477782,30323,Unspecified,,,,,Cytotoxicity against EVSA-T tumor cell line,Other,10602713.0,
174,70886,3,4,,103477782,30323,Unspecified,,,,,Compound is evaluated for lambda-phage induction activity in Escherichia coli (dose at 0.8 ug/mL),Other,6779008.0,
175,70887,3,4,,103477782,30323,Unspecified,,,,,Compound is evaluated for lambda-phage induction activity in Escherichia coli (dose at 1.6 ug/mL),Other,6779008.0,
176,70890,3,4,,103477782,30323,Unspecified,,,,,Compound is evaluated for lambda-phage induction activity in Escherichia coli (dose at 3.1 ug/mL),Other,6779008.0,
177,70893,3,4,,103477782,30323,Unspecified,,,,,Compound is evaluated for lambda-phage induction activity in Escherichia coli (dose at 6.2 ug/mL); Toxic to culture,Other,6779008.0,
178,73594,8,3,,103477782,30323,Inconclusive,,,,,In vitro antiproliferative activity against Fibroblasts; not determined,Other,,
179,80641,4,1,,103477782,30323,Unspecified,,,,,Cytotoxicity against M19 tumor cell line,Other,10602713.0,
180,82976,8,1,,103477782,30323,Active,,,0.04,AC50,In vitro concentration required to induce apoptosis in HL60 cells,Confirmatory,12877593.0,
181,82982,6,2,,103477782,30323,Active,,,0.005,IC50,In vitro inhibitory concentration against proliferation of HL60 cells,Confirmatory,12877593.0,
182,83137,8,1,,103477782,30323,Active,,,10.0,AC50,In vitro concentration required to induce apoptosis in HL60R cells,Confirmatory,12877593.0,
183,83140,6,2,,103477782,30323,Active,,,1.5,IC50,In vitro inhibitory concentration against proliferation of HL60R cells,Confirmatory,12877593.0,
184,83141,6,2,,103477782,30323,Active,,,0.04,IC50,In vitro inhibitory concentration against proliferation of HL60R cells along with 5 (uM) verapamil,Confirmatory,12877593.0,
185,83956,4,1,,103477782,30323,Unspecified,,,,,Tested for the cytotoxicity(1 hour incubation) against human colon tumor cell lines (HT 29).,Other,2296017.0,
186,83957,4,1,,103477782,30323,Unspecified,,,,,Tested for the cytotoxicity (continuous incubation) against human colon tumor cell lines (HT 29) determined by clonogenic assay.,Other,2296017.0,
187,84641,6,2,,103477782,30323,Active,,,0.057999999999999996,EC50,Cytotoxicity that caused a 50% reduction in absorbance at 490 nm in human prostate cancer HTB-81 cells using MTS assay.,Confirmatory,11020285.0,
188,93483,4,1,,103477782,30323,Unspecified,,,,,Cytotoxicity against IGROV tumor cell line,Other,10602713.0,
189,93860,6,3,,103477782,30323,Active,,,0.006999999999999999,IC50,In vitro cytotoxicity using human epidermoid carcinoma (KB-3-1) cells,Confirmatory,,
190,94005,6,2,,103477782,30323,Active,,,0.006999999999999999,IC50,In vitro cytotoxic activity was evaluated using the human epidermoid carcinoma cell line KB-3-1,Confirmatory,12443763.0,
191,94164,6,3,,103477782,30323,Active,,,2.07,IC50,In vitro cytotoxicity using human epidermoid carcinoma (KB-A1) cells,Confirmatory,,
192,94165,6,2,,103477782,30323,Active,,,2.07,IC50,In vitro cytotoxic activity was evaluated using the KB-3-1 resistant to adriamycin (ADR) subline KB-A1,Confirmatory,12443763.0,
193,94919,4,4,,103477782,30323,Unspecified,,,,,Antitumor activity against L-1210 leukemia cell line in BDF1 mice after injecting 0.5 mg/kg ip dose,Other,2391681.0,
194,96037,3,4,,103477782,30323,Unspecified,,,,,"Resistance factor (RF), ratio between the IC50 on the resistant cells and the IC50 on the corresponding sensitive cells of KB cell line",Other,12443763.0,
195,98029,8,1,,103477782,30323,Active,,,0.66,ED50,Compound was evaluated for the 50% inhibition of the incorporation of [3H]- thymidine in the DNA (inhibition of synthesis in leukemia L1210 cells),Confirmatory,3761325.0,
196,98030,8,1,,103477782,30323,Active,,,0.33,ED50,Compound was evaluated for the 50% inhibition of the incorporation of [3H]- thymidine in the RNA (inhibition of synthesis in leukemia L1210 cells),Confirmatory,3761325.0,
197,98033,8,1,,103477782,30323,Active,,,0.66,ED50,Concentration of drug necessary to reduce by 50% the incorporation of tritiated thymidine in the DNA of actively growing L1210 cells,Confirmatory,7086816.0,
198,98034,8,1,,103477782,30323,Active,,,0.33,ED50,Concentration of drug necessary to reduce by 50% the incorporation of tritiated uridine in the RNA of actively growing L1210 cells.,Confirmatory,7086816.0,
199,98376,6,3,,103477782,30323,Active,,,0.033,IC50,In vitro cytotoxicity using murine leukemia L1210 cells from american type culture collection.,Confirmatory,,
200,98730,6,2,,103477782,30323,Active,,,0.04,IC50,In vitro cytotoxic activity was evaluated using the murine leukemia L1210 cell line,Confirmatory,12443763.0,
201,98916,6,2,,103477782,30323,Active,,,0.03,IC50,Inhibitory activity was measured against murine L1210 leukemia cells.,Confirmatory,9733483.0,
202,99208,5,4,,103477782,30323,Active,,,,,"Tested for its inhibitory activity against xenograft (LXFL 529/11, lung, large cell) using a clonogenic assay",Other,,
203,100648,4,1,,103477782,30323,Unspecified,,,,,Compound was evaluated for cytotoxicity against L1210 murine leukemia cells,Other,,
204,101085,4,1,,103477782,30323,Unspecified,,,,,Tested for the cytotoxicity(1 hour incubation) against L1210 leukemia cells.,Other,2296017.0,
205,101086,4,1,,103477782,30323,Unspecified,,,,,Tested for the cytotoxicity (continuous incubation) against L1210 leukemia cells determined by clonogenic assay.,Other,2296017.0,
206,101545,4,1,,103477782,30323,Unspecified,,,,,Cytotoxicity against H 226 tumor cell line,Other,10602713.0,
207,101613,7,2,,103477782,30323,Active,,,0.06,IC50,compound was tested in vitro for inhibition activity against a sensitive human breast carcinoma line cells.,Confirmatory,9258351.0,
208,101742,4,1,,103477782,30323,Unspecified,,,,,Cytotoxicity against MCF-7 tumor cell line,Other,10602713.0,
209,103085,7,3,,103477782,30323,Active,,,2.0,IC50,Compound was tested for its toxicity against doxorubicin resistant human breast cancer cells (MCF-7/ADR).,Confirmatory,9548820.0,
210,103093,7,3,,103477782,30323,Active,,,2.0,IC50,compound was tested in vitro for inhibition activity against doxorubicin resistant counterpart of human breast carcinoma line cells.,Confirmatory,9258351.0,
211,103097,4,5,,103477782,30323,Active,,,0.061,IC50,In vitro antiproliferative activity against Lewis cell lines,Confirmatory,,
212,103904,4,5,,103477782,30323,Active,,,0.039,IC50,Evaluated in vitro for antiproliferative activity against MCF-7 cell lines model of hormone dependent breast cancer,Confirmatory,,
213,103913,7,2,,103477782,30323,Active,,,0.06,IC50,Compound was tested for its toxicity against human breast cancer cells(MCF-7),Confirmatory,9548820.0,
214,105072,4,4,,103477782,30323,Active,,,0.021,IC50,The compound was tested for extracellular cytotoxicity against MDA MB 361(mammary carcinoma cell line) in the presence of stCPG2 prodrug,Confirmatory,10395490.0,
215,105073,4,4,,103477782,30323,Active,,,0.017,IC50,The compound was tested for intracellular cytotoxicity against MDA MB 361(mammary carcinoma cell line) expressing LacZ (beta-galactosidase).,Confirmatory,10395490.0,
216,105075,4,4,,103477782,30323,Active,,,0.036000000000000004,IC50,The compound was tested for intracellular cytotoxicity against MDA MB 361(mammary carcinoma cell line) in the presence of CPG2 prodrug,Confirmatory,10395490.0,
217,106160,7,1,,103477782,30323,Active,,,,,Tested for its inhibitory activity against human melanoma cells (MEFX 989) using a clonogenic assay at 0.01-1.0 uM,Other,,
218,106319,3,5,,103477782,30323,Unspecified,,,,,"Resistance factor (RF), ratio between the IC50 on the resistant cells and the IC50 on the corresponding sensitive cells of MES cell line",Other,12443763.0,
219,106327,6,2,,103477782,30323,Active,,,0.07,IC50,In vitro cytotoxic activity was evaluated using the human uterine sarcoma cell line MES-SA,Confirmatory,12443763.0,
220,106329,6,2,,103477782,30323,Active,,,0.021,IC50,The compound was evaluated for the growth inhibition of MES-SA uterine tumor cell lines using MTT assay.,Confirmatory,10698449.0,
221,106337,6,2,,103477782,30323,Active,,,3.0,IC50,In vitro cytotoxic activity was evaluated using the MES-SA multidrug-resistant subline MES-SA/Dx5,Confirmatory,12443763.0,
222,110796,3,3,,103477782,30323,Unspecified,,,,,Number of mice(with Colon 38 tumors) cured after treatment of 3.9 mg/kg/day dose given as 3 times in a day for 4 days out of 5 mice,Other,12620081.0,
223,111953,3,3,,103477782,30323,Unspecified,,,,,"Chemotherapeutic activity was evaluated by measuring mean tumor diameter on day 12 at 10 mg/kg/day, sc",Other,7452666.0,
224,111954,3,3,,103477782,30323,Unspecified,,,,,"Chemotherapeutic activity was evaluated by measuring mean tumor diameter on day 12 at 11 mg/kg/day, sc",Other,7452666.0,
225,111955,3,3,,103477782,30323,Unspecified,,,,,"Chemotherapeutic activity was evaluated by measuring mean tumor diameter on day 12 at 12(mg/kg)/day, sc",Other,7452666.0,
226,111961,3,3,,103477782,30323,Unspecified,,,,,"Chemotherapeutic activity was evaluated by measuring mean tumor diameter on day 8 at 10 mg/kg/day, sc",Other,7452666.0,
227,111962,3,3,,103477782,30323,Unspecified,,,,,"Chemotherapeutic activity was evaluated by measuring mean tumor diameter on day 8 at 11 mg/kg/day, sc",Other,7452666.0,
228,111963,3,3,,103477782,30323,Unspecified,,,,,"Chemotherapeutic activity was evaluated by measuring mean tumor diameter on day 8 at 12(mg/kg)/day, sc",Other,7452666.0,
229,114263,6,1,,103477782,30323,Unspecified,,,,,In vivo antitumor activity against subcutaneous Colon 38 tumors in mice determined as delay in growth after 3.9 mg/kg/day dose given as 3 times in a day for 4 days,Other,12620081.0,
230,116133,3,4,,103477782,30323,Unspecified,,,,,In vivo growth inhibitory activity was measured against murine P388 leukemia cells as Percent increase in life span at the dose of 2.0 mg/kg/day,Other,7057426.0,
231,116178,3,4,,103477782,30323,Unspecified,,,,,"Chemotherapeutic activity was evaluated by measuring the percent increase in life span of female DBA2 mice intravenously inoculated with L1210 leukemia at 10 mg/kg/day, iv",Other,7452666.0,
232,116179,3,4,,103477782,30323,Unspecified,,,,,"Chemotherapeutic activity was evaluated by measuring the percent increase in life span of female DBA2 mice intravenously inoculated with L1210 leukemia at 11 mg/kg/day, iv",Other,7452666.0,
233,116180,3,4,,103477782,30323,Unspecified,,,,,"Chemotherapeutic activity was evaluated by measuring the percent increase in life span of female DBA2 mice intravenously inoculated with L1210 leukemia at 12(mg/kg)/day, iv",Other,7452666.0,
234,116310,3,4,,103477782,30323,Unspecified,,,,,"Chemotherapeutic activity was evaluated by measuring the percent increase in life span of female DBA2 mice subcutaneously inoculated with L1210 leukemia at 12(mg/kg)/day, sc",Other,7452666.0,
235,116311,3,4,,103477782,30323,Unspecified,,,,,"Percent increase in life span of female DBA2 mice subcutaneously inoculated with L1210 leukemia at 10 mg/kg/day, sc",Other,7452666.0,
236,116312,3,4,,103477782,30323,Unspecified,,,,,"Percent increase in life span of female DBA2 mice subcutaneously inoculated with L1210 leukemia at 11 mg/kg/day, sc",Other,7452666.0,
237,119828,4,4,,103477782,30323,Unspecified,,,,,Percentage rate of O2 consumption by liver microsomes and NADPH in the presence compared to the rate in presence of doxorubicin.,Other,7086816.0,
238,120391,2,4,,103477782,30323,Unspecified,,,,,"Percent median treated tumor size to that of control tumor size in NYH treatment model in mice (in vivo) after intraperitoneal administration of compound (0.5 mg/kg, number of tumors 8)",Other,,
239,121876,3,4,,103477782,30323,Unspecified,,,,,"Chemotherapeutic activity was evaluated by measuring number of survivors on day 30 / total number of mice at 10 mg/kg/day, iv; 0/18",Other,7452666.0,
240,121877,3,4,,103477782,30323,Unspecified,,,,,"Chemotherapeutic activity was evaluated by measuring number of survivors on day 30 / total number of mice at 10 mg/kg/day, sc; 0/58",Other,7452666.0,
241,121878,3,4,,103477782,30323,Unspecified,,,,,"Chemotherapeutic activity was evaluated by measuring number of survivors on day 30 / total number of mice at 11 mg/kg/day, iv; 0/37",Other,7452666.0,
242,121879,3,4,,103477782,30323,Unspecified,,,,,"Chemotherapeutic activity was evaluated by measuring number of survivors on day 30 / total number of mice at 11 mg/kg/day, sc; 3/37",Other,7452666.0,
243,121880,3,4,,103477782,30323,Unspecified,,,,,"Chemotherapeutic activity was evaluated by measuring number of survivors on day 30 / total number of mice at 12(mg/kg)/day, iv; 6/34",Other,7452666.0,
244,121881,3,4,,103477782,30323,Unspecified,,,,,"Chemotherapeutic activity was evaluated by measuring number of survivors on day 30 / total number of mice at 12(mg/kg)/day, sc; 3/36",Other,7452666.0,
245,124500,3,4,,103477782,30323,Unspecified,,,,,"Chemotherapeutic activity was evaluated by measuring percent change in weight on day 8 at 10 mg/kg/day, iv",Other,7452666.0,
246,124501,3,4,,103477782,30323,Unspecified,,,,,"Chemotherapeutic activity was evaluated by measuring percent change in weight on day 8 at 10 mg/kg/day, sc",Other,7452666.0,
247,124502,3,4,,103477782,30323,Unspecified,,,,,"Chemotherapeutic activity was evaluated by measuring percent change in weight on day 8 at 11 mg/kg/day, iv",Other,7452666.0,
248,124503,3,4,,103477782,30323,Unspecified,,,,,"Chemotherapeutic activity was evaluated by measuring percent change in weight on day 8 at 11 mg/kg/day, sc",Other,7452666.0,
249,124504,3,4,,103477782,30323,Unspecified,,,,,"Chemotherapeutic activity was evaluated by measuring percent change in weight on day 8 at 12(mg/kg)/day, iv",Other,7452666.0,
250,124505,3,4,,103477782,30323,Unspecified,,,,,"Chemotherapeutic activity was evaluated by measuring percent change in weight on day 8 at 12(mg/kg)/day, sc",Other,7452666.0,
251,134439,3,4,,103477782,30323,Unspecified,,,,,Effect of 3 mg/kg/dose of compound given iv q4d x 3 against sc human ovarian tumor (SK-OV3) in mice expressed as Mean tumor volume by day 30,Other,10479297.0,
252,136225,3,4,,103477782,30323,Unspecified,,,,,Effect of 3 mg/kg/dose of compound given iv q4d x 3 against sc human ovarian tumor (SK-OV3) in mice expressed as treated/ control ( 1000 mm**3) median tumor volume on day 30,Other,10479297.0,
253,136226,3,4,,103477782,30323,Unspecified,,,,,Effect of 3 mg/kg/dose of compound given iv q4d x 3 against sc human ovarian tumor (SK-OV3) in mice expressed as treated/ control mean tumor volume on day 30,Other,10479297.0,
254,138205,3,5,,103477782,30323,Unspecified,,,,,T/C of median tumor volumes when 3 mg/kg/dose of compound was given to BALB/c mice bearing sc M109 on days 1 and 4 (ip) after inoculation (control ~2000 mm**3),Other,10479297.0,
255,138206,3,5,,103477782,30323,Unspecified,,,,,T/C of median tumor volumes when 3 mg/kg/dose of compound was given to BALB/c mice bearing sc M109 on days 3 and 6 (iv) after inoculation (control ~2000 mm**3),Other,10479297.0,
256,138965,3,4,,103477782,30323,Unspecified,,,,,Effect of 3 mg/kg/dose of compound given iv q4d x 3 against sc human ovarian tumor (SK-OV3) in mice expressed as % tumor volume change from initial by day 30,Other,10479297.0,
257,143811,6,2,,103477782,30323,Active,,,0.22,EC50,Cytotoxicity that caused a 50% reduction in absorbance at 490 nm in normal human fibroblast (NHF) cells using MTS assay.,Confirmatory,11020285.0,
258,143816,4,5,,103477782,30323,Active,,,0.0035,IC50,Evaluated in vitro for antiproliferative activity against NIC-H460 cell lines derived from large cell carcinoma of the lung,Confirmatory,,
259,144381,7,1,,103477782,30323,Active,,,,,Concentration of substrate at which the amount of total cytochrome c reduction is decreased by 10%,Other,8421288.0,
260,144491,3,7,,103477782,30323,Unspecified,,,,,Activity of NADH dehydrogenase was determined,Other,8421288.0,
261,146724,4,5,,103477782,30323,Active,,,0.0039,IC50,Evaluated in vitro for antiproliferative activity against NYH cell lines derived from small cell lung cancer,Confirmatory,,
262,150380,4,5,,103477782,30323,Active,,,0.003,IC50,Compound was evaluated for cytotoxicity against P388 leukemia cell line.,Confirmatory,10479297.0,
263,153073,3,5,,103477782,30323,Unspecified,,,,,Compound was evaluated in vivo for antitumor activity after intraperitoneal administration against P388 (1303) for change in body weight at an optimal dose of 1 mg/kg/injection,Other,1992140.0,
264,153077,3,4,,103477782,30323,Unspecified,,,,,Compound was evaluated in vivo for antitumor activity after intraperitoneal administration against P388 (1303) for % increase in life span at an optimal dose of 1 mg/kg/injection,Other,1992140.0,
265,153081,3,4,,103477782,30323,Unspecified,,,,,Compound was evaluated in vivo for antitumor activity after intraperitoneal administration against P388 (1303) for median day of death at an optimal dose of 1 mg/kg/injection,Other,1992140.0,
266,153085,6,1,,103477782,30323,Unspecified,,,,,Compound was evaluated in vivo for antitumor activity after intraperitoneal administration against P388 (1303) for mortality range at an optimal dose of 1 mg/kg/injection,Other,1992140.0,
267,153090,3,5,,103477782,30323,Unspecified,,,,,Compound was evaluated in vivo for antitumor activity after intraperitoneal administration against P388 (1303) for tumor free survivors at an optimal dose of 1 mg/kg/injection,Other,1992140.0,
268,153093,3,4,,103477782,30323,Unspecified,,,,,Compound was evaluated in vivo for antitumor activity after intraperitoneal administration against P388 (1303) for total dose at an optimal dose of 1 mg/kg/injection,Other,1992140.0,
269,153183,3,5,,103477782,30323,Unspecified,,,,,Antitumor activity in mice against leukemia P388 cells at 1.4 uM/kg was expressed as ratio of average survival time,Other,7310810.0,
270,153319,3,5,,103477782,30323,Unspecified,,,,,Antitumor efficacy at optimal dose of compound was measured against P388 leukemia in mice,Other,7086816.0,
271,153465,3,4,,103477782,30323,Unspecified,,,,,"Compound was evaluated for the antitumor efficacy at optimal dose 8 mg/kg against leukemia P388 in mice on day q4d 5, 9, 13.,",Other,3761325.0,
272,153554,3,5,,103477782,30323,Unspecified,,,,,Compound was evaluated in vivo for antitumor activity after intraperitoneal administration against P388 (1303) for change in body weight at an optimal dose of 1 mg/kg/injection,Other,1992140.0,
273,153555,3,4,,103477782,30323,Unspecified,,,,,Compound was evaluated in vivo for antitumor activity after intraperitoneal administration against P388 (1303) for % increase in life span at an optimal dose of 1 mg/kg/injection,Other,1992140.0,
274,153678,3,4,,103477782,30323,Unspecified,,,,,Compound was evaluated in vivo for antitumor activity after intraperitoneal administration against P388 (1303) for median day of death at an optimal dose of 1 mg/kg/injection,Other,1992140.0,
275,153679,6,1,,103477782,30323,Unspecified,,,,,Compound was evaluated in vivo for antitumor activity after intraperitoneal administration against P388 (1303) for mortality range at an optimal dose of 1 mg/kg/injection,Other,1992140.0,
276,153680,3,5,,103477782,30323,Unspecified,,,,,Compound was evaluated in vivo for antitumor activity after intraperitoneal administration against P388 (1303) for tumor free survivors at an optimal dose of 1 mg/kg/injection,Other,1992140.0,
277,153681,3,4,,103477782,30323,Unspecified,,,,,Compound was evaluated in vivo for antitumor activity after intraperitoneal administration against P388/L-PAM for total dose at an optimal dose of 1 mg/kg/injection,Other,1992140.0,
278,155079,6,8,,103477782,30323,Inactive,119253.0,396766.0,,,Inhibition of Pancreatic elastase at 10e-5 M; NI means no inhibition,Other,1322986.0,
279,155079,6,8,,103477782,30323,Inactive,119258.0,397197.0,,,Inhibition of Pancreatic elastase at 10e-5 M; NI means no inhibition,Other,1322986.0,
280,168257,3,3,,103477782,30323,Unspecified,,,,,Compound was tested for effect of glycoside on superoxide production in rat heart sarcosomes,Other,3018245.0,
281,203866,3,4,,103477782,30323,Unspecified,,,,,Apparent binding affinity to herring sperm DNA at 25 degree Celsius in PBS buffer with pH 7.4,Other,7452665.0,
282,203867,3,5,,103477782,30323,Unspecified,,,,,Maximal binding (nmax) sites to herring sperm DNA. Estimated from Scatchard plots,Other,7452665.0,
283,205641,6,2,,103477782,30323,Unspecified,,,,,Compound was tested for antibacterial activity against Staphylococcus aureus ATCC 25923,Other,3018245.0,
284,205642,6,2,,103477782,30323,Unspecified,,,,,Compound was tested for antibacterial activity against Staphylococcus aureus ATCC 9144,Other,3018245.0,
285,205643,6,2,,103477782,30323,Unspecified,,,,,Compound was tested for antibacterial activity against Staphylococcus aureus WSU-196E,Other,3018245.0,
286,206365,6,2,,103477782,30323,Unspecified,,,,,Compound was tested for antibacterial activity against Staph. epidermidis ATCC 12228,Other,3018245.0,
287,209299,6,2,,103477782,30323,Unspecified,,,,,Compound was tested for antibacterial activity against Strep. pyogenes ATCC 19615,Other,3018245.0,
288,211107,3,7,,103477782,30323,Unspecified,,,,,Binding constant was measured against inhibition of DNA relaxation by topoisomerase I at 20 uM concentration,Other,7932544.0,
289,211114,3,6,,103477782,30323,Unspecified,,,,,Ratio of DNA relaxation times by topoisomerase in presence of 20 uM of compound (t1/e(+drug) / t 1/e(-drug)); Complete inhibition,Other,7932544.0,
290,211116,4,6,,103477782,30323,Unspecified,,,,,Ratio of DNA relaxation times by topoisomerase in presence of 2 uM of compound (t1/e(+drug) / t 1/e(-drug)),Other,7932544.0,
291,212910,3,8,,103477782,30323,Unspecified,,,,,Inhibitory activity against telomerase at 50 uM concentration (Compound released from DNA/DNA heteroduplex derivatized resin [sequence (TTAGGG)3),Other,11591511.0,
292,212911,3,8,,103477782,30323,Unspecified,,,,,Inhibitory activity against telomerase at 50 uM concentration (Compound released from RNA/DNA heteroduplex derivatized resin [sequence (TTAGGG)3),Other,11591511.0,
293,212912,3,8,,103477782,30323,Unspecified,,,,,Inhibitory activity against telomerase at 50 uM concentration (Compound released from underivatized resin,Other,11591511.0,
294,213356,6,4,,103477782,30323,Inactive,,,,,Inhibitory activity against trypsin at 10e-5 M; NI = no inhibition,Other,1322986.0,
295,216116,4,1,,103477782,30323,Unspecified,,,,,Cytotoxicity against WIDR tumor cell line,Other,10602713.0,
296,216275,4,5,,103477782,30323,Active,,,0.047,IC50,In vitro antiproliferative activity against Walker cell line,Confirmatory,,
297,220261,4,5,,103477782,30323,Active,,,0.0074,IC50,In vitro antiproliferative activity against Yoshida cell lines,Confirmatory,,
298,220262,6,3,,103477782,30323,Active,,,0.02,IC50,Concentration inhibiting [3H]TdR incorporation in Yoshida sarcoma tumor cells in vitro in rats,Confirmatory,1322986.0,
299,223791,3,4,,103477782,30323,Unspecified,,,,,Antitumor activity against P-388 leukemia cell line in BDF1 mice after injecting 8.0 mg/kg ip dose,Other,2391681.0,
300,226867,4,3,,103477782,30323,Active,,,0.03818,IC50,Inhibitory concentration in presence of MDR inhibitor XR-9576,Confirmatory,15012986.0,
301,230369,3,5,,103477782,30323,Unspecified,,,,,Resistant Factor against MDR cell lines. Value expressed as ratio of IC50 on the resistant cell and on the corresponding sensitive cells.,Other,,
302,231124,3,4,,103477782,30323,Inconclusive,,,,,Ratio of the extracellular cytotoxicities against MDA MB 361(mammary carcinoma cell line) expressing LacZ and carboxypeptidase stCPG2 of the prodrug.; Not available,Other,10395490.0,
303,231135,4,4,,103477782,30323,Inconclusive,,,,,Ratio of the intracellular cytotoxicities against MDA MB 361(mammary carcinoma cell line) expressing LacZ (beta-galactosidase). between prodrug and drug.; Not available,Other,10395490.0,
304,234842,3,3,,103477782,30323,Unspecified,,,,,NADH oxidation by the compound was determined,Other,8421288.0,
305,256695,4,4,,103477782,30323,Active,,,0.0826,IC50,Cytotoxicity against Jurkat T lymphocytes by MTT assay,Confirmatory,16366602.0,
306,259832,3,4,,103477782,30323,Active,,,,,Increase in the level of drug uptake in Dox-resistant K562 cells in presence of cyclosporine over its absence,Other,16451059.0,
307,259833,3,4,,103477782,30323,Active,,,,,Increase in the level of drug efflux in Dox-resistant K562 cells in presence of cyclosporine over its absence,Other,16451059.0,
308,259834,8,1,,103477782,30323,Active,,,0.015,IC50,Cytotoxicity against K562 cells by MTS,Confirmatory,16451059.0,
309,259835,6,2,,103477782,30323,Unspecified,,,5.0,IC50,Cytotoxicity against Dox-resistant K562 cells by MTS,Confirmatory,16451059.0,
310,259836,3,4,,103477782,30323,Unspecified,,,,,"Drug resistance index, ratio of IC50 in Dox-resistant K562 cells over Dox-sensitive cells",Other,16451059.0,
311,259837,3,5,,103477782,30323,Unspecified,,,,,Cytotoxicity against Dox-resistant K562 cells by MTS at 1 uM and in presence of cyclosporine,Other,16451059.0,
312,259838,3,5,,103477782,30323,Unspecified,,,,,Cytotoxicity against Dox-resistant K562 cells by MTS at 1 uM and in absence of cyclosporine,Other,16451059.0,
313,259842,3,3,,103477782,30323,Unspecified,,,,,"Mortality in mice with Dox-resistant K562 xenografts in 20 days at 5-10 mg/kg, ip",Other,16451059.0,
314,270162,6,2,,103477782,30323,Active,,,2.96,IC50,Cytotoxicity against human HeLa3 cell line by MTT assay,Confirmatory,16942037.0,
315,272491,4,5,,103477782,30323,Active,,,0.977,IC50,Antiproliferative activity against multidrug resistant MDA435/LCC6 cells by ELISA,Confirmatory,17154505.0,
316,272492,4,5,,103477782,30323,Active,,,0.079,IC50,Antiproliferative activity against MDA435/LCC6 cells by ELISA,Confirmatory,17154505.0,
317,272493,4,4,,103477782,30323,Active,,,2.1109999999999998,IC50,Antiproliferative activity against adriamycin resistant P388 cells by ELISA,Confirmatory,17154505.0,
318,272494,4,4,,103477782,30323,Active,,,0.025,IC50,Antiproliferative activity against P388 cells by ELISA,Confirmatory,17154505.0,
319,272510,4,5,,103477782,30323,Active,,,0.129,IC50,"Antiproliferative activity against multidrug resistant MDA435/LCC6 cells in presence of 5 uM 1,13-bis[4'-((5,7-dihydroxy)-4H-chromen-4-on-2-yl)phenyl]-1,4,7,10,13-pentaoxatridecane by ELISA",Confirmatory,17154505.0,
320,272511,4,5,,103477782,30323,Inconclusive,,,,IC50,Antiproliferative activity against multidrug resistant MDA435/LCC6 cells in presence of 5 uM verapamil by ELISA,Confirmatory,17154505.0,
321,272512,3,5,,103477782,30323,Unspecified,,,,,"Relative fold, IC50 in absence to presence of 1,13-bis[4'-((5,7-dihydroxy)-4H-chromen-4-on-2-yl)phenyl]-1,4,7,10,13-pentaoxatridecane in multidrug resistant MDA435/LCC6 cells",Other,17154505.0,
322,272514,4,4,,103477782,30323,Active,,,0.106,IC50,"Antiproliferative activity against adriamycin resistant P388 cells in presence of 5 uM 1,13-bis[4'-((5,7-dihydroxy)-4H-chromen-4-on-2-yl)phenyl]-1,4,7,10,13-pentaoxatridecane by ELISA",Confirmatory,17154505.0,
323,272515,4,4,,103477782,30323,Active,,,0.04,IC50,Antiproliferative activity against adriamycin resistant P388 cells in presence of 5 uM verapamil by ELISA,Confirmatory,17154505.0,
324,272516,3,4,,103477782,30323,Unspecified,,,,,"Relative fold, IC50 in absence to presence of 1,13-bis[4'-((5,7-dihydroxy)-4H-chromen-4-on-2-yl)phenyl]-1,4,7,10,13-pentaoxatridecane in multidrug resistant P388 cells",Other,17154505.0,
325,272517,3,4,,103477782,30323,Unspecified,,,,,"Relative fold, IC50 in absence to presence of verapamil in multidrug resistant P388 cells",Other,17154505.0,
326,280072,4,4,,103477782,30323,Active,,,0.02,IC50,Antiproliferative activity against drug sensitive Messa cell line by Alamar Blue assay,Confirmatory,17286393.0,
327,280073,4,4,,103477782,30323,Unspecified,,,0.4,IC50,Antiproliferative activity against drug resistant Messa/DX5 cell line expressing MDR1 by Alamar Blue assay,Confirmatory,17286393.0,
328,280074,4,5,,103477782,30323,Unspecified,,,0.4,IC50,Antiproliferative activity against drug resistant HCT15 cell line expressing MDR1 by Alamar Blue assay,Confirmatory,17286393.0,
329,280075,4,5,,103477782,30323,Active,,,0.063,IC50,Antiproliferative activity against drug resistant ACHN cell line expressing MDR1 by Alamar Blue assay,Confirmatory,17286393.0,
330,280076,4,5,,103477782,30323,Active,,,0.1,IC50,Antiproliferative activity against drug sensitive NCI-H69 cell line by Alamar Blue assay,Confirmatory,17286393.0,
331,280077,4,4,,103477782,30323,Unspecified,,,1.0,IC50,Antiproliferative activity against drug resistant H69AR cell line expressing MRP1 by Alamar Blue assay,Confirmatory,17286393.0,
332,292449,3,4,,103477782,30323,Active,,,,,Cytotoxicity against CEM cells after 72 hrs,Other,17608396.0,
333,292450,3,4,,103477782,30323,Active,,,,,Cytotoxicity against MCF7 cells after 72 hrs,Other,17608396.0,
334,292451,3,4,,103477782,30323,Active,,,,,Cytotoxicity against K562 cells after 72 hrs,Other,17608396.0,
335,292452,4,4,,103477782,30323,Inconclusive,,,,,Cytotoxicity against ARN8 cells after 72 hrs,Other,17608396.0,
336,292453,3,4,,103477782,30323,Active,,,,,Cytotoxicity against human G361 cells after 72 hrs,Other,17608396.0,
337,292454,3,4,,103477782,30323,Active,,,,,Cytotoxicity against HeLa cells after 72 hrs,Other,17608396.0,
338,292455,3,4,,103477782,30323,Active,,,,,Cytotoxicity against HOS cells after 72 hrs,Other,17608396.0,
339,292456,4,4,,103477782,30323,Inconclusive,,,,,Cytotoxicity against A549 cells after 72 hrs,Other,17608396.0,
340,292457,4,5,,103477782,30323,Inconclusive,,,,,Cytotoxicity against mouse NIH 3T3 cells after 72 hrs,Other,17608396.0,
341,307356,6,2,,103477782,30323,Unspecified,,,,,Displacement of methyl green from DNA,Other,17428583.0,
342,310118,5,3,,103477782,30323,Active,,,18.6209,IC50,Cytotoxicity against human A2780/ADR cells after 72 hrs by MTT assay,Confirmatory,17890094.0,
343,310119,6,1,,103477782,30323,Active,,,0.11749000000000001,IC50,Cytotoxicity against human A2780 cells after 72 hrs by MTT assay,Confirmatory,17890094.0,
344,333400,6,3,,103477782,30323,Unspecified,,,,,Cytotoxicity against mouse NS1 cells after 72 hrs by microtiter plate assay,Other,15497950.0,
345,333401,5,1,,103477782,30323,Unspecified,,,,,Antibacterial activity against Bacillus subtilis ATCC 6633 after 24 hrs by microtiter plate assay,Other,15497950.0,
346,336010,6,3,,103477782,30323,Unspecified,,,,,Displacement of methyl green from DNA after 24 hrs by microtiter assay,Other,1479377.0,
347,336011,6,3,,103477782,30323,Unspecified,,,,,Displacement of ethidium bromide from calf thymus type 1 DNA after 24 hrs by microtiter assay,Other,1479377.0,
348,345311,6,4,,103477782,30323,Active,,,1.01,IC50,Intrinsic cytotoxicity against mouse NIH/3T3 cells overexpressing MDR1 after 72 hrs by MTT assay,Confirmatory,18954040.0,
349,345312,6,3,,103477782,30323,Active,,,0.044000000000000004,IC50,Intrinsic cytotoxicity against wild type mouse NIH/3T3 cells after 72 hrs by MTT assay,Confirmatory,18954040.0,
350,345313,3,5,,103477782,30323,Unspecified,,,,,"Resistance index, ratio of IC50 for mouse NIH/3T3 cells expressing MDR1 to IC50 for wild type mouse NIH/3T3 cells",Other,18954040.0,
351,354538,3,4,,103477782,30323,Inactive,,,,,Cytotoxicity against rat C6 cells at 50 ug/mL to 2.5 mg/mL after 3 days treated 4 hrs before db-cAMP challenge by MTT assay,Other,8988604.0,
352,354542,3,4,,103477782,30323,Inactive,,,,,Inhibition of tubulin polymerization in rat C6 cells at 50 ug/mL to 2.5 mg/mL after 4 hrs,Other,8988604.0,
353,354543,3,4,,103477782,30323,Inactive,,,,,Cytotoxicity against rat C6 cells assessed as cell release at 50 ug/mL to 2.5 mg/mL after 5 hrs by MTT assay in absence of db-cAMP,Other,8988604.0,
354,355251,10,1,,103477782,30323,Unspecified,,,,IC50,Inhibition of HIV1 recombinant reverse transcriptase p66/p51 expressed in Escherichia coli,Confirmatory,9322359.0,
355,355578,9,1,,103477782,30323,Active,,,0.133,IC50,Antiproliferative activity against human HT-29 cells after 96 hrs by MTT assay,Confirmatory,2778449.0,
356,355580,3,5,,103477782,30323,Unspecified,,,,,Antiproliferative activity against human HT-29 cells at 1 ug after 48 hrs by two-layer agar-diffusion method,Other,2778449.0,
357,355581,3,5,,103477782,30323,Inactive,,,,,Antiproliferative activity against human HT-29 cells at 0.1 ug after 48 hrs by two-layer agar-diffusion method,Other,2778449.0,
358,355582,3,5,,103477782,30323,Inactive,,,,,Antiproliferative activity against human HT-29 cells at 0.01 ug after 48 hrs by two-layer agar-diffusion method,Other,2778449.0,
359,355583,9,1,,103477782,30323,Active,,,0.027999999999999997,IC50,Antiproliferative activity against mouse P388 cells after 48 hrs by MTT assay,Confirmatory,2778449.0,
360,355584,3,5,,103477782,30323,Unspecified,,,,,Antiproliferative activity against mouse P388 cells at 1 ug after 48 hrs by two-layer agar-diffusion method,Other,2778449.0,
361,355585,3,5,,103477782,30323,Unspecified,,,,,Antiproliferative activity against mouse P388 cells at 0.1 ug after 48 hrs by two-layer agar-diffusion method,Other,2778449.0,
362,355586,3,5,,103477782,30323,Unspecified,,,,,Antiproliferative activity against mouse P388 cells at 0.01 ug after 48 hrs by two-layer agar-diffusion method,Other,2778449.0,
363,357845,4,4,,103477782,30323,Unspecified,,,,,Binding affinity to calf thymus DNA assessed as reduction in DNA peak by pre-incubation method,Other,1812211.0,
364,357846,4,4,,103477782,30323,Inconclusive,,,,,Binding affinity to yeast tRNA assessed as reduction in tRNA peak by pre-incubation method,Other,1812211.0,
365,362440,3,4,,103477782,30323,Active,,,,,Induction of apoptotic activity in human KB cells at 1 uM after 24 hrs,Other,18680275.0,
366,386570,8,1,,103477782,30323,Unspecified,,,,,Binding affinity to calf thymus DNA in BPES buffer assessed as binding constant K/10'5 by fluorescence titration,Other,18788722.0,
367,396065,7,2,,103477782,30323,Active,,,,IC50,Cytotoxicity against human HL60 cells after 48 hrs by trypan blue exclusion method,Confirmatory,18339455.0,
368,396070,8,1,,103477782,30323,Active,,,38.0,AC50,Induction of apoptosis in multidrug resistant human HL60 cells after 48 hrs,Confirmatory,18339455.0,
369,397122,6,3,,103477782,30323,Unspecified,,,,,Inhibition of HIV1 RT,Other,1710653.0,
370,400016,3,5,,103477782,30323,Unspecified,,,,,Cytotoxicity against human HeLa cells assessed as inhibition of colony formation at 25 ng/ml relative to control,Other,3861771.0,
371,400017,3,5,,103477782,30323,Unspecified,,,,,Cytotoxicity against human HeLa cells assessed as colony formation at 12.5 ng/ml relative to control,Other,3861771.0,
372,400018,3,5,,103477782,30323,Unspecified,,,,,Cytotoxicity against human HeLa cells assessed as colony formation at 6.2 ng/ml relative to control,Other,3861771.0,
373,400021,7,1,,103477782,30323,Unspecified,,,,,Cytotoxicity against human HeLa cells assessed as inhibition of colony formation relative to control,Other,3861771.0,
374,400022,7,1,,103477782,30323,Unspecified,,,,,Cytotoxicity against mouse P388 cells,Other,3861771.0,
375,400023,7,1,,103477782,30323,Unspecified,,,,,Cytotoxicity against doxorubicin resistant mouse P388 cells,Other,3861771.0,
376,400024,3,5,,103477782,30323,Unspecified,,,,,"Antitumor activity against mouse P388 cells xenografted in mouse assessed as median survival time at 2.9 mg/kg, ip relative to control",Other,3861771.0,
377,400025,3,5,,103477782,30323,Unspecified,,,,,"Antitumor activity against mouse P388 cells xenografted in mouse assessed as median survival time at 4.4 mg/kg, ip relative to control",Other,3861771.0,
378,400026,3,5,,103477782,30323,Unspecified,,,,,"Antitumor activity against mouse P388 cells xenografted in mouse assessed as median survival time at 6.6 mg/kg, ip relative to control",Other,3861771.0,
379,400031,3,5,,103477782,30323,Unspecified,,,,,"Toxicity in mouse P388 cells xenografted mouse assessed as induction of death at 2.9 mg/kg, ip",Other,3861771.0,
380,400032,3,5,,103477782,30323,Unspecified,,,,,"Toxicity in mouse P388 cells xenografted mouse assessed as induction of death at 4.4 mg/kg, ip",Other,3861771.0,
381,409954,4,9,,103477782,30323,Inactive,341940599.0,17161.0,,,Inhibition of mouse brain MAOA,Other,18834112.0,
382,409956,4,9,,103477782,30323,Inactive,341940629.0,109731.0,,,Inhibition of mouse brain MAOB,Other,18834112.0,
383,434959,1,1,,85788867,30323,Inactive,,,,,Fluorescence Cell-Based Primary HTS to Measure Inhibition of Y box Binding Protein 1 Expression,Screening,,
384,445445,7,1,,103477782,30323,Unspecified,,,,,Permeability at pH 6.5 by PAMPA method,Other,19947605.0,
385,445446,3,4,,103477782,30323,Unspecified,,,,,Oral bioavailability in human,Other,19947605.0,
386,456324,5,2,,103477782,30323,Active,,,0.044000000000000004,GI50,Growth inhibition of human NCI60 cells,Confirmatory,19944612.0,
387,467955,6,2,,103477782,30323,Unspecified,,,,,Cytotoxicity against human KB cells after 48 hrs by MTT assay,Other,19606850.0,
388,467956,6,3,,103477782,30323,Unspecified,,,,,Cytotoxicity against human multidrug resistant KB-C2 cells after 48 hrs by MTT assay,Other,19606850.0,
389,467958,6,2,,103477782,30323,Unspecified,,,,,Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay,Other,19606850.0,
390,467959,6,2,,103477782,30323,Unspecified,,,,,Cytotoxicity against human K562 cells after 48 hrs by MTT assay,Other,19606850.0,
391,467960,6,2,,103477782,30323,Unspecified,,,,,Cytotoxicity against human doxorubicin-resistant K562 cells after 48 hrs by MTT assay,Other,19606850.0,
392,467961,6,2,,103477782,30323,Unspecified,,,,,Cytotoxicity against human COLO205 cells after 48 hrs by MTT assay,Other,19606850.0,
393,469437,5,2,,103477782,30323,Active,,,0.02,GI50,Cytotoxicity against human MDA-MB-231 cells after 72 hrs by sulforhodamine B assay,Confirmatory,19968258.0,
394,469438,5,2,,103477782,30323,Active,,,0.08,GI50,Cytotoxicity against human A549 cells after 72 hrs by sulforhodamine B assay,Confirmatory,19968258.0,
395,469439,5,2,,103477782,30323,Active,,,0.07,GI50,Cytotoxicity against human HT-29 cells after 72 hrs by sulforhodamine B assay,Confirmatory,19968258.0,
396,471987,3,4,,103477782,30323,Unspecified,,,,,Cytotoxicity against HEK293 cells at 400 nM after 48 hrs by resazurin conversion-based fluorometric assay,Other,19739598.0,
397,472409,5,2,,103477782,30323,Active,,,0.64,IC50,Cytotoxicity against human KB cells after 48 hrs by MTT assay,Confirmatory,20363142.0,
398,472410,5,3,,103477782,30323,Active,,,16.2,IC50,Cytotoxicity against human multidrug-resistant KB-C2 cells after 48 hrs by MTT assay,Confirmatory,20363142.0,
399,477295,3,3,,103477782,30323,Unspecified,,,,,"Octanol-water partition coefficient, log P of the compound",Other,20106561.0,
400,485281,1,1,,29215022,30323,Inconclusive,254220970.0,,17.7828,Potency,qHTS Assay for Identification of Novel General Anesthetics,Confirmatory,,
401,485290,1,1,,11114094,30323,Inactive,20150581.0,,22.3872,Potency,qHTS Assay for Inhibitors of Tyrosyl-DNA Phosphodiesterase (TDP1),Confirmatory,,
402,485290,1,1,,29215022,30323,Inactive,20150581.0,,15.8489,Potency,qHTS Assay for Inhibitors of Tyrosyl-DNA Phosphodiesterase (TDP1),Confirmatory,,
403,492223,3,5,,103477782,30323,Unspecified,,,,,Cytotoxicity against human MCF7 cells at 4 ug/ml after 48 hrs by sulforhodamine B assay relative to control,Other,20591678.0,
404,492224,3,5,,103477782,30323,Unspecified,,,,,Cytotoxicity against human NCI-H460 cells at 4 ug/ml after 48 hrs by sulforhodamine B assay relative to control,Other,20591678.0,
405,492225,3,5,,103477782,30323,Unspecified,,,,,Cytotoxicity against human SF268 cells at 4 ug/ml after 48 hrs by sulforhodamine B assay relative to control,Other,20591678.0,
406,492226,5,2,,103477782,30323,Active,,,0.86,GI50,Cytotoxicity against human MCF7 cells after 72 hrs by XTT assay,Confirmatory,20591678.0,
407,492227,5,2,,103477782,30323,Active,,,0.38,GI50,Cytotoxicity against human NCI-H460 cells after 72 hrs by XTT assay,Confirmatory,20591678.0,
408,492228,5,2,,103477782,30323,Active,,,0.6,GI50,Cytotoxicity against human SF268 cells after 72 hrs by XTT assay,Confirmatory,20591678.0,
409,492229,5,2,,103477782,30323,Active,,,1.77,GI50,Cytotoxicity against human Detroit 551 cells after 72 hrs by XTT assay,Confirmatory,20591678.0,
410,492230,3,5,,103477782,30323,Unspecified,,,,,"Selectivity index, ratio of GI50 for human Detroit 551 cells to GI50 for human MCF7 cells",Other,20591678.0,
411,492231,3,5,,103477782,30323,Unspecified,,,,,"Selectivity index, ratio of GI50 for human Detroit 551 cells to GI50 for human NCI-H460 cells",Other,20591678.0,
412,492232,3,5,,103477782,30323,Unspecified,,,,,"Selectivity index, ratio of GI50 for human Detroit 551 cells to GI50 for human SF268 cells",Other,20591678.0,
413,492233,5,2,,103477782,30323,Active,,,0.0074,GI50,Cytotoxicity against human K562 cells after 72 hrs by XTT assay,Confirmatory,20591678.0,
414,492234,3,5,,103477782,30323,Unspecified,,,,,"Selectivity index, ratio of GI50 for human Detroit 551 cells to GI50 for human K562 cells",Other,20591678.0,
415,492961,1,1,,29215022,30323,Inconclusive,72386991.0,3656265.0,7.9433,Potency,qHTS Assay to Find Inhibitors of T. brucei phosphofructokinase: hit validation,Confirmatory,,
416,504327,1,1,,11114094,30323,Inconclusive,153791535.0,2648.0,0.3162,Potency,qHTS Assay for Inhibitors of GCN5L2,Confirmatory,,
417,504327,1,1,,29215022,30323,Inactive,153791535.0,2648.0,,Potency,qHTS Assay for Inhibitors of GCN5L2,Confirmatory,,
418,504332,1,1,,29215022,30323,Active,168985070.0,,15.8489,Potency,qHTS Assay for Inhibitors of Histone Lysine Methyltransferase G9a,Confirmatory,,
419,504370,1,1,,11114094,30323,Active,13124873.0,865.0,0.2512,Potency,qHTS Assay for Compounds Blocking the Interaction Between CBF-beta and RUNX1 for the Treatment of Acute Myeloid Leukemia: ME-1 cellular proliferation,Confirmatory,,
420,504370,1,1,,11114094,30323,Active,49574546.0,861.0,0.2512,Potency,qHTS Assay for Compounds Blocking the Interaction Between CBF-beta and RUNX1 for the Treatment of Acute Myeloid Leukemia: ME-1 cellular proliferation,Confirmatory,,
421,504375,1,2,,11114094,30323,Inconclusive,13124873.0,865.0,15.8489,Potency,qHTS Assay for Compounds Blocking the Interaction Between CBF-beta and RUNX1 for the Treatment of Acute Myeloid Leukemia: Hit Validation with Orthogonal Assay,Confirmatory,,
422,504375,1,2,,11114094,30323,Inconclusive,49574546.0,861.0,15.8489,Potency,qHTS Assay for Compounds Blocking the Interaction Between CBF-beta and RUNX1 for the Treatment of Acute Myeloid Leukemia: Hit Validation with Orthogonal Assay,Confirmatory,,
423,504749,1,3,,29215022,30323,Unspecified,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
424,504749,1,3,1.0,29215022,30323,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
425,504749,1,3,2.0,29215022,30323,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
426,504749,1,3,3.0,29215022,30323,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
427,504749,1,3,4.0,29215022,30323,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
428,504749,1,3,5.0,29215022,30323,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
429,504749,1,3,6.0,29215022,30323,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
430,504749,1,3,7.0,29215022,30323,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
431,504749,1,3,8.0,29215022,30323,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
432,504749,1,3,9.0,29215022,30323,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
433,504749,1,3,10.0,29215022,30323,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
434,504749,1,3,11.0,29215022,30323,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
435,504749,1,3,12.0,29215022,30323,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
436,504749,1,3,13.0,29215022,30323,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
437,504749,1,3,14.0,29215022,30323,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
438,504749,1,3,15.0,29215022,30323,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
439,504749,1,3,16.0,29215022,30323,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
440,504749,1,3,17.0,29215022,30323,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
441,504749,1,3,18.0,29215022,30323,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
442,504749,1,3,19.0,29215022,30323,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
443,504749,1,3,20.0,29215022,30323,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
444,504749,1,3,21.0,29215022,30323,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
445,504749,1,3,22.0,29215022,30323,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
446,504749,1,3,23.0,29215022,30323,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
447,504749,1,3,24.0,29215022,30323,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
448,504749,1,3,25.0,29215022,30323,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
449,504749,1,3,26.0,29215022,30323,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
450,504749,1,3,27.0,29215022,30323,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
451,504749,1,3,28.0,29215022,30323,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
452,504749,1,3,29.0,29215022,30323,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
453,504749,1,3,30.0,29215022,30323,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
454,504749,1,3,31.0,29215022,30323,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
455,504749,1,3,32.0,29215022,30323,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
456,504749,1,3,33.0,29215022,30323,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
457,504749,1,3,34.0,29215022,30323,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
458,504749,1,3,35.0,29215022,30323,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
459,504749,1,3,36.0,29215022,30323,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
460,504749,1,3,37.0,29215022,30323,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
461,504749,1,3,38.0,29215022,30323,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
462,504749,1,3,39.0,29215022,30323,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
463,504749,1,3,40.0,29215022,30323,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
464,504749,1,3,41.0,29215022,30323,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
465,504749,1,3,42.0,29215022,30323,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
466,504749,1,3,43.0,29215022,30323,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
467,504749,1,3,44.0,29215022,30323,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
468,504749,1,3,45.0,29215022,30323,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
469,504749,1,3,46.0,29215022,30323,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
470,504749,1,3,47.0,29215022,30323,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
471,504749,1,3,48.0,29215022,30323,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
472,504749,1,3,49.0,29215022,30323,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
473,504749,1,3,50.0,29215022,30323,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
474,504749,1,3,51.0,29215022,30323,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
475,504749,1,3,52.0,29215022,30323,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
476,504749,1,3,53.0,29215022,30323,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
477,504749,1,3,54.0,29215022,30323,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
478,504749,1,3,55.0,29215022,30323,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
479,504749,1,3,56.0,29215022,30323,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
480,504749,1,3,57.0,29215022,30323,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
481,504749,1,3,58.0,29215022,30323,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
482,504749,1,3,59.0,29215022,30323,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
483,504749,1,3,60.0,29215022,30323,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
484,504749,1,3,61.0,29215022,30323,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
485,504832,1,1,,29215022,30323,Active,,,0.7569,Potency,"Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 48 hour incubation",Confirmatory,,
486,504834,1,1,,29215022,30323,Active,,,0.6746,Potency,"Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 96 hour incubation",Confirmatory,,
487,504845,1,1,,11114094,30323,Inactive,86301163.0,5999.0,,Potency,Inhibitors of Regulator of G Protein Signaling (RGS) 4: qHTS,Confirmatory,,
488,504847,1,1,,11114094,30323,Inconclusive,63054845.0,7421.0,15.8489,Potency,Inhibitors of the vitamin D receptor (VDR): qHTS,Confirmatory,,
489,504847,1,1,,29215022,30323,Inactive,63054845.0,7421.0,,Potency,Inhibitors of the vitamin D receptor (VDR): qHTS,Confirmatory,,
490,504865,1,1,,11114094,30323,Active,118600387.0,7398.0,44.6684,Potency,Inhibitors of USP1/UAF1: Pilot qHTS,Confirmatory,,
491,504865,1,1,,29215022,30323,Active,118600387.0,7398.0,39.8107,Potency,Inhibitors of USP1/UAF1: Pilot qHTS,Confirmatory,,
492,512633,2,3,,103477782,30323,Active,,,,,Binding affinity to human c-MYC Pu24I G-quadruplex structure assessed as stabilization of G-quadruplex by NMR spectroscopy,Other,16408022.0,
493,515168,4,1,,103477782,30323,Unspecified,,,,,Binding affinity to histone H1 containing chromatin in chicken erythroleukemic cells mononucleosomes transformed with Marek's virus by Scatchard plot analysis,Other,20698509.0,
494,515169,4,1,,103477782,30323,Unspecified,,,,,Binding affinity to histone H1 depleted chromatin in chicken erythroleukemic cells mononucleosomes transformed with Marek's virus by Scatchard plot analysis,Other,20698509.0,
495,536031,1,4,,103477782,30323,Unspecified,,,,,Binding affinity to calf thymus DNA assessed as change in melting temperature at drug/DNA ratio 1,Other,20961767.0,
496,536034,1,3,,103477782,30323,Inconclusive,,,,,Displacement of DNA-bound ethidium bromide from calf thymus DNA by fluorescence assay,Other,20961767.0,
497,537733,2,3,,103477782,30323,Active,,,,,Binding affinity to Candida albicans CaCdr1p expressed in yeast AD1-8u,Other,20739103.0,
498,537734,5,2,,103477782,30323,Unspecified,,,,,Antifungal activity against yeast AD1-8u expressing Candida albicans CaMdr1p by agar disk diffusion assay,Other,20739103.0,
499,537735,2,3,,103477782,30323,Inactive,,,,,Binding affinity to Candida albicans CaMdr1p expressed in yeast AD1-8u,Other,20739103.0,
500,537736,5,2,,103477782,30323,Unspecified,,,,,Antifungal activity against yeast AD1-8u expressing Candida albicans CaCdr1p by agar disk diffusion assay,Other,20739103.0,
501,550988,1,4,,103477782,30323,Unspecified,,,,,Cytotoxicity against human MCF7 cells assessed as cell viability at 25 uM after 24 hrs by MTS assay,Other,21094049.0,
502,550989,1,4,,103477782,30323,Unspecified,,,,,Cytotoxicity against human MCF7 cells assessed as cell viability at 20 uM after 24 hrs by MTS assay,Other,21094049.0,
503,550990,1,4,,103477782,30323,Unspecified,,,,,Cytotoxicity against human HT-29 cells assessed as cell viability at 25 uM after 24 hrs by MTS assay,Other,21094049.0,
504,550991,1,4,,103477782,30323,Unspecified,,,,,Cytotoxicity against human HT-29 cells assessed as cell viability at 20 uM after 24 hrs by MTS assay,Other,21094049.0,
505,550992,1,4,,103477782,30323,Unspecified,,,,,Cytotoxicity against human HepG2 cells assessed as cell viability at 25 uM after 24 hrs by MTS assay,Other,21094049.0,
506,550993,1,4,,103477782,30323,Unspecified,,,,,Cytotoxicity against human HepG2 cells assessed as cell viability at 16 uM after 24 hrs by MTS assay,Other,21094049.0,
507,550994,4,2,,103477782,30323,Active,,,5.5,IC50,Cytotoxicity against human MCF7 cells after 24 hrs by MTS assay,Confirmatory,21094049.0,
508,550995,4,2,,103477782,30323,Active,,,0.4,IC50,Cytotoxicity against human HT-29 cells after 24 hrs by MTS assay,Confirmatory,21094049.0,
509,550996,4,2,,103477782,30323,Active,,,0.7,IC50,Cytotoxicity against human HepG2 cells after 24 hrs by MTS assay,Confirmatory,21094049.0,
510,551000,4,3,,103477782,30323,Active,,,10.5,IC50,Cytotoxicity against human CRL7761 cells after 3 days by MTS assay,Confirmatory,21094049.0,
511,551001,4,2,,103477782,30323,Active,,,2.5,IC50,Cytotoxicity against african green monkey Vero cells after 3 days by MTS assay,Confirmatory,21094049.0,
512,551002,4,3,,103477782,30323,Active,,,1.8,IC50,Cytotoxicity against mouse NIH/3T3 cells after 3 days by MTS assay,Confirmatory,21094049.0,
513,551010,3,9,,103477782,30323,Active,12644118.0,7150.0,,,Inhibition of human recombinant DNA topoisomerase 1-mediated DNA cleavage assessed as decrease in relaxation of supercoiled plasmid substrate DNA at 5 uM after 30 mins by agarose gel electrophoresis,Other,21094049.0,
514,551012,3,9,,103477782,30323,Inactive,13959709.0,7153.0,,,Inhibition of human recombinant DNA topoisomerase 2alpha-mediated DNA cleavage assessed as decrease in relaxation of supercoiled plasmid substrate DNA at 20 uM after 30 mins by agarose gel electrophoresis,Other,21094049.0,
515,551550,4,2,,103477782,30323,Unspecified,,,,,Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay,Other,21109433.0,
516,586923,1,3,,103477782,30323,Unspecified,,,,,"Resistant index, ratio of EC50 for tafenoquine-resistant promastigotes of Leishmania major R4 to EC50 for promastigotes of Leishmania major MHOM/JL/80/Friedlin",Other,21199921.0,
517,586924,4,2,,103477782,30323,Active,,,0.38,EC50,Antileishmanial activity against tafenoquine-resistant promastigotes of Leishmania major R4 assessed as inhibition of parasite growth after 72 hrs by MTT assay,Confirmatory,21199921.0,
518,586925,4,2,,103477782,30323,Active,,,0.22,EC50,Antileishmanial activity against wild type promastigotes of Leishmania major MHOM/JL/80/Friedlin assessed as inhibition of parasite growth after 72 hrs by MTT assay,Confirmatory,21199921.0,
519,588211,2,3,,103477782,30323,Unspecified,,,,,"Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans",Other,20014752.0,
520,588212,2,3,,103477782,30323,Unspecified,,,,,"Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents",Other,20014752.0,
521,588213,2,3,,103477782,30323,Unspecified,,,,,"Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents",Other,20014752.0,
522,588214,2,3,,103477782,30323,Unspecified,,,,,"FDA HLAED, liver enzyme composite activity",Other,16472241.0,
523,588215,2,3,,103477782,30323,Unspecified,,,,,"FDA HLAED, alkaline phosphatase increase",Other,16472241.0,
524,588216,2,3,,103477782,30323,Unspecified,,,,,"FDA HLAED, serum glutamic oxaloacetic transaminase (SGOT) increase",Other,16472241.0,
525,588217,2,3,,103477782,30323,Unspecified,,,,,"FDA HLAED, serum glutamic pyruvic transaminase (SGPT) increase",Other,16472241.0,
526,588218,2,3,,103477782,30323,Unspecified,,,,,"FDA HLAED, lactate dehydrogenase (LDH) increase",Other,16472241.0,
527,588219,2,3,,103477782,30323,Unspecified,,,,,"FDA HLAED, gamma-glutamyl transferase (GGT) increase",Other,16472241.0,
528,588379,1,2,,11114094,30323,Inactive,13399304.0,60489.0,,Potency,qHTS for inhibitors of Vif-A3G interactions: Validation,Confirmatory,,
529,588579,1,1,,11114094,30323,Active,7705344.0,51426.0,5.0119,Potency,qHTS for Inhibitors of Polymerase Kappa,Confirmatory,,
530,588579,1,1,,29215022,30323,Active,7705344.0,51426.0,11.9173,Potency,qHTS for Inhibitors of Polymerase Kappa,Confirmatory,,
531,588834,2,1,,144204447,30323,Inactive,325651834.0,3757.0,,Potency,qHTS Assay for Small Molecule Inhibitors of the Human hERG Channel Activity,Confirmatory,,
532,591078,1,4,,103477782,30323,Unspecified,,,,,Binding affinity to poly(dAT)2 assessed as change in melting temperature at compound to polynucleotide ratio of 1,Other,21439821.0,
533,597391,4,2,,103477782,30323,Unspecified,,,,,Cytotoxicity against human KB cells after 6 hrs by MTT assay,Other,21493075.0,
534,597392,4,3,,103477782,30323,Unspecified,,,,,Cytotoxicity against human KB-C2 cells after 6 hrs by MTT assay,Other,21493075.0,
535,597393,4,2,,103477782,30323,Unspecified,,,,,Cytotoxicity against human MCF7 cells after 6 hrs by MTT assay,Other,21493075.0,
536,597394,4,3,,103477782,30323,Unspecified,,,,,Cytotoxicity against human colchicine-resistant KB-C2 cells after 6 hrs by MTT assay,Other,21493075.0,
537,597395,4,2,,103477782,30323,Unspecified,,,,,Cytotoxicity against human doxorubicin-resistant K562 cells after 6 hrs by MTT assay,Other,21493075.0,
538,597396,4,2,,103477782,30323,Unspecified,,,,,Cytotoxicity against human K562 cells after 6 hrs by MTT assay,Other,21493075.0,
539,602332,1,1,,11114094,30323,Inactive,168984549.0,,,Potency,qHTS for Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in Human Glioma: qHTS,Confirmatory,,
540,602332,1,1,,29215022,30323,Inactive,168984549.0,,,Potency,qHTS for Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in Human Glioma: qHTS,Confirmatory,,
541,606427,3,2,,103477782,30323,Active,,,5.03,IC50,Anticancer activity against human MCF7 cells,Confirmatory,21599000.0,
542,606428,3,2,,103477782,30323,Active,,,0.38,IC50,Anticancer activity against human NCI-H460 cells,Confirmatory,21599000.0,
543,606429,3,2,,103477782,30323,Active,,,0.6,IC50,Anticancer activity against human SF268 cells,Confirmatory,21599000.0,
544,606430,3,2,,103477782,30323,Active,,,0.88,IC50,Antiproliferative activity against human MRC5 cells,Confirmatory,21599000.0,
545,606437,1,4,,103477782,30323,Unspecified,,,,,"Selectivity index, ratio of IC50 of human MRC5 cells to IC50 for human NCI-H460 cells",Other,21599000.0,
546,606438,1,4,,103477782,30323,Unspecified,,,,,"Selectivity index, ratio of IC50 of human MRC5 cells to IC50 for human MCF7 cells",Other,21599000.0,
547,606439,1,4,,103477782,30323,Unspecified,,,,,"Selectivity index, ratio of IC50 of human MRC5 cells to IC50 for human SF268 cells",Other,21599000.0,
548,624030,1,2,,29215022,30323,Inconclusive,160794.0,,8.0875,Potency,Biochemical firefly luciferase enzyme assay for NPC,Confirmatory,,
549,624031,1,2,,29215022,30323,Inactive,,,,Potency,S16 Schwann cell viability assay (CellTiter-Glo assay),Confirmatory,,
550,624032,1,2,,29215022,30323,Inactive,8393992.0,24660.0,,Potency,S16 Schwann cell PMP22 intronic element firefly luciferase assay,Confirmatory,,
551,624044,1,2,,29215022,30323,Active,8393992.0,24660.0,0.1258,Potency,S16 Schwann cell PMP22 intronic element beta-lactamase assay,Confirmatory,,
552,624101,1,2,,85788867,30323,Inactive,62203298.0,3417.0,,,Development of  IDH1/2 inhibitors (CTD2project) Measured in Biochemical System Using Plate Reader - 2107-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
553,624137,1,1,,85788867,30323,Inactive,881546.0,3400.0,,,SMM ID4 Measured in Biochemical System Using Small Molecule MicroArray - 2128-01_Other_SinglePoint_HTS_Activity,Screening,,
554,624156,1,1,,85788867,30323,Active,,,,,Fluorescence Cell-Based Primary  HTS to Identify Reactive Oxygen Species Inducers in Cancer Cells Measured in Cell-Based System Using Plate Reader and Imaging Combination - 2044-01_Activator_SinglePoint_HTS_Activity,Screening,,
555,624160,1,1,,29215022,30323,Active,,,5.6454,Potency,qHTS Fluorescence Polarization (FP) Assay for Inhibitors of MLL CXXC domain - DNA interaction: Fluorescein FP,Confirmatory,,
556,624161,1,1,,29215022,30323,Active,,,11.2641,Potency,qHTS Fluorescence Polarization (FP) Assay for Inhibitors of MLL CXXC domain - DNA interaction: Texas Red FP,Confirmatory,,
557,624162,1,2,,29215022,30323,Inactive,,,68.5308,Potency,qHTS Fluorescence Polarization (FP) Assay for Inhibitors of MLL CXXC domain - DNA interaction: HTRF Assay,Confirmatory,,
558,624170,1,1,,29215022,30323,Inactive,71051501.0,2744.0,,Potency,qHTS for Inhibitors of Glutaminase (GLS),Confirmatory,,
559,624172,1,1,,29215022,30323,Inactive,1724069.0,2740.0,,Potency,qHTS of GLP-1 Receptor Agonists,Confirmatory,,
560,624173,1,3,,29215022,30323,Inactive,62359610.0,,,Potency,qHTS of Trypanosoma Brucei Inhibitors,Confirmatory,,
561,624260,1,1,,85788867,30323,Inactive,109633019.0,7468.0,,,NSD2 Inhibitors Measured in Biochemical System Using Plate Reader - 2115-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
562,624296,1,1,,29215022,30323,Inactive,7705682.0,51053.0,,Potency,A quantitative high throughput screen for small molecules that induce DNA re-replication in MCF 10a normal breast cells.,Confirmatory,,
563,624297,1,1,,29215022,30323,Inactive,7705682.0,51053.0,5.3091,Potency,A quantitative high throughput screen for small molecules that induce DNA re-replication in SW480 colon adenocarcinoma cells.,Confirmatory,,
564,624349,1,2,,92307396,30323,Inactive,,,,,A screen for compounds that inhibit liver stage malaria,Other,,
565,624349,1,2,,92308820,30323,Active,,,,,A screen for compounds that inhibit liver stage malaria,Other,,
566,624606,1,9,,103477782,30323,Unspecified,136729.0,54658.0,,,Specific activity of expressed human recombinant UGT1A1,Other,10836148.0,
567,624609,1,9,,103477782,30323,Unspecified,29840832.0,54578.0,,,Specific activity of expressed human recombinant UGT1A6,Other,10836148.0,
568,624612,1,9,,103477782,30323,Unspecified,29839451.0,54600.0,,,Specific activity of expressed human recombinant UGT1A9,Other,10836148.0,
569,624622,3,1,,103477782,30323,Unspecified,238054374.0,5243.0,,,Apparent permeability (Papp) from apical to basolateral side determined in MDR1-MDCKII cells,Other,11602674.0,
570,624623,3,1,,103477782,30323,Unspecified,238054374.0,5243.0,,,Apparent permeability (Papp) from basolateral to apical side determined in MDR1-MDCKII cells,Other,11602674.0,
571,624626,1,9,,103477782,30323,Unspecified,238054374.0,5243.0,,,Ratio of apparent permeability from basolateral to apical side over apical to basolateral side determined in MDR1-MDCKII cells,Other,11602674.0,
572,624628,1,9,,103477782,30323,Unspecified,238054374.0,5243.0,,,Drug-stimulated Pgp ATPase activity ratio determined in MDR1-Sf9 cell membranes with test compound at a concentration of 20uM,Other,11602674.0,
573,624629,1,9,,103477782,30323,Unspecified,238054374.0,5243.0,,,Inhibition of Pgp expressed in MDR1-MDCKII cells measured by calcein-AM assay,Other,11602674.0,
574,625144,5,5,,103477782,30323,Unspecified,239977155.0,,,IC50,DRUGMATRIX: Leukotriene LTC4 Synthase enzyme inhibition (substrate: LTA4),Confirmatory,,
575,625145,4,7,,103477782,30323,Unspecified,20138087.0,10800.0,,IC50,DRUGMATRIX: Cysteinyl leukotriene receptor 1 radioligand binding (ligand: [3H]LTD4),Confirmatory,,
576,625146,5,5,,103477782,30323,Unspecified,126397.0,100009114.0,,IC50,DRUGMATRIX: Lipoxygenase 15-LO enzyme inhibition (substrate: Linoleic acid),Confirmatory,,
577,625147,4,7,,103477782,30323,Unspecified,395398606.0,4159.0,,IC50,DRUGMATRIX: Melanocortin MC3 radioligand binding (ligand: [125I] NDP-alpha-MSH),Confirmatory,,
578,625148,4,7,,103477782,30323,Unspecified,60392672.0,4160.0,,IC50,DRUGMATRIX: Melanocortin MC4 radioligand binding (ligand: [125I] NDP-alpha-MSH),Confirmatory,,
579,625149,4,7,,103477782,30323,Unspecified,729996.0,4161.0,,IC50,DRUGMATRIX: Melanocortin MC5 radioligand binding (ligand: [125I] NDP-alpha-MSH),Confirmatory,,
580,625150,5,5,,103477782,30323,Unspecified,113978.0,4128.0,,IC50,DRUGMATRIX: Monoamine Oxidase MAO-A enzyme inhibition (substrate: Kynuramine),Confirmatory,,
581,625151,4,7,,103477782,30323,Unspecified,113118.0,1128.0,,IC50,DRUGMATRIX: Muscarinic M1 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
582,625152,4,7,,103477782,30323,Unspecified,113122.0,1129.0,,IC50,DRUGMATRIX: Muscarinic M2 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
583,625153,4,7,,103477782,30323,Unspecified,113125.0,1131.0,,IC50,DRUGMATRIX: Muscarinic M3 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
584,625154,4,7,,103477782,30323,Unspecified,23503039.0,1132.0,,IC50,DRUGMATRIX: Muscarinic M4 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
585,625155,4,7,,103477782,30323,Unspecified,543761.0,1133.0,,IC50,DRUGMATRIX: Muscarinic M5 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
586,625156,1,9,,103477782,30323,Unspecified,128997.0,4886.0,,,DRUGMATRIX: Neuropeptide Y Y1 radioligand binding (ligand: [125I] Peptide YY),Other,,
587,625157,6,2,,103477782,30323,Unspecified,1352610.0,4887.0,,IC50,DRUGMATRIX: Neuropeptide Y Y2 radioligand binding (ligand: [125I] Peptide YY),Confirmatory,,
588,625158,3,4,,103477782,30323,Unspecified,,,,IC50,DRUGMATRIX: Nicotinic Acetylcholine radioligand binding (ligand: [125I] Epibatidine),Confirmatory,,
589,625159,5,5,,103477782,30323,Unspecified,266646.0,24598.0,,IC50,"DRUGMATRIX: Nitric Oxide Synthase, Neuronal (nNOS) radioligand binding (ligand: [3H]L-Arginine)",Confirmatory,,
590,625160,1,9,,103477782,30323,Unspecified,266649.0,18126.0,,,"DRUGMATRIX: Nitric Oxide Synthase, Inducible (iNOS) enzyme inhibition (substrate: L-Arginine)",Other,,
591,625161,4,7,,103477782,30323,Unspecified,311033488.0,4985.0,,IC50,"DRUGMATRIX: Opiate delta1 (OP1, DOP) radioligand binding (ligand: [3H] Naltrindole)",Confirmatory,,
592,625162,4,7,,103477782,30323,Unspecified,116242691.0,4986.0,,IC50,"DRUGMATRIX: Opiate kappa (OP2, KOP) radioligand binding (ligand: [3H] Diprenorphine)",Confirmatory,,
593,625163,4,7,,103477782,30323,Unspecified,2851402.0,4988.0,,IC50,"DRUGMATRIX: Opiate mu (OP3, MOP) radioligand binding (ligand: [3H] Diprenorphine)",Confirmatory,,
594,625164,1,6,,103477782,30323,Unspecified,,,,,DRUGMATRIX: Phorbol Ester radioligand binding (ligand: [3H] PDBu),Other,,
595,625165,3,4,,103477782,30323,Unspecified,,,,IC50,DRUGMATRIX: Phosphodiesterase PDE3 enzyme inhibition (substrate: [3H]cAMP + cAMP),Confirmatory,,
596,625166,3,4,,103477782,30323,Unspecified,,,,IC50,DRUGMATRIX: Phosphodiesterase PDE4 enzyme inhibition (substrate: [3H]cAMP + cAMP),Confirmatory,,
597,625167,5,5,,103477782,30323,Unspecified,317373261.0,8654.0,,IC50,DRUGMATRIX: Phosphodiesterase PDE5 enzyme inhibition (substrate: [3H]cGMP + cGMP),Confirmatory,,
598,625168,4,7,,103477782,30323,Unspecified,129557.0,5724.0,,IC50,DRUGMATRIX: Platelet Activating Factor (PAF) radioligand binding (ligand: [3H] PAF),Confirmatory,,
599,625169,1,6,,103477782,30323,Unspecified,,,,,DRUGMATRIX: Platelet-Derived Growth Factor (PDGF) radioligand binding (ligand: [125I] PDGF),Other,,
600,625170,3,4,,103477782,30323,Unspecified,,,,IC50,DRUGMATRIX: Potassium Channel [KATP] radioligand binding (ligand: [3H] Glyburide),Confirmatory,,
601,625171,4,7,,103477782,30323,Unspecified,7531135.0,3757.0,,IC50,DRUGMATRIX: Potassium Channel HERG radioligand binding (ligand: [3H] Astemizole),Confirmatory,,
602,625172,4,7,,103477782,30323,Unspecified,75071465.0,,,IC50,DRUGMATRIX: Progesterone radioligand binding (ligand: [3H] R-5020),Confirmatory,,
603,625173,5,5,,103477782,30323,Unspecified,2822103.0,100009274.0,,IC50,"DRUGMATRIX: Peptidase, Angiotensin Converting Enzyme enzyme inhibition (substrate: FAPGG)",Confirmatory,,
604,625174,5,5,,103477782,30323,Unspecified,266321.0,834.0,,IC50,"DRUGMATRIX: Protease, Caspase 1 enzyme inhibition (substrate: Ac-YVAD-AMC)",Confirmatory,,
605,625175,5,5,,103477782,30323,Unspecified,115725.0,1511.0,,IC50,"DRUGMATRIX: Protease, Cathepsin G enzyme inhibition (substrate: Suc-Ala-Ala-Pro-Phe-AMC)",Confirmatory,,
606,625176,1,9,,103477782,30323,Unspecified,119292.0,1991.0,,,"DRUGMATRIX: Peptidase, ELA2 (Neutrophil Elastase 2) enzyme inhibition (substrate: N-MeOSuc-Ala-Ala-Pro-Val-pNA)",Other,,
607,625177,5,5,,103477782,30323,Unspecified,116852.0,4312.0,,IC50,"DRUGMATRIX: Peptidase, Matrix Metalloprotease-1 (MMP-1) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Confirmatory,,
608,625178,5,5,,103477782,30323,Unspecified,269849668.0,4318.0,,IC50,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Confirmatory,,
609,625179,1,9,,103477782,30323,Unspecified,317373571.0,5578.0,,,DRUGMATRIX: Protein Serine/Threonine Kinase PKCalpha enzyme inhibition (substrate: Histone),Other,,
610,625180,5,5,,103477782,30323,Unspecified,232066.0,5595.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Kinase, ERK1 enzyme inhibition (substrate: Myelin Basic Protein)",Confirmatory,,
611,625181,5,5,,103477782,30323,Unspecified,119554.0,5594.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Kinase, ERK2 enzyme inhibition (substrate: Myelin Basic Protein)",Confirmatory,,
612,625182,5,5,,103477782,30323,Unspecified,2499600.0,1432.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Kinase, p38alpha enzyme inhibition (substrate: Myelin Basic Protein)",Confirmatory,,
613,625183,5,5,,103477782,30323,Unspecified,1352673.0,5530.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Phosphatase, PPP3CA (Calcineurin, PP2B) enzyme inhibition (substrate: DiFMUP)",Confirmatory,,
614,625184,5,5,,103477782,30323,Unspecified,2811086.0,1956.0,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, EGF Receptor enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
615,625185,5,5,,103477782,30323,Unspecified,125370.0,2534.0,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, Fyn enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
616,625186,5,5,,103477782,30323,Unspecified,119533.0,2064.0,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, ERBB2 (HER2) enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
617,625187,5,5,,103477782,30323,Unspecified,125474.0,3932.0,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, LCK enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
618,625188,1,9,,103477782,30323,Unspecified,33112650.0,5788.0,,,"DRUGMATRIX: Protein Tyrosine Phosphatase, PTPRC (CD45) enzyme inhibition (substrate: DiFMUP)",Other,,
619,625189,1,7,,103477782,30323,Unspecified,,,,,"DRUGMATRIX: Purinergic P2X radioligand binding (ligand: [3H] alpha, beta-Methylene-ATP)",Other,,
620,625190,4,5,,103477782,30323,Unspecified,,,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT1A radioligand binding (ligand: [3H] 8-OH-DPAT),Confirmatory,,
621,625191,4,7,,103477782,30323,Unspecified,112815.0,25075.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT1B radioligand binding (ligand: [125I] Cyanopindolol),Confirmatory,,
622,625192,4,7,,103477782,30323,Unspecified,543727.0,3356.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Confirmatory,,
623,625193,5,5,,103477782,30323,Unspecified,113037.0,43.0,,IC50,DRUGMATRIX: Acetylcholinesterase enzyme inhibition (substrate: acetylthiocholine),Confirmatory,,
624,625194,4,7,,103477782,30323,Unspecified,231473.0,134.0,,IC50,DRUGMATRIX: Adenosine A1 radioligand binding (ligand: DPCPX),Confirmatory,,
625,625195,4,7,,103477782,30323,Unspecified,543740.0,135.0,,IC50,DRUGMATRIX: Adenosine A2A radioligand binding (ligand: AB-MECA),Confirmatory,,
626,625196,5,6,,103477782,30323,Unspecified,803374855.0,140.0,,IC50,DRUGMATRIX: Adenosine A3 radioligand binding (ligand: AB-MECA),Confirmatory,,
627,625197,3,4,,103477782,30323,Unspecified,,,,IC50,DRUGMATRIX: Sodium/nucleoside co-transporter radioligand binding (ligand: nitrobenzylthioinosine),Confirmatory,,
628,625198,4,7,,103477782,30323,Unspecified,1168247.0,29412.0,,IC50,DRUGMATRIX: Alpha-1A adrenergic receptor radioligand binding (ligand: prazosin),Confirmatory,,
629,625199,4,7,,103477782,30323,Unspecified,543734.0,24173.0,,IC50,DRUGMATRIX: Alpha-1B adrenergic receptor radioligand binding (ligand: prazosin),Confirmatory,,
630,625200,4,7,,103477782,30323,Unspecified,1168243.0,146.0,,IC50,DRUGMATRIX: Alpha-1D adrenergic receptor radioligand binding (ligand: prazosin),Confirmatory,,
631,625201,4,7,,103477782,30323,Unspecified,1351829.0,150.0,,IC50,DRUGMATRIX: Alpha-2A adrenergic receptor radioligand binding (ligand: MK-912),Confirmatory,,
632,625202,4,7,,103477782,30323,Unspecified,613504690.0,151.0,,IC50,DRUGMATRIX: Alpha-2B adrenergic receptor radioligand binding (ligand: Rauwolscine),Confirmatory,,
633,625203,4,7,,103477782,30323,Unspecified,20141211.0,152.0,,IC50,DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912),Confirmatory,,
634,625204,4,7,,103477782,30323,Unspecified,48429211.0,153.0,,IC50,DRUGMATRIX: Adrenergic beta1 radioligand binding (ligand: [125I] Cyanopindolol),Confirmatory,,
635,625205,4,7,,103477782,30323,Unspecified,296439450.0,154.0,,IC50,DRUGMATRIX: Adrenergic beta2 radioligand binding (ligand: [3H] CGP-12177),Confirmatory,,
636,625206,4,7,,103477782,30323,Unspecified,461604.0,155.0,,IC50,DRUGMATRIX: Adrenergic beta3 radioligand binding (ligand: [125I] Cyanopindolol),Confirmatory,,
637,625207,4,7,,103477782,30323,Unspecified,128616.0,6530.0,,IC50,DRUGMATRIX: Norepinephrine Transporter radioligand binding (ligand: [125I] RTI-55),Confirmatory,,
638,625208,5,5,,103477782,30323,Unspecified,1168407.0,24192.0,,IC50,DRUGMATRIX: Aldose Reductase enzyme inhibition (substrate: DL-Glyceraldehyde),Confirmatory,,
639,625209,4,7,,103477782,30323,Unspecified,1703214.0,186.0,,IC50,DRUGMATRIX: Angiotensin AT2 radioligand binding (ligand: [125I] CGP-42112A),Confirmatory,,
640,625210,3,4,,103477782,30323,Unspecified,,,,IC50,"DRUGMATRIX: ATPase, Na+/K+ enzyme inhibition (substrate: ATP)",Confirmatory,,
641,625211,1,6,,103477782,30323,Unspecified,,,,,DRUGMATRIX: Atrial Natriuretic Factor (ANF) radioligand binding (ligand: [125I] ANF (rat)),Other,,
642,625212,3,4,,103477782,30323,Unspecified,,,,IC50,DRUGMATRIX: beta-Lactamase enzyme inhibition (substrate: Nitrocefin),Confirmatory,,
643,625213,4,7,,103477782,30323,Unspecified,2506481.0,624.0,,IC50,DRUGMATRIX: Bradykinin B2 radioligand binding (ligand: [3H] Bradykinin),Confirmatory,,
644,625214,1,9,,103477782,30323,Unspecified,550544247.0,799.0,,,DRUGMATRIX: Calcitonin radioligand binding (ligand: [125I] Calcitonin (salmon)),Other,,
645,625215,3,4,,103477782,30323,Unspecified,,,,IC50,"DRUGMATRIX: Calcium Channel Type L, Benzothiazepine radioligand binding (ligand: [3H] Diltiazem)",Confirmatory,,
646,625216,3,4,,103477782,30323,Unspecified,,,,IC50,"DRUGMATRIX: Calcium Channel Type L, Dihydropyridine radioligand binding (ligand: [3H] Nitrendipine)",Confirmatory,,
647,625217,4,7,,103477782,30323,Unspecified,1168220.0,3357.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2B radioligand binding (ligand: [3H] Lysergic acid diethylamide),Confirmatory,,
648,625218,4,7,,103477782,30323,Unspecified,112816.0,3358.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2C radioligand binding (ligand: [3H] Mesulergine),Confirmatory,,
649,625219,3,4,,103477782,30323,Unspecified,,,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT3 radioligand binding (ligand: [3H] GR-65630),Confirmatory,,
650,625220,4,7,,103477782,30323,Unspecified,6224984.0,100135548.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT4 radioligand binding (ligand: [3H] GR-113808),Confirmatory,,
651,625221,4,7,,103477782,30323,Unspecified,1703010.0,3362.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT6 radioligand binding (ligand: [3H] Lysergic acid diethylamide),Confirmatory,,
652,625222,4,7,,103477782,30323,Unspecified,400630.0,6532.0,,IC50,"DRUGMATRIX: Transporter, Serotonin (5-Hydroxytryptamine) (SERT) radioligand binding (ligand: [3H] Paroxetine)",Confirmatory,,
653,625223,4,7,,103477782,30323,Unspecified,74752153.0,10280.0,,IC50,DRUGMATRIX: Sigma1 radioligand binding (ligand: [3H] Haloperidol),Confirmatory,,
654,625224,3,4,,103477782,30323,Unspecified,,,,IC50,DRUGMATRIX: Sigma2 radioligand binding (ligand: [3H] Ifenprodil),Confirmatory,,
655,625225,3,4,,103477782,30323,Unspecified,,,,IC50,"DRUGMATRIX: Sodium Channel, Site 2 radioligand binding (ligand: [3H] Batrachotoxin)",Confirmatory,,
656,625226,4,7,,103477782,30323,Unspecified,128359.0,6869.0,,IC50,DRUGMATRIX: Tachykinin NK1 radioligand binding (ligand: [3H] Substance P),Confirmatory,,
657,625227,4,7,,103477782,30323,Unspecified,229462950.0,6865.0,,IC50,DRUGMATRIX: Tachykinin NK2 radioligand binding (ligand: [3H] SR-48968),Confirmatory,,
658,625228,4,7,,103477782,30323,Unspecified,113832.0,24208.0,,IC50,DRUGMATRIX: Androgen (Testosterone) AR radioligand binding (ligand: [3H] Mibolerone),Confirmatory,,
659,625229,5,5,,103477782,30323,Unspecified,254763392.0,6916.0,,IC50,DRUGMATRIX: Thromboxane Synthetase enzyme inhibition (substrate: PGH2),Confirmatory,,
660,625230,1,6,,103477782,30323,Unspecified,,,,,"DRUGMATRIX: Tumor Necrosis Factor (TNF), Non-Selective radioligand binding (ligand: [125I] TNF-alpha)",Other,,
661,625231,4,7,,103477782,30323,Unspecified,143811474.0,2321.0,,IC50,DRUGMATRIX: Vascular Endothelial Growth Factor (VEGF) radioligand binding (ligand: [125I] VEGF),Confirmatory,,
662,625232,1,9,,103477782,30323,Unspecified,418253.0,7433.0,,,DRUGMATRIX: Vasoactive Intestinal Peptide VIP1 radioligand binding (ligand: [125I] VIP),Other,,
663,625233,4,7,,103477782,30323,Unspecified,586197.0,552.0,,IC50,DRUGMATRIX: Vasopressin V1A radioligand binding (ligand: [125I] PhenylacetylTyr(Me)PheGlnAsnArgProArgTyr),Confirmatory,,
664,625234,3,4,,103477782,30323,Unspecified,,,,IC50,"DRUGMATRIX: Calcium Channel Type L, Phenylalkylamine radioligand binding (ligand: [3H] (-)-Desmethoxyverapamil (D-888))",Confirmatory,,
665,625235,4,7,,103477782,30323,Unspecified,115562.0,1268.0,,IC50,DRUGMATRIX: Cannabinoid CB1 radioligand binding (ligand: [3H] SR141716A),Confirmatory,,
666,625236,5,5,,103477782,30323,Unspecified,115456.0,760.0,,IC50,DRUGMATRIX: Carbonic Anhydrase II enzyme inhibition (substrate: 4-Nitrophenyl acetate (4-NPA)),Confirmatory,,
667,625237,4,7,,103477782,30323,Unspecified,1168965.0,729230.0,,IC50,DRUGMATRIX: Chemokine CCR2B radioligand binding (ligand: [125I] MCP-1),Confirmatory,,
668,625238,4,7,,103477782,30323,Unspecified,1705894.0,1233.0,,IC50,DRUGMATRIX: Chemokine CCR4 radioligand binding (ligand: [125I] TARC),Confirmatory,,
669,625239,4,7,,103477782,30323,Unspecified,1705896.0,1234.0,,IC50,DRUGMATRIX: Chemokine CCR5 radioligand binding (ligand: [125I] MIP-1alpha),Confirmatory,,
670,625240,1,9,,103477782,30323,Unspecified,108936015.0,3577.0,,,DRUGMATRIX: Chemokine CXCR1 (IL-8A),Other,,
671,625241,4,7,,103477782,30323,Unspecified,1352454.0,3579.0,,IC50,DRUGMATRIX: Chemokine CXCR2 (IL-8B) radioligand binding (ligand: [125I] IL-8),Confirmatory,,
672,625242,4,7,,103477782,30323,Unspecified,416772.0,886.0,,IC50,"DRUGMATRIX: Cholecystokinin CCKA radioligand binding (ligand: [3H] L-364,718)",Confirmatory,,
673,625243,5,5,,103477782,30323,Unspecified,317373262.0,5742.0,,IC50,DRUGMATRIX: Cyclooxygenase COX-1 enzyme inhibition (substrate: Arachidonic acid),Confirmatory,,
674,625244,5,5,,103477782,30323,Unspecified,3915797.0,5743.0,,IC50,DRUGMATRIX: Cyclooxygenase COX-2 enzyme inhibition (substrate: Arachidonic acid),Confirmatory,,
675,625245,5,5,,103477782,30323,Unspecified,117144.0,1544.0,,IC50,"DRUGMATRIX: CYP450, 1A2 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
676,625246,1,9,,103477782,30323,Unspecified,308153612.0,1548.0,,,"DRUGMATRIX: CYP450, 2A6 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Other,,
677,625247,5,5,,103477782,30323,Unspecified,60416369.0,1557.0,,IC50,"DRUGMATRIX: CYP450, 2C19 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
678,625248,5,5,,103477782,30323,Unspecified,6686268.0,1559.0,,IC50,"DRUGMATRIX: CYP450, 2C9 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
679,625249,5,5,,103477782,30323,Unspecified,84028191.0,1565.0,,IC50,"DRUGMATRIX: CYP450, 2D6 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
680,625250,5,5,,103477782,30323,Unspecified,117250.0,1571.0,,IC50,"DRUGMATRIX: CYP450, 2E1 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
681,625251,5,5,,103477782,30323,Unspecified,116241312.0,1576.0,,IC50,"DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin)",Confirmatory,,
682,625252,4,7,,103477782,30323,Unspecified,118228.0,1812.0,,IC50,DRUGMATRIX: Dopamine D1 radioligand binding (ligand: [3H] SCH-23390),Confirmatory,,
683,625253,4,7,,103477782,30323,Unspecified,118206.0,1813.0,,IC50,DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone),Confirmatory,,
684,625254,4,7,,103477782,30323,Unspecified,1169206.0,1814.0,,IC50,DRUGMATRIX: Dopamine D3 radioligand binding (ligand: [3H] Spiperone),Confirmatory,,
685,625255,4,7,,103477782,30323,Unspecified,1345939.0,1815.0,,IC50,DRUGMATRIX: Dopamine D4.2 radioligand binding (ligand: [3H] Spiperone),Confirmatory,,
686,625256,4,7,,103477782,30323,Unspecified,266667.0,6531.0,,IC50,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),Confirmatory,,
687,625257,4,7,,103477782,30323,Unspecified,119606.0,1909.0,,IC50,DRUGMATRIX: Endothelin ETA radioligand binding (ligand: [125I] Endothelin-1),Confirmatory,,
688,625258,4,7,,103477782,30323,Unspecified,544257.0,2099.0,,IC50,DRUGMATRIX: Estrogen ERalpha radioligand binding (ligand: [3H] Estradiol),Confirmatory,,
689,625259,4,7,,103477782,30323,Unspecified,6166154.0,2100.0,,IC50,DRUGMATRIX: Estrogen ERbeta radioligand binding (ligand: [3H] Estradiol),Confirmatory,,
690,625260,3,4,,103477782,30323,Unspecified,,,,IC50,"DRUGMATRIX: GABAA, Muscimol, Central radioligand binding (ligand: [3H] Muscimol)",Confirmatory,,
691,625261,3,4,,103477782,30323,Unspecified,,,,IC50,"DRUGMATRIX: GABAA, Flunitrazepam, Central radioligand binding (ligand: [3H] Flunitrazepam)",Confirmatory,,
692,625262,3,4,,103477782,30323,Unspecified,,,,IC50,"DRUGMATRIX: GABAA, Chloride Channel, TBOB radioligand binding (ligand: [3H] TBOB)",Confirmatory,,
693,625263,4,7,,103477782,30323,Unspecified,121069.0,2908.0,,IC50,DRUGMATRIX: Glucocorticoid radioligand binding (ligand: [3H] Dexamethasone),Confirmatory,,
694,625264,3,4,,103477782,30323,Unspecified,,,,IC50,"DRUGMATRIX: Glutamate, AMPA radioligand binding (ligand: [3H] AMPA)",Confirmatory,,
695,625265,1,6,,103477782,30323,Unspecified,,,,,"DRUGMATRIX: Glutamate, Kainate radioligand binding (ligand: [3H] Kainic acid)",Other,,
696,625266,3,4,,103477782,30323,Unspecified,,,,IC50,"DRUGMATRIX: Glutamate, NMDA, Agonism radioligand binding (ligand: [3H] CGP-39653)",Confirmatory,,
697,625267,3,4,,103477782,30323,Unspecified,,,,IC50,"DRUGMATRIX: Glutamate, NMDA, Phencyclidine radioligand binding (ligand: [3H] TCP)",Confirmatory,,
698,625268,4,2,,103477782,30323,Unspecified,121579.0,24397.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
699,625268,4,2,,103477782,30323,Unspecified,121580.0,114516.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
700,625268,4,2,,103477782,30323,Unspecified,121604.0,25456.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
701,625268,4,2,,103477782,30323,Unspecified,12230887.0,25674.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
702,625269,4,7,,103477782,30323,Unspecified,547645.0,3269.0,,IC50,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",Confirmatory,,
703,625270,4,7,,103477782,30323,Unspecified,123120.0,3274.0,,IC50,DRUGMATRIX: Histamine H2 radioligand binding (ligand: [125I] Aminopotentidine),Confirmatory,,
704,625271,5,5,,103477782,30323,Unspecified,123343.0,3156.0,,IC50,DRUGMATRIX: HMG-CoA Reductase enzyme inhibition (substrate: [14C]HMG-CoA),Confirmatory,,
705,625272,3,4,,103477782,30323,Unspecified,,,,IC50,"DRUGMATRIX: Imidazoline I2, Central radioligand binding (ligand: [3H] Idazoxan)",Confirmatory,,
706,625273,4,6,,103477782,30323,Unspecified,124531.0,24954.0,,IC50,DRUGMATRIX: Insulin radioligand binding (ligand: [125I] Insulin),Confirmatory,,
707,625274,1,6,,103477782,30323,Unspecified,,,,,DRUGMATRIX: Interleukin IL-1 radioligand binding (ligand: [125I] interleukin 1beta),Other,,
708,625275,3,4,,103477782,30323,Unspecified,,,,IC50,"DRUGMATRIX: Leukotriene, BLT (LTB4) radioligand binding (ligand: [3H]LTB4)",Confirmatory,,
709,625279,1,3,,103477782,30323,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia,Other,22194678.0,
710,625280,1,3,,103477782,30323,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis,Other,22194678.0,
711,625281,1,3,,103477782,30323,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis,Other,22194678.0,
712,625282,1,3,,103477782,30323,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis,Other,22194678.0,
713,625283,1,3,,103477782,30323,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests,Other,22194678.0,
714,625284,1,3,,103477782,30323,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure,Other,22194678.0,
715,625285,1,3,,103477782,30323,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis,Other,22194678.0,
716,625286,1,3,,103477782,30323,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis,Other,22194678.0,
717,625287,1,3,,103477782,30323,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly,Other,22194678.0,
718,625288,1,3,,103477782,30323,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice,Other,22194678.0,
719,625289,1,3,,103477782,30323,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease,Other,22194678.0,
720,625290,1,3,,103477782,30323,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty,Other,22194678.0,
721,625291,1,3,,103477782,30323,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal,Other,22194678.0,
722,625292,1,3,,103477782,30323,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score,Other,22194678.0,
723,644953,1,3,,103477782,30323,Unspecified,,,,,Binding affinity to human pre-hsa-mir-155 miRNA assessed as inhibition of dicer-catalysed (33P)-labelled pre-miRNA processing at 1 mM after 1 hr by PAGE analysis,Other,22257890.0,
724,651548,1,1,,85788867,30323,Inactive,21361095.0,2146.0,,,EZH2/PRC2 methyltransferase inhibitors Measured in Biochemical System Using Plate Reader - 2125-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
725,651631,4,1,,144204447,30323,Active,269849759.0,7157.0,0.7498,Potency-Replicate_1,qHTS assay for small molecule agonists of the p53 signaling pathway,Confirmatory,,
726,651632,4,1,,144204447,30323,Active,296439460.0,79915.0,0.3758,Potency-Replicate_1,qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5,Confirmatory,,
727,651633,4,1,,144204447,30323,Inconclusive,,,0.0119,Potency-Replicate_1,qHTS assay for small molecule agonists of the p53 signaling pathway - cell viability,Confirmatory,,
728,651634,4,1,,144204447,30323,Active,,,9.4392,Potency-Replicate_1,qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5 - cell viability,Confirmatory,,
729,652048,1,2,,144204447,30323,Inactive,89191863.0,1814.0,,,qHTS of D3 Dopamine Receptor Agonist: qHTS,Screening,,
730,652051,1,1,,144204447,30323,Inactive,89191863.0,1814.0,,,qHTS of D3 Dopamine Receptor Potentiators: qHTS,Screening,,
731,659492,3,5,,103477782,30323,Inconclusive,2498443.0,3065.0,,IC50,Inhibition of HDAC1/2 in human HeLa cell nuclear extract using Fluor de Lys as substrate after 15 mins by fluorometric analysis,Confirmatory,22260166.0,
732,659492,3,5,,103477782,30323,Inconclusive,68068066.0,3066.0,,IC50,Inhibition of HDAC1/2 in human HeLa cell nuclear extract using Fluor de Lys as substrate after 15 mins by fluorometric analysis,Confirmatory,22260166.0,
733,659493,4,5,,103477782,30323,Inconclusive,2498443.0,3065.0,,IC50,Inhibition of HDAC1 in human HeLa cell nuclear extract using Fluor de Lys as substrate after 15 mins by fluorometric analysis,Confirmatory,22260166.0,
734,659494,4,5,,103477782,30323,Inconclusive,205371758.0,10013.0,,IC50,Inhibition of HDAC6 in human HeLa cell nuclear extract using Fluor de Lys as substrate after 15 mins by fluorometric analysis,Confirmatory,22260166.0,
735,659495,4,5,,103477782,30323,Inconclusive,29839394.0,55869.0,,IC50,Inhibition of HDAC8 in human HeLa cell nuclear extract using Fluor de Lys as substrate after 15 mins by fluorometric analysis,Confirmatory,22260166.0,
736,659633,1,5,,103477782,30323,Active,,,,,Inhibition of Topoisomerase 2 assessed as kinetoplast DNA decatenation at 50 uM after 10 mins by electrophoretic analysis,Other,22260166.0,
737,659634,2,2,,103477782,30323,Active,,,0.09,IC50,Antiproliferative activity against human DU145 cells after 72 hrs by MTS assay,Confirmatory,22260166.0,
738,659635,2,3,,103477782,30323,Active,,,0.17,IC50,Antiproliferative activity against human SKMES1 cells after 72 hrs by MTS assay,Confirmatory,22260166.0,
739,659636,2,2,,103477782,30323,Active,,,0.95,IC50,Antiproliferative activity against human MCF7 cells after 72 hrs by MTS assay,Confirmatory,22260166.0,
740,659638,1,3,,103477782,30323,Inactive,2498443.0,3065.0,,,Inhibition of HDAC in human DU145 cells assessed as upregulation of p21waf1 protein expression at 0.1 uM after 24 hrs by Western blot analysis,Other,22260166.0,
741,659638,1,3,,103477782,30323,Inactive,3334210.0,8841.0,,,Inhibition of HDAC in human DU145 cells assessed as upregulation of p21waf1 protein expression at 0.1 uM after 24 hrs by Western blot analysis,Other,22260166.0,
742,659638,1,3,,103477782,30323,Inactive,19865267.0,9734.0,,,Inhibition of HDAC in human DU145 cells assessed as upregulation of p21waf1 protein expression at 0.1 uM after 24 hrs by Western blot analysis,Other,22260166.0,
743,659638,1,3,,103477782,30323,Inactive,26394832.0,79885.0,,,Inhibition of HDAC in human DU145 cells assessed as upregulation of p21waf1 protein expression at 0.1 uM after 24 hrs by Western blot analysis,Other,22260166.0,
744,659638,1,3,,103477782,30323,Inactive,27734403.0,83933.0,,,Inhibition of HDAC in human DU145 cells assessed as upregulation of p21waf1 protein expression at 0.1 uM after 24 hrs by Western blot analysis,Other,22260166.0,
745,659638,1,3,,103477782,30323,Inactive,29839394.0,55869.0,,,Inhibition of HDAC in human DU145 cells assessed as upregulation of p21waf1 protein expression at 0.1 uM after 24 hrs by Western blot analysis,Other,22260166.0,
746,659638,1,3,,103477782,30323,Inactive,30913097.0,51564.0,,,Inhibition of HDAC in human DU145 cells assessed as upregulation of p21waf1 protein expression at 0.1 uM after 24 hrs by Western blot analysis,Other,22260166.0,
747,659638,1,3,,103477782,30323,Inactive,68068066.0,3066.0,,,Inhibition of HDAC in human DU145 cells assessed as upregulation of p21waf1 protein expression at 0.1 uM after 24 hrs by Western blot analysis,Other,22260166.0,
748,659638,1,3,,103477782,30323,Inactive,205371758.0,10013.0,,,Inhibition of HDAC in human DU145 cells assessed as upregulation of p21waf1 protein expression at 0.1 uM after 24 hrs by Western blot analysis,Other,22260166.0,
749,659638,1,3,,103477782,30323,Inactive,259016348.0,9759.0,,,Inhibition of HDAC in human DU145 cells assessed as upregulation of p21waf1 protein expression at 0.1 uM after 24 hrs by Western blot analysis,Other,22260166.0,
750,659638,1,3,,103477782,30323,Inactive,296434519.0,10014.0,,,Inhibition of HDAC in human DU145 cells assessed as upregulation of p21waf1 protein expression at 0.1 uM after 24 hrs by Western blot analysis,Other,22260166.0,
751,659642,1,4,,103477782,30323,Unspecified,2498443.0,3065.0,,,Inhibition of HDAC in human DU145 cells assessed as histone H4 acetylation after 24 hrs by Western blot analysis,Other,22260166.0,
752,659642,1,4,,103477782,30323,Unspecified,3334210.0,8841.0,,,Inhibition of HDAC in human DU145 cells assessed as histone H4 acetylation after 24 hrs by Western blot analysis,Other,22260166.0,
753,659642,1,4,,103477782,30323,Unspecified,19865267.0,9734.0,,,Inhibition of HDAC in human DU145 cells assessed as histone H4 acetylation after 24 hrs by Western blot analysis,Other,22260166.0,
754,659642,1,4,,103477782,30323,Unspecified,26394832.0,79885.0,,,Inhibition of HDAC in human DU145 cells assessed as histone H4 acetylation after 24 hrs by Western blot analysis,Other,22260166.0,
755,659642,1,4,,103477782,30323,Unspecified,27734403.0,83933.0,,,Inhibition of HDAC in human DU145 cells assessed as histone H4 acetylation after 24 hrs by Western blot analysis,Other,22260166.0,
756,659642,1,4,,103477782,30323,Unspecified,29839394.0,55869.0,,,Inhibition of HDAC in human DU145 cells assessed as histone H4 acetylation after 24 hrs by Western blot analysis,Other,22260166.0,
757,659642,1,4,,103477782,30323,Unspecified,30913097.0,51564.0,,,Inhibition of HDAC in human DU145 cells assessed as histone H4 acetylation after 24 hrs by Western blot analysis,Other,22260166.0,
758,659642,1,4,,103477782,30323,Unspecified,68068066.0,3066.0,,,Inhibition of HDAC in human DU145 cells assessed as histone H4 acetylation after 24 hrs by Western blot analysis,Other,22260166.0,
759,659642,1,4,,103477782,30323,Unspecified,205371758.0,10013.0,,,Inhibition of HDAC in human DU145 cells assessed as histone H4 acetylation after 24 hrs by Western blot analysis,Other,22260166.0,
760,659642,1,4,,103477782,30323,Unspecified,259016348.0,9759.0,,,Inhibition of HDAC in human DU145 cells assessed as histone H4 acetylation after 24 hrs by Western blot analysis,Other,22260166.0,
761,659642,1,4,,103477782,30323,Unspecified,296434519.0,10014.0,,,Inhibition of HDAC in human DU145 cells assessed as histone H4 acetylation after 24 hrs by Western blot analysis,Other,22260166.0,
762,659644,1,3,,103477782,30323,Active,2498443.0,3065.0,,,Inhibition of HDAC in human DU145 cells assessed as histone H3 hyperacetylation at 0.1 to 0.5 uM after 24 hrs by Western blot analysis,Other,22260166.0,
763,659644,1,3,,103477782,30323,Active,3334210.0,8841.0,,,Inhibition of HDAC in human DU145 cells assessed as histone H3 hyperacetylation at 0.1 to 0.5 uM after 24 hrs by Western blot analysis,Other,22260166.0,
764,659644,1,3,,103477782,30323,Active,19865267.0,9734.0,,,Inhibition of HDAC in human DU145 cells assessed as histone H3 hyperacetylation at 0.1 to 0.5 uM after 24 hrs by Western blot analysis,Other,22260166.0,
765,659644,1,3,,103477782,30323,Active,26394832.0,79885.0,,,Inhibition of HDAC in human DU145 cells assessed as histone H3 hyperacetylation at 0.1 to 0.5 uM after 24 hrs by Western blot analysis,Other,22260166.0,
766,659644,1,3,,103477782,30323,Active,27734403.0,83933.0,,,Inhibition of HDAC in human DU145 cells assessed as histone H3 hyperacetylation at 0.1 to 0.5 uM after 24 hrs by Western blot analysis,Other,22260166.0,
767,659644,1,3,,103477782,30323,Active,29839394.0,55869.0,,,Inhibition of HDAC in human DU145 cells assessed as histone H3 hyperacetylation at 0.1 to 0.5 uM after 24 hrs by Western blot analysis,Other,22260166.0,
768,659644,1,3,,103477782,30323,Active,30913097.0,51564.0,,,Inhibition of HDAC in human DU145 cells assessed as histone H3 hyperacetylation at 0.1 to 0.5 uM after 24 hrs by Western blot analysis,Other,22260166.0,
769,659644,1,3,,103477782,30323,Active,68068066.0,3066.0,,,Inhibition of HDAC in human DU145 cells assessed as histone H3 hyperacetylation at 0.1 to 0.5 uM after 24 hrs by Western blot analysis,Other,22260166.0,
770,659644,1,3,,103477782,30323,Active,205371758.0,10013.0,,,Inhibition of HDAC in human DU145 cells assessed as histone H3 hyperacetylation at 0.1 to 0.5 uM after 24 hrs by Western blot analysis,Other,22260166.0,
771,659644,1,3,,103477782,30323,Active,259016348.0,9759.0,,,Inhibition of HDAC in human DU145 cells assessed as histone H3 hyperacetylation at 0.1 to 0.5 uM after 24 hrs by Western blot analysis,Other,22260166.0,
772,659644,1,3,,103477782,30323,Active,296434519.0,10014.0,,,Inhibition of HDAC in human DU145 cells assessed as histone H3 hyperacetylation at 0.1 to 0.5 uM after 24 hrs by Western blot analysis,Other,22260166.0,
773,659646,1,8,,103477782,30323,Inactive,205371758.0,10013.0,,,Inhibition of HDAC6-mediated tubulin acetylation in human DU145 cells at 90 nM after 4 hrs by Western blot analysis,Other,22260166.0,
774,659647,1,8,,103477782,30323,Active,205371758.0,10013.0,,,Inhibition of HDAC6-mediated tubulin acetylation in human DU145 cells at 500 nM after 4 hrs by Western blot analysis,Other,22260166.0,
775,659650,1,2,,103477782,30323,Inactive,,,,,Inhibition of HDAC in human DU145 cells assessed as upregulation of p21 expression at IC50 concentration after 4 hrs by Western blot analysis relative to control,Other,22260166.0,
776,659651,1,2,,103477782,30323,Inactive,,,,,Inhibition of HDAC in human DU145 cells assessed as upregulation of p21 expression at 5 times IC50 concentration after 4 hrs by Western blot analysis relative to control,Other,22260166.0,
777,659652,1,8,,103477782,30323,Active,13959709.0,7153.0,,,Inhibition of topoisomerase 2 in human DU145 cells assessed as stabilization of enzyme-DNA cleavage complex at 90 nM after 30 mins by immunoblot analysis,Other,22260166.0,
778,659655,1,8,,103477782,30323,Active,13959709.0,7153.0,,,Inhibition of topoisomerase 2 in human DU145 cells assessed as stabilization of enzyme-DNA cleavage complex at 90 nM after 72 hrs by immunoblot analysis,Other,22260166.0,
779,659658,1,2,,103477782,30323,Active,,,,,Drug uptake in human DU145 cell nucleus at 1 uM after 4 hrs by confocal microscopic analysis,Other,22260166.0,
780,659659,1,2,,103477782,30323,Active,,,,,Drug uptake in human DU145 cell perinuclear region at 1 uM after 4 hrs by confocal microscopic analysis,Other,22260166.0,
781,659662,1,2,,103477782,30323,Active,,,,,Drug uptake in human A549 cell nucleus at 1 uM after 4 hrs by confocal microscopic analysis,Other,22260166.0,
782,659663,1,2,,103477782,30323,Active,,,,,Drug uptake in human A549 cell perinuclear region at 1 uM after 4 hrs by confocal microscopic analysis,Other,22260166.0,
783,659911,1,5,,103477782,30323,Unspecified,,,,,Antiproliferative activity against human MONO-MAC-6 cells assessed as cell viability at 10'-7 M after 24 hrs by cell counting method relative to untreated control,Other,22480495.0,
784,659913,1,5,,103477782,30323,Unspecified,,,,,Antiproliferative activity against human MONO-MAC-6 cells assessed as inhibition of cell viability at 10'-9 M after 24 hrs by cell counting method,Other,22480495.0,
785,659914,2,2,,103477782,30323,Active,,,0.4,IC50,Cytostatic activity against human MCF7 cells after 4 days by MTT assay,Confirmatory,22480495.0,
786,659915,2,2,,103477782,30323,Active,,,0.1,IC50,Cytostatic activity against human LNCAP cells after 4 days by MTT assay,Confirmatory,22480495.0,
787,659916,2,2,,103477782,30323,Active,,,0.2,IC50,Cytostatic activity against human HT-29 cells after 4 days by MTT assay,Confirmatory,22480495.0,
788,659917,1,5,,103477782,30323,Unspecified,,,,,Antiproliferative activity against human MONO-MAC-6 cells assessed as inhibition of cell viability at 10'-9 M after 48 hrs by cell counting method,Other,22480495.0,
789,659918,1,5,,103477782,30323,Unspecified,,,,,Antiproliferative activity against human MONO-MAC-6 cells assessed as inhibition of cell viability at 10'-9 M after 72 hrs by cell counting method,Other,22480495.0,
790,659919,1,5,,103477782,30323,Unspecified,,,,,Antiproliferative activity against human MONO-MAC-6 cells assessed as inhibition of cell viability at 10'-8 M after 24 hrs by cell counting method,Other,22480495.0,
791,659920,1,5,,103477782,30323,Unspecified,,,,,Antiproliferative activity against human MONO-MAC-6 cells assessed as inhibition of cell viability at 10'-8 M after 48 hrs by cell counting method,Other,22480495.0,
792,659921,1,5,,103477782,30323,Unspecified,,,,,Antiproliferative activity against human MONO-MAC-6 cells assessed as inhibition of cell viability at 10'-8 M after 72 hrs by cell counting method,Other,22480495.0,
793,659922,1,5,,103477782,30323,Unspecified,,,,,Antiproliferative activity against human MONO-MAC-6 cells assessed as inhibition of cell viability at 10'-7 M after 24 hrs by cell counting method,Other,22480495.0,
794,659923,1,5,,103477782,30323,Unspecified,,,,,Antiproliferative activity against human MONO-MAC-6 cells assessed as inhibition of cell viability at 10'-7 M after 48 hrs by cell counting method,Other,22480495.0,
795,659924,1,5,,103477782,30323,Unspecified,,,,,Antiproliferative activity against human MONO-MAC-6 cells assessed as inhibition of cell viability at 10'-7 M after 72 hrs by cell counting method,Other,22480495.0,
796,659925,1,5,,103477782,30323,Unspecified,,,,,Antiproliferative activity against human MONO-MAC-6 cells assessed as inhibition of cell viability at 10'-6 M after 24 hrs by cell counting method,Other,22480495.0,
797,659926,1,5,,103477782,30323,Unspecified,,,,,Antiproliferative activity against human MONO-MAC-6 cells assessed as inhibition of cell viability at 10'-6 M after 48 hrs by cell counting method,Other,22480495.0,
798,659927,1,5,,103477782,30323,Unspecified,,,,,Antiproliferative activity against human MONO-MAC-6 cells assessed as inhibition of cell viability at 10'-6 M after 72 hrs by cell counting method,Other,22480495.0,
799,659929,1,5,,103477782,30323,Unspecified,,,,,Antiproliferative activity against human MONO-MAC-6 cells assessed as cell viability at 10'-9 to 10'-6 M after 48 hrs by cell counting method relative to untreated control,Other,22480495.0,
800,659932,1,5,,103477782,30323,Unspecified,,,,,Antiproliferative activity against human MONO-MAC-6 cells assessed as cell viability at 10'-9 to 10'-6 M after 72 hrs by cell counting method relative to untreated control,Other,22480495.0,
801,659939,1,5,,103477782,30323,Unspecified,,,,,Induction of adhesion in human MONO-MAC-6 cells at 10'-8 to 10'-6 M after 24 hrs by electrical impedence method relative to control,Other,22480495.0,
802,659940,1,5,,103477782,30323,Unspecified,,,,,Induction of adhesion in human MONO-MAC-6 cells at 10'-7 M after 1.5 hrs by electrical impedence method relative to control,Other,22480495.0,
803,660074,1,4,,103477782,30323,Unspecified,,,,,Antitumor activity against mouse C26 cells allografted in Balb/C mouse assessed as tumor growth inhibition,Other,22480495.0,
804,678783,1,8,,103477782,30323,Unspecified,269849624.0,368.0,,,TP_TRANSPORTER: drug resistance in MRP6-expressing CHO cells,Other,12414644.0,
805,678804,1,8,,103477782,30323,Unspecified,67462103.0,9429.0,,,TP_TRANSPORTER: ATP hydrolysis in membrane vesicle from BCRP-expressing Sf9 cells,Other,11437380.0,
806,678933,1,9,,103477782,30323,Unspecified,126927.0,18669.0,,,TP_TRANSPORTER: increase in brain concentration in mdr1a/1b(-/-) mouse,Other,11785684.0,
807,678933,1,9,,103477782,30323,Unspecified,239938877.0,18671.0,,,TP_TRANSPORTER: increase in brain concentration in mdr1a/1b(-/-) mouse,Other,11785684.0,
808,678963,1,8,,103477782,30323,Unspecified,67462103.0,9429.0,,,TP_TRANSPORTER: uptake in BCRP-expressing oocyte cells,Other,14645676.0,
809,679010,3,6,,103477782,30323,Unspecified,296439301.0,4363.0,0.07,Ki,TP_TRANSPORTER: inhibition of LTC4 uptake in membrane vesicles from SR3A cells,Confirmatory,9647783.0,
810,679011,3,6,,103477782,30323,Unspecified,296439301.0,4363.0,8.0,IC50,TP_TRANSPORTER: inhibition of E217betaG uptake (E217betaG: 0.05 uM) in membrane vesicle from MRP1-expressing HeLa cells,Confirmatory,8621644.0,
811,679076,1,8,,103477782,30323,Unspecified,238054374.0,5243.0,,,TP_TRANSPORTER: transepithelial transport of Rhodamine 123 in the presence of Daunorubicin (Daunomycin) at a concentration of 80uM in MDR1-expressing MDCK cells,Other,15067695.0,
812,679089,1,8,,103477782,30323,Unspecified,238054374.0,5243.0,,,TP_TRANSPORTER: transepithelial transport of Hoechst 33342 in the presence of Daunorubicin (Daunomycin) at a concentration of 80uM in MDR1-expressing MDCK cells,Other,15067695.0,
813,679243,1,8,,103477782,30323,Unspecified,238054374.0,5243.0,,,TP_TRANSPORTER: transepithelial transport (basal to apical) in MDR1-expressing LLC-PK1 cells,Other,10746169.0,
814,679275,1,9,,103477782,30323,Unspecified,238054374.0,5243.0,,,TP_TRANSPORTER: transepithelial transport (apical to basal) of Daunorubicin (Daunomycin) at a concentration of 200 nM in MDR1-expressing LLC-PK1 cells,Other,11785684.0,
815,679292,2,7,,103477782,30323,Unspecified,81872789.0,29503.0,,Km,TP_TRANSPORTER: uptake (apical to cell) in OCT2-expressing NIH3T3 cells,Confirmatory,10220855.0,
816,679495,1,8,,103477782,30323,Unspecified,52783101.0,17250.0,,,TP_TRANSPORTER: efflux in Mrp1-expressing HEK293 cells,Other,9281595.0,
817,679990,1,8,,103477782,30323,Unspecified,296439301.0,4363.0,,,TP_TRANSPORTER: growth inhibition in hMRP1-expressing tobacco,Other,16830181.0,
818,680082,1,8,,103477782,30323,Unspecified,238054374.0,5243.0,,,"TP_TRANSPORTER: inhibition of Azidopine photoaffinity labelling (Azidopine: 0.4 uM, Daunorubicin: 400 uM) in membranes from MDR1-expressing LLC-PK1 cells",Other,10746169.0,
819,680879,1,8,,103477782,30323,Unspecified,1170902.0,24646.0,,,"TP_TRANSPORTER: RNase protection assay in vitro, rat hepatoma H-4-II-E cells",Other,9624121.0,
820,681098,1,8,,103477782,30323,Unspecified,296439301.0,4363.0,,,"TP_TRANSPORTER: inhibition of LTC4 uptake(LTC4: 0.05 uM, Daunorubicin: 30 uM) in membrane vesicles from SR3A cells",Other,9647783.0,
821,681111,3,6,,103477782,30323,Unspecified,296439301.0,4363.0,0.95,Ki,TP_TRANSPORTER: inhibition of DNP-SG uptake in membrane vesicles from GLC4/ADR cells,Confirmatory,9188796.0,
822,681121,1,8,,103477782,30323,Unspecified,238054374.0,5243.0,,,TP_TRANSPORTER: inhibition of Calcein-AM efflux in MDR1-expressing MDCKII cells,Other,11602674.0,
823,681132,1,8,,103477782,30323,Unspecified,238054374.0,5243.0,,,TP_TRANSPORTER: ATP hydrolysis in MDR1-expressing Sf9 cells,Other,11602674.0,
824,681148,1,7,,103477782,30323,Unspecified,262527527.0,8647.0,,,TP_TRANSPORTER: inhibitory effect of typical BSEP inhibitors (Verapamil & Cyclosporin A) in SK-E2 cells (expressing BSEP),Other,12739759.0,
825,681164,2,8,,103477782,30323,Unspecified,238054374.0,5243.0,1.74,Km,TP_TRANSPORTER: ATP hydrolysis in membrane fraction from High Five (BTI-TN5B1-4) cells,Confirmatory,11785684.0,
826,681170,1,8,,103477782,30323,Unspecified,52783101.0,17250.0,,,TP_TRANSPORTER: drug resistance in MRP1-expressing HEK293 cells,Other,12867490.0,
827,681356,3,6,,103477782,30323,Unspecified,238054374.0,5243.0,111.0,Ki,TP_TRANSPORTER: inhibition of Digoxin transepithelial transport (basal to apical) in MDR1-expressing MDCK cells,Confirmatory,12134945.0,
828,681383,3,6,,103477782,30323,Unspecified,238054374.0,5243.0,2.5,Ki,TP_TRANSPORTER: inhibition of Taxol transepithelial transport (basal to apical) in Caco-2 cells,Confirmatory,11405287.0,
829,681510,2,7,,103477782,30323,Unspecified,296439301.0,4363.0,1.4,Km,TP_TRANSPORTER: efflux in GLC4/ADR cells,Confirmatory,7945406.0,
830,681566,2,7,,103477782,30323,Unspecified,338817847.0,27413.0,,Km,TP_TRANSPORTER: intracellular accumulation in Bsep-expressing LLC-PK1 cells,Confirmatory,10617675.0,
831,681588,1,8,,103477782,30323,Unspecified,67462103.0,9429.0,,,TP_TRANSPORTER: ATPase assay in membrane vesicle from BCRP-expressing Lactococcus lactis cells,Other,12668685.0,
832,681596,3,6,,103477782,30323,Unspecified,308153583.0,1244.0,49.4,Ki,TP_TRANSPORTER: inhibition of Vinblastine transepithelial transport (basal to apical) in MRP2-expressing MDCK cells,Confirmatory,12134946.0,
833,681609,1,8,,103477782,30323,Unspecified,296439301.0,4363.0,,,TP_TRANSPORTER: drug resistance in MRP1-expressing PEAKSTABEL cells,Other,12657726.0,
834,681613,2,7,,103477782,30323,Unspecified,238054374.0,5243.0,,Km,TP_TRANSPORTER: intracellular accumulation in MDR1-expressing LLC-PK1 cells,Confirmatory,10617675.0,
835,683863,1,7,,103477782,30323,Unspecified,13959709.0,7153.0,,,Inhibition of human topoisomerase 2-mediated [3H]TdR-labeled catenated kinetoplast DNA decatenation after 15 to 30 mins by scintillation counting,Other,22944121.0,
836,685500,2,2,,103477782,30323,Active,,,9.12,IC50,HARVARD: Cytotoxicity in HepG2 cell line,Confirmatory,22586124.0,
837,685501,2,2,,103477782,30323,Active,,,2.99,IC50,HARVARD: Inhibition of liver stage Plasmodium berghei infection in HepG2 cells,Confirmatory,22586124.0,
838,685502,2,2,,103477782,30323,Active,,,0.34,IC50,HARVARD: Inhibition of blood stage Plasmodium falciparum 3D7 infection,Confirmatory,22586124.0,
839,685503,2,2,,103477782,30323,Active,,,0.155,IC50,HARVARD: Inhibition of blood stage Plasmodium falciparum Dd2 infection,Confirmatory,22586124.0,
840,686977,2,1,,49699346,30323,Inactive,9657203.0,2615631.0,,IC50,Vibrio cholerae assay for pro-quorum sensing small molecules,Confirmatory,,
841,686978,1,1,,11114094,30323,Active,79154014.0,55775.0,0.0376,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in absence of CPT,Confirmatory,,
842,686978,1,1,,144204447,30323,Active,79154014.0,55775.0,0.0266,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in absence of CPT,Confirmatory,,
843,686979,1,1,,11114094,30323,Active,79154014.0,55775.0,0.0237,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in presence of CPT,Confirmatory,,
844,686979,1,1,,144204447,30323,Active,79154014.0,55775.0,0.0211,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in presence of CPT,Confirmatory,,
845,688705,2,2,,103477782,30323,Active,,,26.9,IC50,Cytotoxicity against PMA-stimulated human THP1 cells after 72 hrs by MTT assay,Confirmatory,22939695.0,
846,688707,2,2,,103477782,30323,Unspecified,,,179.8,IC50,Antileishmanial activity against promastigotes of multidrug-resistant Leishmania tropica after 72 hrs by MTT assay,Confirmatory,22939695.0,
847,688708,2,2,,103477782,30323,Active,,,2.8,IC50,Antileishmanial activity against promastigotes of wild type Leishmania tropica LRC after 72 hrs by MTT assay,Confirmatory,22939695.0,
848,688711,1,2,,103477782,30323,Unspecified,,,,,Resistance ratio of IC50 for multidrug-resistant Leishmania tropica and IC50 for wild type Leishmania tropica LRC,Other,22939695.0,
849,695925,2,2,,103477782,30323,Unspecified,,,139.0,IC50,Inhibition of HIV-1 reverse transcriptase using Poly(rA).p(dT) (12 to 18) as substrate after 30 mins by single point PCR assay,Confirmatory,22695131.0,
850,704301,1,7,,103477782,30323,Unspecified,113600.0,10327.0,,,Activity of human AKR1A1 expressed in Escherichia coli BL21 assessed per mg protein in presence of 0.2 mM NADPH,Other,22982121.0,
851,704302,2,8,,103477782,30323,Unspecified,118519.0,873.0,,Km,Activity of human recombinant His6-tagged carbonyl reductase 1 expressed in Escherichia coli BL21(DE3) using menadione as substrate by Michaelis-Menten plot analysis,Confirmatory,22982121.0,
852,704305,2,8,,103477782,30323,Unspecified,118519.0,873.0,,Km,Activity of human carbonyl reductase 1,Confirmatory,22982121.0,
853,704306,1,7,,103477782,30323,Unspecified,113600.0,10327.0,,,Ratio of Vmax to Km for human aldo-keto reductase 1A1,Other,22982121.0,
854,704307,1,8,,103477782,30323,Unspecified,118519.0,873.0,,,Ratio of Vmax to Km for human carbonyl reductase 1,Other,22982121.0,
855,718074,5,1,,103477782,30323,Unspecified,,,,,Binding affinity to calf thymus DNA assessed as binding constant by spectrofluorimetry based McGhee von Hippel method,Other,23122936.0,
856,720516,2,1,,144204447,30323,Active,296439460.0,79915.0,0.5108189999999999,ATAD5 Potency (uM),qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5: Summary,Summary,,
857,720532,1,1,,11114094,30323,Inconclusive,420597.0,,3.1623,Potency,qHTS for Inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
858,720532,1,1,,144204447,30323,Inconclusive,420597.0,,0.8913,Potency,qHTS for Inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
859,720533,1,1,,11114094,30323,Active,,,35.4813,Potency,qHTS for Inhibitors of binding or entry into cells for Lassa Virus,Confirmatory,,
860,720533,1,1,,144204447,30323,Inactive,,,,Potency,qHTS for Inhibitors of binding or entry into cells for Lassa Virus,Confirmatory,,
861,720552,2,1,,144204447,30323,Active,269849759.0,7157.0,1.02904,Ratio Potency (uM),qHTS assay for small molecule agonists of the p53 signaling pathway: Summary,Summary,,
862,720634,2,1,,144204447,30323,Inactive,,,0.9439,Potency-Replicate_1,qHTS assay for small molecule disruptors of the mitochondrial membrane potential - cell viability,Confirmatory,,
863,720635,2,1,,144204447,30323,Active,,,1.496,Potency-Replicate_1,qHTS assay for small molecule disruptors of the mitochondrial membrane potential,Confirmatory,,
864,720637,2,1,,144204447,30323,Active,,,1.88336,Ratio Potency (uM),qHTS assay for small molecule disruptors of the mitochondrial membrane potential: Summary,Summary,,
865,720641,1,2,,92307396,30323,Inactive,15923709.0,,,,A screen for compounds that inhibit the activity of LtaS in Staphylococcus aureus,Other,,
866,720641,1,2,,92308820,30323,Inactive,15923709.0,,,,A screen for compounds that inhibit the activity of LtaS in Staphylococcus aureus,Other,,
867,720674,2,2,,144204447,30323,Inconclusive,,,11.2202,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HepG2 cells,Confirmatory,,
868,720675,2,2,,144204447,30323,Inconclusive,,,12.5893,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HepG2 cells,Confirmatory,,
869,720678,2,1,,144204447,30323,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HEK293 cells,Confirmatory,,
870,720679,2,1,,144204447,30323,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HEK293 cells,Confirmatory,,
871,720680,2,1,,144204447,30323,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HEK293 cells,Confirmatory,,
872,720681,2,1,,144204447,30323,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HEK293 cell free culture,Confirmatory,,
873,720682,2,1,,144204447,30323,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HEK293 cell free culture,Confirmatory,,
874,720683,2,1,,144204447,30323,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HEK293 cell free culture,Confirmatory,,
875,720684,2,1,,144204447,30323,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HepG2 cell free culture,Confirmatory,,
876,720685,2,1,,144204447,30323,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HepG2 cell free culture,Confirmatory,,
877,720686,2,1,,144204447,30323,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HepG2 cell free culture,Confirmatory,,
878,720687,2,2,,144204447,30323,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HepG2 cells,Confirmatory,,
879,720691,4,1,,144204447,30323,Active,311348376.0,2908.0,3.0107,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the glucocorticoid receptor (GR) signaling pathway,Confirmatory,,
880,720692,3,1,,144204447,30323,Inconclusive,311348376.0,2908.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway,Confirmatory,,
881,720693,3,1,,144204447,30323,Active,,,7.5624,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway - cell viability counter screen,Confirmatory,,
882,720717,1,3,,92308820,30323,Active,1718329.0,,,,Chemical Probes of Kaposi's Sarcoma Herpes Virus Latent Infection,Other,,
883,720719,2,1,,144204447,30323,Active,311348376.0,2908.0,0.7003689999999999,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the glucocorticoid receptor (GR) signaling pathway: Summary,Summary,,
884,720725,2,1,,144204447,30323,Inconclusive,311348376.0,2908.0,,,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway: Summary,Summary,,
885,726430,1,2,,103477782,30323,Unspecified,,,,,Ratio of IC50 for mouse L5178Y cells expressing p-gp to IC50 for mouse L5178Y cells,Other,23199479.0,
886,726432,1,2,,103477782,30323,Active,,,7.73,IC50,Cytotoxicity against mouse L5178Y cells expressing p-gp after 24 hrs by MTT assay,Confirmatory,23199479.0,
887,726433,1,2,,103477782,30323,Active,,,0.73,IC50,Cytotoxicity against mouse L5178Y cells after 24 hrs by MTT assay,Confirmatory,23199479.0,
888,731870,1,3,,103477782,30323,Unspecified,,,,,Cellular uptake in mouse DA-3 cell lysosome at 10 uM after 30 mins by LysoTracker green staining-based confocal microscopic analysis relative to control,Other,24900668.0,
889,731872,1,3,,103477782,30323,Inactive,,,,,Cellular uptake in mouse DA-3 cell nucleus at 10 uM after 30 mins by DRAQ5 deep red staining-based confocal microscopic analysis relative to control,Other,24900668.0,
890,731876,1,3,,103477782,30323,Active,,,0.14,IC50,Displacement of SYBR from phage lambda DNA by FID assay,Confirmatory,24900668.0,
891,731877,1,3,,103477782,30323,Active,,,0.84,IC50,Displacement of YOYO1 from phage lambda DNA by FID assay,Confirmatory,24900668.0,
892,731879,1,3,,103477782,30323,Active,,,,,Cytotoxicity against mouse DA-3 cells assessed as reduction in cell viability at 20 uM after 60 mins by XTT assay,Other,24900668.0,
893,731881,1,3,,103477782,30323,Unspecified,,,,,Cytotoxicity against mouse DA-3 cells assessed as reduction in cell viability at 20 uM after 180 mins by XTT assay relative to control,Other,24900668.0,
894,731882,1,3,,103477782,30323,Active,,,25.5,IC50,Cytotoxicity against human ES2 cells after 24 hrs by XTT assay,Confirmatory,24900668.0,
895,731883,1,3,,103477782,30323,Active,,,1.9,IC50,Cytotoxicity against mouse DA-3 cells after 24 hrs by XTT assay,Confirmatory,24900668.0,
896,731884,1,4,,103477782,30323,Active,,,20.6,IC50,Cytotoxicity against human SKOV3 cells after 24 hrs by XTT assay,Confirmatory,24900668.0,
897,731885,1,3,,103477782,30323,Active,,,33.9,IC50,Cytotoxicity against human MCF7 cells after 24 hrs by XTT assay,Confirmatory,24900668.0,
898,743012,3,1,,144204447,30323,Active,,,0.0237,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - wild type cell line,Confirmatory,,
899,743014,3,1,,144204447,30323,Active,,,0.0376,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - Rev3 mutant cell line,Confirmatory,,
900,743015,3,1,,144204447,30323,Active,,,0.0106,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - Rad54/Ku70 mutant cell line,Confirmatory,,
901,743033,3,1,,144204447,30323,Inconclusive,,,1.0682,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway - cell viability counter screen,Confirmatory,,
902,743035,2,1,,144204447,30323,Active,124375976.0,367.0,2.1314,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway,Confirmatory,,
903,743036,2,1,,144204447,30323,Active,124375976.0,367.0,0.9521,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway,Confirmatory,,
904,743040,3,1,,144204447,30323,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen  receptor (AR) signaling pathway using the MDA cell line,Confirmatory,,
905,743041,3,1,,144204447,30323,Inconclusive,,,17.5507,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway using the MDA cell line - cell viability counter screen,Confirmatory,,
906,743042,3,1,,144204447,30323,Active,124375976.0,367.0,14.9601,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway using the MDA cell line,Confirmatory,,
907,743053,2,1,,144204447,30323,Active,124375976.0,367.0,0.952052,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway: Summary,Summary,,
908,743054,2,1,,144204447,30323,Inconclusive,124375976.0,367.0,1.74422,AR Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line: Summary,Summary,,
909,743063,2,1,,144204447,30323,Inconclusive,124375976.0,367.0,3.3780099999999997,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway: Summary,Summary,,
910,743064,3,1,,144204447,30323,Active,,,1.0591,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway - cell viability counter screen,Confirmatory,,
911,743065,3,1,,144204447,30323,Active,399498506.0,24831.0,0.5956,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway,Confirmatory,,
912,743066,3,1,,144204447,30323,Inconclusive,399498506.0,24831.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the thyroid receptor (TR) signaling pathway,Confirmatory,,
913,743067,2,1,,144204447,30323,Inconclusive,399498506.0,24831.0,0.618872,TR Potency (uM),qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway: Summary,Summary,,
914,743069,2,1,,144204447,30323,Active,348019627.0,2099.0,8.4852,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway,Confirmatory,,
915,743074,2,1,,144204447,30323,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway - cell viability counter screen,Confirmatory,,
916,743075,2,1,,144204447,30323,Active,348019627.0,2099.0,0.4772,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway,Confirmatory,,
917,743077,2,1,,144204447,30323,Active,348019627.0,2099.0,0.47668900000000003,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway: Summary,Summary,,
918,743078,2,1,,144204447,30323,Active,348019627.0,2099.0,7.5624199999999995,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway: Summary,Summary,,
919,743079,3,1,,144204447,30323,Active,348019627.0,2099.0,0.5308,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line,Confirmatory,,
920,743080,3,1,,144204447,30323,Inconclusive,348019627.0,2099.0,2.6603,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line,Confirmatory,,
921,743081,3,1,,144204447,30323,Active,,,21.1317,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line - cell viability counter screen,Confirmatory,,
922,743083,3,1,,144204447,30323,Active,119597822.0,1588.0,3.7578,Potency-Replicate_1,qHTS assay to identify aromatase inhibitors,Confirmatory,,
923,743084,3,1,,144204447,30323,Active,,,10.5909,Potency-Replicate_1,qHTS assay to identify aromatase inhibitors - cell viability counter screen,Confirmatory,,
924,743085,3,1,,144204447,30323,Inconclusive,51095037.0,196.0,14.9601,Potency-Replicate_1,qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway,Confirmatory,,
925,743086,3,1,,144204447,30323,Active,,,5.9557,Potency-Replicate_1,qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway - cell viability counter screen,Confirmatory,,
926,743091,2,1,,144204447,30323,Inconclusive,348019627.0,2099.0,2.66032,ER Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line: Summary,Summary,,
927,743094,3,1,,144204447,30323,Inconclusive,216409692.0,5468.0,4.7716,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway,Confirmatory,,
928,743122,2,1,,144204447,30323,Inconclusive,51095037.0,196.0,2.66032,AhR Potency (uM),qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway: Summary,Summary,,
929,743139,2,1,,144204447,30323,Active,119597822.0,1588.0,,,qHTS assay to identify aromatase inhibitors: Summary,Summary,,
930,743140,2,1,,144204447,30323,Inconclusive,216409692.0,5468.0,6.24205,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway: Summary,Summary,,
931,743191,3,1,,170465048,30323,Inconclusive,216409692.0,5468.0,0.1496,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway,Confirmatory,,
932,743194,3,1,,170465048,30323,Active,,,33.4889,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway - cell viability counter screen,Confirmatory,,
933,743199,2,1,,170465048,30323,Active,216409692.0,5468.0,,,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway: Summary,Summary,,
934,743202,4,1,,170465048,30323,Inconclusive,20149576.0,4780.0,26.6011,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway,Confirmatory,,
935,743203,3,1,,170465048,30323,Active,,,13.3322,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway - cell viability counter screen,Confirmatory,,
936,743209,3,1,,170465048,30323,Inconclusive,,,1.1882,Potency-Replicate_1,qHTS assay for small molecule activators of the heat shock response signaling pathway - cell viability counter screen,Confirmatory,,
937,743210,4,1,,170465048,30323,Inconclusive,4504517.0,3315.0,,Potency-Replicate_1,qHTS assay for small molecule activators of the heat shock response signaling pathway,Confirmatory,,
938,743211,3,1,,170465048,30323,Active,,,33.4889,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway - cell viability counter screen,Confirmatory,,
939,743212,3,1,,170465048,30323,Inconclusive,216409690.0,5467.0,0.1333,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway,Confirmatory,,
940,743213,3,1,,170465048,30323,Inconclusive,,,33.4889,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway - cell viability counter screen,Confirmatory,,
941,743215,3,1,,170465048,30323,Inconclusive,216409690.0,5467.0,0.7497,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway,Confirmatory,,
942,743217,3,1,,170465048,30323,Active,325495553.0,9971.0,3.3489,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway,Confirmatory,,
943,743218,3,1,,170465048,30323,Active,,,0.0024,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway - cell viability counter screen,Confirmatory,,
944,743219,3,1,,170465048,30323,Inconclusive,20149576.0,4780.0,,Ratio Potency (uM),qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway: Summary,Summary,,
945,743220,3,1,,170465048,30323,Inconclusive,325495553.0,9971.0,1.0590000000000002,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway,Confirmatory,,
946,743221,3,1,,170465048,30323,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway - cell viability counter screen,Confirmatory,,
947,743222,3,1,,170465048,30323,Inconclusive,216409708.0,7421.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway,Confirmatory,,
948,743223,3,1,,170465048,30323,Inconclusive,216409708.0,7421.0,1.8996,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway,Confirmatory,,
949,743224,3,1,,170465048,30323,Inconclusive,,,0.2371,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway - cell viability counter screen,Confirmatory,,
950,743225,3,1,,170465048,30323,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway - cell viability counter screen,Confirmatory,,
951,743226,2,1,,170465048,30323,Active,216409690.0,5467.0,,,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway: Summary,Summary,,
952,743227,2,1,,170465048,30323,Inactive,216409690.0,5467.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway: Summary,Summary,,
953,743228,3,1,,170465048,30323,Inactive,4504517.0,3315.0,,Ratio Potency (uM),qHTS assay for small molecule activators of the heat shock response signaling pathway: Summary,Summary,,
954,743239,2,1,,170465048,30323,Inconclusive,325495553.0,9971.0,2.66011,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway: Summary,Summary,,
955,743240,2,1,,170465048,30323,Active,325495553.0,9971.0,,,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway: Summary,Summary,,
956,743241,2,1,,170465048,30323,Inactive,216409708.0,7421.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway: Summary,Summary,,
957,743242,2,1,,170465048,30323,Active,216409708.0,7421.0,,,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway: Summary,Summary,,
958,743244,1,1,,144204447,30323,Active,,,6.3096,Potency,qHTS Assay for Identifying Gametocytocidal Compounds,Confirmatory,,
959,748704,1,1,,103477782,30323,Active,,,,,Induction of tau K19 (unknown origin) disaggregation assessed as decrease in paired helical filament formation measured disassembly-inducing half maxima after 10 days by thioflavin S fluorescence assay in presence of heparin,Other,23484434.0,
960,748708,1,1,,103477782,30323,Active,,,1.1,IC50,Inhibition of tau K19 (unknown origin) aggregation assessed as inhibition of paired helical filament formation after 10 days by thioflavin S fluorescence assay in presence of heparin,Confirmatory,23484434.0,
961,927797,1,3,,103477782,30323,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: R070710,Other,,
962,927798,1,3,,103477782,30323,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: R070710,Other,,
963,927799,1,3,,103477782,30323,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: R070710,Other,,
964,927800,1,3,,103477782,30323,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: R070710,Other,,
965,927801,1,3,,103477782,30323,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: R070710,Other,,
966,927802,1,3,,103477782,30323,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: LYM (Lymphocytes); Study_ID: R070710,Other,,
967,927803,1,3,,103477782,30323,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: R070710,Other,,
968,927804,1,3,,103477782,30323,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: R070710,Other,,
969,927805,1,3,,103477782,30323,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: R070710,Other,,
970,927806,1,3,,103477782,30323,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: R070710,Other,,
971,927807,1,3,,103477782,30323,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: R070710,Other,,
972,927808,1,3,,103477782,30323,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: BASO (Basophils); Study_ID: R070710,Other,,
973,927809,1,3,,103477782,30323,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: EOS (Eosinophils); Study_ID: R070710,Other,,
974,927810,1,3,,103477782,30323,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: MONO (Monocytes); Study_ID: R070710,Other,,
975,927811,1,3,,103477782,30323,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: R070710,Other,,
976,927812,1,3,,103477782,30323,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: R070710,Other,,
977,927813,1,3,,103477782,30323,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: R070710,Other,,
978,941338,1,3,,103477782,30323,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: EOS (Eosinophils); Study_ID: R070710,Other,,
979,941339,1,3,,103477782,30323,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: R070710,Other,,
980,941340,1,3,,103477782,30323,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: R070710,Other,,
981,941341,1,3,,103477782,30323,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: R070710,Other,,
982,941342,1,3,,103477782,30323,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: R070710,Other,,
983,941343,1,3,,103477782,30323,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: R070710,Other,,
984,941344,1,3,,103477782,30323,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: R070710,Other,,
985,941345,1,3,,103477782,30323,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: R070710,Other,,
986,941346,1,3,,103477782,30323,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: LYM (Lymphocytes); Study_ID: R070710,Other,,
987,941347,1,3,,103477782,30323,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: R070710,Other,,
988,941348,1,3,,103477782,30323,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: R070710,Other,,
989,941349,1,3,,103477782,30323,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: R070710,Other,,
990,941350,1,3,,103477782,30323,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: BASO (Basophils); Study_ID: R070710,Other,,
991,941351,1,3,,103477782,30323,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: R070710,Other,,
992,943370,1,3,,103477782,30323,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: R070710,Other,,
993,943371,1,3,,103477782,30323,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: R070710,Other,,
994,943372,1,3,,103477782,30323,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: MONO (Monocytes); Study_ID: R070710,Other,,
995,943373,1,3,,103477782,30323,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: R070710,Other,,
996,943374,1,3,,103477782,30323,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: R070710,Other,,
997,943375,1,3,,103477782,30323,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: R070710,Other,,
998,944006,1,3,,103477782,30323,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: R070710,Other,,
999,944007,1,3,,103477782,30323,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: R070710,Other,,
1000,944008,1,3,,103477782,30323,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: R070710,Other,,
1001,944009,1,3,,103477782,30323,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: R070710,Other,,
1002,944010,1,3,,103477782,30323,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: R070710,Other,,
1003,944011,1,3,,103477782,30323,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: R070710,Other,,
1004,944012,1,3,,103477782,30323,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: R070710,Other,,
1005,944013,1,3,,103477782,30323,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: R070710,Other,,
1006,944014,1,3,,103477782,30323,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: EOS (Eosinophils); Study_ID: R070710,Other,,
1007,944015,1,3,,103477782,30323,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: LYM (Lymphocytes); Study_ID: R070710,Other,,
1008,944016,1,3,,103477782,30323,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: MONO (Monocytes); Study_ID: R070710,Other,,
1009,944017,1,3,,103477782,30323,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: R070710,Other,,
1010,944018,1,3,,103477782,30323,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: R070710,Other,,
1011,944019,1,3,,103477782,30323,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Hematology; Assay: BASO (Basophils); Study_ID: R070710,Other,,
1012,944020,1,3,,103477782,30323,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: BASO (Basophils); Study_ID: S020311,Other,,
1013,944021,1,3,,103477782,30323,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: S020311,Other,,
1014,944022,1,3,,103477782,30323,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: S020311,Other,,
1015,944023,1,3,,103477782,30323,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: S020311,Other,,
1016,944024,1,3,,103477782,30323,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: EOS (Eosinophils); Study_ID: S020311,Other,,
1017,944025,1,3,,103477782,30323,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: S020311,Other,,
1018,944026,1,3,,103477782,30323,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: RBCNUC (Nucleated Erythrocytes); Study_ID: S020311,Other,,
1019,944027,1,3,,103477782,30323,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: LYM (Lymphocytes); Study_ID: S020311,Other,,
1020,944028,1,3,,103477782,30323,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: S020311,Other,,
1021,944029,1,3,,103477782,30323,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: S020311,Other,,
1022,944030,1,3,,103477782,30323,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: S020311,Other,,
1023,944031,1,3,,103477782,30323,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: NEUTSG (Neutrophils, Segmented); Study_ID: S020311",Other,,
1024,944032,1,3,,103477782,30323,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: S020311,Other,,
1025,944033,1,3,,103477782,30323,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: S020311,Other,,
1026,944034,1,3,,103477782,30323,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: S020311,Other,,
1027,944035,1,3,,103477782,30323,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: MONO (Monocytes); Study_ID: S020311,Other,,
1028,944036,1,3,,103477782,30323,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: S020311,Other,,
1029,944037,1,3,,103477782,30323,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: S020311,Other,,
1030,944038,1,3,,103477782,30323,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: S020311,Other,,
1031,947265,1,3,,103477782,30323,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: BASO (Basophils); Study_ID: S020311,Other,,
1032,947266,1,3,,103477782,30323,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: NEUTSG (Neutrophils, Segmented); Study_ID: S020311",Other,,
1033,947267,1,3,,103477782,30323,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: EOS (Eosinophils); Study_ID: S020311,Other,,
1034,947268,1,3,,103477782,30323,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: S020311,Other,,
1035,947269,1,3,,103477782,30323,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: S020311,Other,,
1036,947270,1,3,,103477782,30323,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: S020311,Other,,
1037,947271,1,3,,103477782,30323,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: RBCNUC (Nucleated Erythrocytes); Study_ID: S020311,Other,,
1038,947272,1,3,,103477782,30323,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: LYM (Lymphocytes); Study_ID: S020311,Other,,
1039,947273,1,3,,103477782,30323,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: S020311,Other,,
1040,947274,1,3,,103477782,30323,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: S020311,Other,,
1041,947275,1,3,,103477782,30323,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: S020311,Other,,
1042,947276,1,3,,103477782,30323,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: S020311,Other,,
1043,947277,1,3,,103477782,30323,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: S020311,Other,,
1044,947278,1,3,,103477782,30323,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: MONO (Monocytes); Study_ID: S020311,Other,,
1045,947279,1,3,,103477782,30323,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: S020311,Other,,
1046,947280,1,3,,103477782,30323,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: S020311,Other,,
1047,947281,1,3,,103477782,30323,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: S020311,Other,,
1048,947408,1,3,,103477782,30323,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: S020311,Other,,
1049,947409,1,3,,103477782,30323,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: S020311,Other,,
1050,951786,1,3,,103477782,30323,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: R070710,Other,,
1051,951787,1,3,,103477782,30323,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: R070710,Other,,
1052,951788,1,3,,103477782,30323,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: R070710,Other,,
1053,951789,1,3,,103477782,30323,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: R070710,Other,,
1054,951790,1,3,,103477782,30323,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: R070710,Other,,
1055,951791,1,3,,103477782,30323,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: R070710,Other,,
1056,952422,1,3,,103477782,30323,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: R070710,Other,,
1057,952423,1,3,,103477782,30323,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: R070710,Other,,
1058,952424,1,3,,103477782,30323,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: CO2 (Carbon Dioxide); Study_ID: R070710,Other,,
1059,952425,1,3,,103477782,30323,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: R070710,Other,,
1060,952426,1,3,,103477782,30323,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: R070710,Other,,
1061,952427,1,3,,103477782,30323,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: URATE (Urate); Study_ID: R070710,Other,,
1062,952428,1,3,,103477782,30323,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: R070710,Other,,
1063,952429,1,3,,103477782,30323,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: R070710,Other,,
1064,952430,1,3,,103477782,30323,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: R070710,Other,,
1065,952431,1,3,,103477782,30323,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: R070710,Other,,
1066,952432,1,3,,103477782,30323,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: LIPASE (Triacylglycerol Lipase); Study_ID: R070710,Other,,
1067,952433,1,3,,103477782,30323,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: R070710,Other,,
1068,952434,1,3,,103477782,30323,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: CK (Creatine Kinase); Study_ID: R070710,Other,,
1069,952435,1,3,,103477782,30323,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: R070710,Other,,
1070,952436,1,3,,103477782,30323,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: R070710,Other,,
1071,952437,1,3,,103477782,30323,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: R070710,Other,,
1072,952438,1,3,,103477782,30323,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: R070710,Other,,
1073,952439,1,3,,103477782,30323,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: R070710,Other,,
1074,952440,1,3,,103477782,30323,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: LIPASE (Triacylglycerol Lipase); Study_ID: R070710,Other,,
1075,952441,1,3,,103477782,30323,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: R070710,Other,,
1076,952442,1,3,,103477782,30323,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: CK (Creatine Kinase); Study_ID: R070710,Other,,
1077,952443,1,3,,103477782,30323,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: R070710,Other,,
1078,952444,1,3,,103477782,30323,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: R070710,Other,,
1079,952445,1,3,,103477782,30323,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: R070710,Other,,
1080,952446,1,3,,103477782,30323,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: R070710,Other,,
1081,952447,1,3,,103477782,30323,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: R070710,Other,,
1082,952448,1,3,,103477782,30323,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: R070710,Other,,
1083,952449,1,3,,103477782,30323,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: CO2 (Carbon Dioxide); Study_ID: R070710,Other,,
1084,952450,1,3,,103477782,30323,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: R070710,Other,,
1085,952451,1,3,,103477782,30323,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: R070710,Other,,
1086,952452,1,3,,103477782,30323,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: R070710,Other,,
1087,952453,1,3,,103477782,30323,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: URATE (Urate); Study_ID: R070710,Other,,
1088,952454,1,3,,103477782,30323,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: S020311,Other,,
1089,952455,1,3,,103477782,30323,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: S020311,Other,,
1090,953632,1,3,,103477782,30323,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: S020311,Other,,
1091,953633,1,3,,103477782,30323,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: S020311,Other,,
1092,953634,1,3,,103477782,30323,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: S020311,Other,,
1093,953635,1,3,,103477782,30323,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: LIPASE (Triacylglycerol Lipase); Study_ID: S020311,Other,,
1094,953636,1,3,,103477782,30323,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: S020311,Other,,
1095,953637,1,3,,103477782,30323,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: S020311,Other,,
1096,953638,1,3,,103477782,30323,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: CO2 (Carbon Dioxide); Study_ID: S020311,Other,,
1097,953639,1,3,,103477782,30323,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: S020311,Other,,
1098,953640,1,3,,103477782,30323,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: S020311,Other,,
1099,954273,1,3,,103477782,30323,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: URATE (Urate); Study_ID: S020311,Other,,
1100,954274,1,3,,103477782,30323,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: S020311,Other,,
1101,954275,1,3,,103477782,30323,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: S020311,Other,,
1102,954276,1,3,,103477782,30323,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: S020311,Other,,
1103,954277,1,3,,103477782,30323,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: S020311,Other,,
1104,954278,1,3,,103477782,30323,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: S020311,Other,,
1105,954279,1,3,,103477782,30323,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: CK (Creatine Kinase); Study_ID: S020311,Other,,
1106,954280,1,3,,103477782,30323,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: S020311,Other,,
1107,964422,1,3,,103477782,30323,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: S020311,Other,,
1108,964423,1,3,,103477782,30323,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: S020311,Other,,
1109,964424,1,3,,103477782,30323,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: S020311,Other,,
1110,964425,1,3,,103477782,30323,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: CK (Creatine Kinase); Study_ID: S020311,Other,,
1111,964426,1,3,,103477782,30323,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: LIPASE (Triacylglycerol Lipase); Study_ID: S020311,Other,,
1112,964427,1,3,,103477782,30323,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: S020311,Other,,
1113,964428,1,3,,103477782,30323,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: S020311,Other,,
1114,964429,1,3,,103477782,30323,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: S020311,Other,,
1115,964430,1,3,,103477782,30323,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: S020311,Other,,
1116,964431,1,3,,103477782,30323,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: S020311,Other,,
1117,964432,1,3,,103477782,30323,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: URATE (Urate); Study_ID: S020311,Other,,
1118,964433,1,3,,103477782,30323,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: S020311,Other,,
1119,964434,1,3,,103477782,30323,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: S020311,Other,,
1120,964435,1,3,,103477782,30323,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: S020311,Other,,
1121,964436,1,3,,103477782,30323,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: CO2 (Carbon Dioxide); Study_ID: S020311,Other,,
1122,964437,1,3,,103477782,30323,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: S020311,Other,,
1123,964438,1,3,,103477782,30323,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: S020311,Other,,
1124,964439,1,3,,103477782,30323,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: S020311,Other,,
1125,964440,1,3,,103477782,30323,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: S020311,Other,,
1126,964693,1,3,,103477782,30323,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: LIPASE (Triacylglycerol Lipase); Study_ID: R070710,Other,,
1127,965072,1,3,,103477782,30323,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: R070710,Other,,
1128,965073,1,3,,103477782,30323,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: R070710,Other,,
1129,965074,1,3,,103477782,30323,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: R070710,Other,,
1130,965075,1,3,,103477782,30323,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: R070710,Other,,
1131,965076,1,3,,103477782,30323,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: R070710,Other,,
1132,965077,1,3,,103477782,30323,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: R070710,Other,,
1133,965078,1,3,,103477782,30323,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: R070710,Other,,
1134,965079,1,3,,103477782,30323,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: R070710,Other,,
1135,965080,1,3,,103477782,30323,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: URATE (Urate); Study_ID: R070710,Other,,
1136,965081,1,3,,103477782,30323,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: R070710,Other,,
1137,965082,1,3,,103477782,30323,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: R070710,Other,,
1138,965083,1,3,,103477782,30323,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: R070710,Other,,
1139,965084,1,3,,103477782,30323,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: CO2 (Carbon Dioxide); Study_ID: R070710,Other,,
1140,965085,1,3,,103477782,30323,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: R070710,Other,,
1141,965086,1,3,,103477782,30323,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: CK (Creatine Kinase); Study_ID: R070710,Other,,
1142,965087,1,3,,103477782,30323,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: R070710,Other,,
1143,965088,1,3,,103477782,30323,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: R070710,Other,,
1144,965089,1,3,,103477782,30323,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: R070710,Other,,
1145,995526,1,3,,103477782,30323,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Right Ventricle, Mineralization; Study_ID: R070710",Other,,
1146,995527,1,4,,103477782,30323,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Thigh Muscle; Assay: Right Biceps Femoris, Myocyte, Inflammation; Study_ID: R070710",Other,,
1147,995528,1,3,,103477782,30323,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Right Ventricle, Fibrosis; Study_ID: R070710",Other,,
1148,995529,1,4,,103477782,30323,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Thigh Muscle; Assay: Right Soleus, Myocyte, Regeneration; Study_ID: R070710",Other,,
1149,995530,1,3,,103477782,30323,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Right Atrium, Cellular Infiltrate, Mixed Cell; Study_ID: R070710",Other,,
1150,995531,1,3,,103477782,30323,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Intramyocardial Arteries, Cellular Infiltrate, Mixed Cell; Study_ID: R070710",Other,,
1151,995532,1,3,,103477782,30323,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Right Ventricle, Myocyte, Degeneration; Study_ID: R070710",Other,,
1152,995533,1,3,,103477782,30323,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Intramyocardial Arteries, Degeneration; Study_ID: R070710",Other,,
1153,995534,1,3,,103477782,30323,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Right Atrium, Cellular Infiltrate, Mononuclear Cell; Study_ID: R070710",Other,,
1154,995535,1,4,,103477782,30323,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Thigh Muscle; Assay: Right Gastrocnemius, Myocyte, Regeneration; Study_ID: R070710",Other,,
1155,995536,1,3,,103477782,30323,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Intramyocardial Arteries, Necrosis, Fibrinoid; Study_ID: R070710",Other,,
1156,995537,1,4,,103477782,30323,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Thigh Muscle; Assay: Right Biceps Femoris, Myocyte, Degeneration; Study_ID: R070710",Other,,
1157,995538,1,4,,103477782,30323,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Thigh Muscle; Assay: Right Biceps Femoris, Myocyte, Regeneration; Study_ID: R070710",Other,,
1158,995539,1,4,,103477782,30323,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Thigh Muscle; Assay: Right Soleus, Myocyte, Degeneration; Study_ID: R070710",Other,,
1159,995540,1,4,,103477782,30323,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Thigh Muscle; Assay: Right Soleus, Myocyte, Inflammation; Study_ID: R070710",Other,,
1160,995541,1,3,,103477782,30323,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Right Ventricle, Cellular Infiltrate, Mixed Cell; Study_ID: R070710",Other,,
1161,1002930,1,3,,103477782,30323,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Right Atrium, Myocyte, Degeneration; Study_ID: R070710",Other,,
1162,1002931,1,3,,103477782,30323,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Epicardium, Cellular Infiltrate, Mixed Cell; Study_ID: R070710",Other,,
1163,1002932,1,3,,103477782,30323,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Right Ventricle, Cellular Infiltrate, Mononuclear Cell; Study_ID: R070710",Other,,
1164,1002933,1,4,,103477782,30323,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Thigh Muscle; Assay: Right Gastrocnemius, Myocyte, Degeneration; Study_ID: R070710",Other,,
1165,1002934,1,3,,103477782,30323,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Right Ventricle, Mineralization; Study_ID: R070710",Other,,
1166,1002935,1,4,,103477782,30323,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Thigh Muscle; Assay: Right Biceps Femoris, Myocyte, Inflammation; Study_ID: R070710",Other,,
1167,1002936,1,3,,103477782,30323,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Right Ventricle, Fibrosis; Study_ID: R070710",Other,,
1168,1002937,1,4,,103477782,30323,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Thigh Muscle; Assay: Right Soleus, Myocyte, Regeneration; Study_ID: R070710",Other,,
1169,1002938,1,3,,103477782,30323,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Right Atrium, Cellular Infiltrate, Mixed Cell; Study_ID: R070710",Other,,
1170,1002939,1,3,,103477782,30323,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Intramyocardial Arteries, Cellular Infiltrate, Mixed Cell; Study_ID: R070710",Other,,
1171,1002940,1,3,,103477782,30323,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Right Ventricle, Myocyte, Degeneration; Study_ID: R070710",Other,,
1172,1002941,1,3,,103477782,30323,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Intramyocardial Arteries, Degeneration; Study_ID: R070710",Other,,
1173,1002942,1,3,,103477782,30323,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Right Atrium, Cellular Infiltrate, Mononuclear Cell; Study_ID: R070710",Other,,
1174,1002943,1,4,,103477782,30323,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Thigh Muscle; Assay: Right Gastrocnemius, Myocyte, Inflammation; Study_ID: R070710",Other,,
1175,1002944,1,4,,103477782,30323,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Thigh Muscle; Assay: Right Gastrocnemius, Myocyte, Regeneration; Study_ID: R070710",Other,,
1176,1003528,1,3,,103477782,30323,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Intramyocardial Arteries, Necrosis, Fibrinoid; Study_ID: R070710",Other,,
1177,1003529,1,4,,103477782,30323,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Thigh Muscle; Assay: Right Biceps Femoris, Myocyte, Degeneration; Study_ID: R070710",Other,,
1178,1003530,1,4,,103477782,30323,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Thigh Muscle; Assay: Right Biceps Femoris, Myocyte, Regeneration; Study_ID: R070710",Other,,
1179,1003531,1,4,,103477782,30323,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Thigh Muscle; Assay: Right Soleus, Myocyte, Degeneration; Study_ID: R070710",Other,,
1180,1003532,1,4,,103477782,30323,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Thigh Muscle; Assay: Right Soleus, Myocyte, Inflammation; Study_ID: R070710",Other,,
1181,1003533,1,3,,103477782,30323,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Right Ventricle, Cellular Infiltrate, Mixed Cell; Study_ID: R070710",Other,,
1182,1003534,1,3,,103477782,30323,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Right Atrium, Myocyte, Degeneration; Study_ID: R070710",Other,,
1183,1003535,1,3,,103477782,30323,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Epicardium, Cellular Infiltrate, Mixed Cell; Study_ID: R070710",Other,,
1184,1003536,1,3,,103477782,30323,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Right Ventricle, Cellular Infiltrate, Mononuclear Cell; Study_ID: R070710",Other,,
1185,1003537,1,4,,103477782,30323,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Thigh Muscle; Assay: Right Gastrocnemius, Myocyte, Degeneration; Study_ID: R070710",Other,,
1186,1003538,1,4,,103477782,30323,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Thigh Muscle; Assay: Right Gastrocnemius, Myocyte, Inflammation; Study_ID: R070710",Other,,
1187,1026535,1,3,,103477782,30323,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Lipid Accumulation, Microvesicular; Study_ID: S020311",Other,,
1188,1026536,1,3,,103477782,30323,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Necrosis, Apoptotic; Study_ID: S020311",Other,,
1189,1026537,1,3,,103477782,30323,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Increased Mitoses; Study_ID: S020311",Other,,
1190,1026538,1,3,,103477782,30323,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Lipid Accumulation, Microvesicular; Study_ID: S020311",Other,,
1191,1026539,1,3,,103477782,30323,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Necrosis, Apoptotic; Study_ID: S020311",Other,,
1192,1026540,1,3,,103477782,30323,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Hypertrophy; Study_ID: S020311",Other,,
1193,1026541,1,3,,103477782,30323,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Lipid Accumulation, Macrovesicular; Study_ID: S020311",Other,,
1194,1026542,1,3,,103477782,30323,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Heart; Assay: Right Ventricle, Myocyte, Degeneration; Study_ID: S020311",Other,,
1195,1026543,1,3,,103477782,30323,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Heart; Assay: Right Ventricle, Myocyte, Lipid Accumulation; Study_ID: S020311",Other,,
1196,1026544,1,3,,103477782,30323,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Heart; Assay: Intramyocardial Arteries, Degeneration; Study_ID: S020311",Other,,
1197,1026545,1,3,,103477782,30323,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Heart; Assay: Intramyocardial Arteries, Perivascular Edema; Study_ID: S020311",Other,,
1198,1026546,1,3,,103477782,30323,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Single Hepatocyte Necrosis; Study_ID: S020311,Other,,
1199,1026547,1,3,,103477782,30323,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct Hyperplasia; Study_ID: S020311,Other,,
1200,1026548,1,3,,103477782,30323,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Hypertrophy; Study_ID: S020311",Other,,
1201,1026549,1,3,,103477782,30323,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Lipid Accumulation, Macrovesicular; Study_ID: S020311",Other,,
1202,1026550,1,3,,103477782,30323,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Fibrosis; Study_ID: S020311",Other,,
1203,1026551,1,3,,103477782,30323,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Heart; Assay: Left Ventricle, Fibrosis; Study_ID: S020311",Other,,
1204,1026552,1,3,,103477782,30323,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Heart; Assay: Papillary Muscle, Cellular Infiltrate, Mixed Cell; Study_ID: S020311",Other,,
1205,1026553,1,3,,103477782,30323,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Heart; Assay: Right Atrium, Cellular Infiltrate, Mononuclear Cell; Study_ID: S020311",Other,,
1206,1027097,1,3,,103477782,30323,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Heart; Assay: Epicardium, Hyperplasia; Study_ID: S020311",Other,,
1207,1027098,1,3,,103477782,30323,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Heart; Assay: Intramyocardial Arteries, Cellular Infiltrate, Mononuclear Cell; Study_ID: S020311",Other,,
1208,1027099,1,3,,103477782,30323,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Heart; Assay: Intramyocardial Arteries, Necrosis, Fibrinoid; Study_ID: S020311",Other,,
1209,1027100,1,3,,103477782,30323,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Heart; Assay: Intramyocardial Arteries, Perivascular Fibrosis; Study_ID: S020311",Other,,
1210,1027101,1,3,,103477782,30323,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Nuclear Cytoplasmic Condensation; Study_ID: S020311,Other,,
1211,1027102,1,3,,103477782,30323,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S020311",Other,,
1212,1027103,1,3,,103477782,30323,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Lipid Accumulation, Microvesicular; Study_ID: S020311",Other,,
1213,1027104,1,3,,103477782,30323,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Necrosis, Oncocytic; Study_ID: S020311",Other,,
1214,1027105,1,3,,103477782,30323,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Multinucleated; Study_ID: S020311",Other,,
1215,1027106,1,3,,103477782,30323,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Malignant Lymphoma; Study_ID: S020311,Other,,
1216,1027107,1,3,,103477782,30323,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S020311",Other,,
1217,1027108,1,3,,103477782,30323,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Neutrophilic; Study_ID: S020311",Other,,
1218,1027109,1,3,,103477782,30323,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Heart; Assay: Left Ventricle, Cellular Infiltrate, Mixed Cell; Study_ID: S020311",Other,,
1219,1027110,1,3,,103477782,30323,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Heart; Assay: Left Ventricle, Cellular Infiltrate, Mononuclear Cell; Study_ID: S020311",Other,,
1220,1027111,1,3,,103477782,30323,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Heart; Assay: Left Ventricle, Myocyte, Degeneration; Study_ID: S020311",Other,,
1221,1027112,1,3,,103477782,30323,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Heart; Assay: Interventricular Septum, Cellular Infiltrate, Mononuclear Cell; Study_ID: S020311",Other,,
1222,1027113,1,3,,103477782,30323,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Degeneration; Study_ID: S020311",Other,,
1223,1027114,1,3,,103477782,30323,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Necrosis, Oncocytic; Study_ID: S020311",Other,,
1224,1027115,1,3,,103477782,30323,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Lipid Accumulation, Microvesicular; Study_ID: S020311",Other,,
1225,1027116,1,3,,103477782,30323,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Oval Cell, Hyperplasia; Study_ID: S020311",Other,,
1226,1027702,1,3,,103477782,30323,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Subcapsular, Fibrosis; Study_ID: S020311",Other,,
1227,1027703,1,3,,103477782,30323,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Heart; Assay: Papillary Muscle, Cellular Infiltrate, Mononuclear Cell; Study_ID: S020311",Other,,
1228,1027704,1,3,,103477782,30323,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Heart; Assay: Endocardium, Cellular Infiltrate, Mononuclear Cell; Study_ID: S020311",Other,,
1229,1027705,1,3,,103477782,30323,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Heart; Assay: Intramyocardial Arteries, Tunica Media, Hypertrophy; Study_ID: S020311",Other,,
1230,1027706,1,3,,103477782,30323,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Thrombus; Study_ID: S020311",Other,,
1231,1027707,1,3,,103477782,30323,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Clear Cell Focus; Study_ID: S020311,Other,,
1232,1027708,1,3,,103477782,30323,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Cytoplasm, Eosinophilia; Study_ID: S020311",Other,,
1233,1027709,1,3,,103477782,30323,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Glycogen Accumulation; Study_ID: S020311",Other,,
1234,1027710,1,3,,103477782,30323,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Granulomatous; Study_ID: S020311",Other,,
1235,1027711,1,3,,103477782,30323,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Heart; Assay: Left Atrium, Myocyte, Degeneration; Study_ID: S020311",Other,,
1236,1027712,1,3,,103477782,30323,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Heart; Assay: Right Ventricle, Cellular Infiltrate, Mixed Cell; Study_ID: S020311",Other,,
1237,1027713,1,3,,103477782,30323,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Heart; Assay: Interventricular Septum, Cellular Infiltrate, Mixed Cell; Study_ID: S020311",Other,,
1238,1027714,1,3,,103477782,30323,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Heart; Assay: Interventricular Septum, Fibrosis; Study_ID: S020311",Other,,
1239,1027715,1,3,,103477782,30323,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Heart; Assay: Interventricular Septum, Myocyte, Degeneration; Study_ID: S020311",Other,,
1240,1027716,1,3,,103477782,30323,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Autolysis; Study_ID: S020311,Other,,
1241,1027717,1,3,,103477782,30323,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct, Necrosis, Oncocytic; Study_ID: S020311",Other,,
1242,1027718,1,3,,103477782,30323,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Glycogen Accumulation; Study_ID: S020311",Other,,
1243,1027719,1,3,,103477782,30323,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Lipid Accumulation, Macrovesicular; Study_ID: S020311",Other,,
1244,1027720,1,3,,103477782,30323,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Necrosis, Oncocytic; Study_ID: S020311",Other,,
1245,1027721,1,3,,103477782,30323,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Necrosis, Oncocytic; Study_ID: S020311",Other,,
1246,1029665,1,3,,103477782,30323,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Heart; Assay: Left Atrium, Fibrosis; Study_ID: S020311",Other,,
1247,1029666,1,3,,103477782,30323,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Heart; Assay: Papillary Muscle, Myocyte, Degeneration; Study_ID: S020311",Other,,
1248,1029667,1,3,,103477782,30323,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Heart; Assay: Right Ventricle, Cellular Infiltrate, Mononuclear Cell; Study_ID: S020311",Other,,
1249,1029668,1,3,,103477782,30323,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct Dilatation; Study_ID: S020311,Other,,
1250,1029669,1,3,,103477782,30323,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Mesothelial Cell, Hyperplasia; Study_ID: S020311",Other,,
1251,1029670,1,3,,103477782,30323,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular Fibrosis; Study_ID: S020311,Other,,
1252,1029671,1,3,,103477782,30323,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Atrophy; Study_ID: S020311",Other,,
1253,1029672,1,3,,103477782,30323,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Cytoplasm, Eosinophilia; Study_ID: S020311",Other,,
1254,1029673,1,3,,103477782,30323,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Degeneration; Study_ID: S020311",Other,,
1255,1029674,1,3,,103477782,30323,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Mineralization; Study_ID: S020311",Other,,
1256,1029675,1,3,,103477782,30323,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Necrosis, Apoptotic; Study_ID: S020311",Other,,
1257,1029676,1,3,,103477782,30323,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Subcapsular, Mineralization; Study_ID: S020311",Other,,
1258,1029677,1,3,,103477782,30323,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Extramedullary Hematopoiesis; Study_ID: S020311",Other,,
1259,1029678,1,3,,103477782,30323,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S020311",Other,,
1260,1029679,1,3,,103477782,30323,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Heart; Assay: Right Ventricle, Fibrosis; Study_ID: S020311",Other,,
1261,1029680,1,3,,103477782,30323,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Heart; Assay: Intramyocardial Arteries, Cellular Infiltrate, Mixed Cell; Study_ID: S020311",Other,,
1262,1029681,1,3,,103477782,30323,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Heart; Assay: Left Atrium, Cellular Infiltrate, Mononuclear Cell; Study_ID: S020311",Other,,
1263,1029682,1,3,,103477782,30323,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S020311",Other,,
1264,1029683,1,3,,103477782,30323,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Necrosis, Apoptotic; Study_ID: S020311",Other,,
1265,1029684,1,3,,103477782,30323,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Diffuse, Cytoplasm, Eosinophilia; Study_ID: S020311",Other,,
1266,1029685,1,3,,103477782,30323,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Lipid Accumulation, Macrovesicular; Study_ID: S020311",Other,,
1267,1029726,1,3,,103477782,30323,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Right Atrium, Myocyte, Degeneration; Study_ID: R070710",Other,,
1268,1029727,1,3,,103477782,30323,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Epicardium, Cellular Infiltrate, Mixed Cell; Study_ID: R070710",Other,,
1269,1029728,1,3,,103477782,30323,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Right Ventricle, Cellular Infiltrate, Mononuclear Cell; Study_ID: R070710",Other,,
1270,1029729,1,4,,103477782,30323,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Thigh Muscle; Assay: Right Gastrocnemius, Myocyte, Degeneration; Study_ID: R070710",Other,,
1271,1029730,1,4,,103477782,30323,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Thigh Muscle; Assay: Right Gastrocnemius, Myocyte, Inflammation; Study_ID: R070710",Other,,
1272,1029731,1,3,,103477782,30323,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Right Ventricle, Mineralization; Study_ID: R070710",Other,,
1273,1029732,1,4,,103477782,30323,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Thigh Muscle; Assay: Right Biceps Femoris, Myocyte, Inflammation; Study_ID: R070710",Other,,
1274,1029733,1,3,,103477782,30323,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Right Ventricle, Fibrosis; Study_ID: R070710",Other,,
1275,1029734,1,4,,103477782,30323,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Thigh Muscle; Assay: Right Soleus, Myocyte, Regeneration; Study_ID: R070710",Other,,
1276,1029735,1,3,,103477782,30323,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Right Atrium, Cellular Infiltrate, Mixed Cell; Study_ID: R070710",Other,,
1277,1029736,1,3,,103477782,30323,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Intramyocardial Arteries, Cellular Infiltrate, Mixed Cell; Study_ID: R070710",Other,,
1278,1029737,1,3,,103477782,30323,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Right Ventricle, Myocyte, Degeneration; Study_ID: R070710",Other,,
1279,1029738,1,3,,103477782,30323,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Intramyocardial Arteries, Degeneration; Study_ID: R070710",Other,,
1280,1029739,1,3,,103477782,30323,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Right Atrium, Cellular Infiltrate, Mononuclear Cell; Study_ID: R070710",Other,,
1281,1029740,1,4,,103477782,30323,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Thigh Muscle; Assay: Right Gastrocnemius, Myocyte, Regeneration; Study_ID: R070710",Other,,
1282,1029741,1,3,,103477782,30323,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Intramyocardial Arteries, Necrosis, Fibrinoid; Study_ID: R070710",Other,,
1283,1029742,1,4,,103477782,30323,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Thigh Muscle; Assay: Right Biceps Femoris, Myocyte, Degeneration; Study_ID: R070710",Other,,
1284,1029743,1,4,,103477782,30323,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Thigh Muscle; Assay: Right Biceps Femoris, Myocyte, Regeneration; Study_ID: R070710",Other,,
1285,1029744,1,4,,103477782,30323,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Thigh Muscle; Assay: Right Soleus, Myocyte, Degeneration; Study_ID: R070710",Other,,
1286,1029745,1,4,,103477782,30323,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Thigh Muscle; Assay: Right Soleus, Myocyte, Inflammation; Study_ID: R070710",Other,,
1287,1029746,1,3,,103477782,30323,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % saline; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Right Ventricle, Cellular Infiltrate, Mixed Cell; Study_ID: R070710",Other,,
1288,1030263,1,3,,103477782,30323,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Heart; Assay: Epicardium, Cellular Infiltrate, Mixed Cell; Study_ID: S020311",Other,,
1289,1030264,1,3,,103477782,30323,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Heart; Assay: Epicardium, Cellular Infiltrate, Mononuclear Cell; Study_ID: S020311",Other,,
1290,1030265,1,3,,103477782,30323,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: S020311",Other,,
1291,1030266,1,3,,103477782,30323,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Diffuse, Hypertrophy; Study_ID: S020311",Other,,
1292,1030267,1,3,,103477782,30323,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Erythrophagocytosis; Study_ID: S020311",Other,,
1293,1030850,1,3,,103477782,30323,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Glycogen Accumulation; Study_ID: S020311",Other,,
1294,1030851,1,3,,103477782,30323,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Subcapsular, Necrosis, Oncocytic; Study_ID: S020311",Other,,
1295,1030852,1,3,,103477782,30323,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: S020311",Other,,
1296,1030853,1,3,,103477782,30323,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: S020311",Other,,
1297,1034572,1,3,,103477782,30323,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M2; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Edema; Study_ID: S020311",Other,,
1298,1079931,1,1,,103477782,30323,Unspecified,,,,,"Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]",Other,15646539.0,
1299,1079932,1,1,,103477782,30323,Unspecified,,,,,"Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]",Other,15646539.0,
1300,1079933,1,1,,103477782,30323,Unspecified,,,,,"Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is number of references indexed. [column 'AIGUE' in source]",Other,15646539.0,
1301,1079934,1,1,,103477782,30323,Unspecified,,,,,"Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]",Other,15646539.0,
1302,1079935,1,1,,103477782,30323,Unspecified,,,,,"Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]",Other,15646539.0,
1303,1079936,1,1,,103477782,30323,Unspecified,,,,,"Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]",Other,15646539.0,
1304,1079937,1,1,,103477782,30323,Unspecified,,,,,"Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]",Other,15646539.0,
1305,1079938,1,1,,103477782,30323,Unspecified,,,,,"Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]",Other,15646539.0,
1306,1079939,1,1,,103477782,30323,Unspecified,,,,,"Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]",Other,15646539.0,
1307,1079940,1,1,,103477782,30323,Unspecified,,,,,"Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]",Other,15646539.0,
1308,1079941,1,1,,103477782,30323,Unspecified,,,,,"Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]",Other,15646539.0,
1309,1079942,1,1,,103477782,30323,Unspecified,,,,,"Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]",Other,15646539.0,
1310,1079943,1,1,,103477782,30323,Unspecified,,,,,"Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]",Other,15646539.0,
1311,1079944,1,1,,103477782,30323,Unspecified,,,,,"Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]",Other,15646539.0,
1312,1079945,1,1,,103477782,30323,Unspecified,,,,,Animal toxicity known. [column 'TOXIC' in source],Other,15646539.0,
1313,1079946,1,1,,103477782,30323,Unspecified,,,,,Presence of at least one case with successful reintroduction. [column 'REINT' in source],Other,15646539.0,
1314,1079947,1,1,,103477782,30323,Unspecified,,,,,Comments (NB not yet translated). [column 'COMMENTAIRES' in source],Other,15646539.0,
1315,1079948,1,1,,103477782,30323,Unspecified,,,,,"Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]",Other,15646539.0,
1316,1079949,1,1,,103477782,30323,Unspecified,,,,,Proposed mechanism(s) of liver damage. [column 'MEC' in source],Other,15646539.0,
1317,1094663,1,2,,103477782,30323,Active,,,,,Inhibition of Sus scrofa (pig) left ventricle Ca2+-ATPase activity of cardiac myosin assessed as inorganic phosphorus released from protein at 0.05 to 0.4 uM,Other,,
1318,1094664,1,2,,103477782,30323,Active,,,,,Inhibition of Sus scrofa (pig) left ventricle Ca2+-ATPase activity of cardiac myosin assessed as inorganic phosphorus released from protein at 0.2 uM after 10 min,Other,,
1319,1094665,1,2,,103477782,30323,Active,,,,,Inhibition of Sus scrofa (pig) left ventricle Ca2+-ATPase activity of cardiac myosin assessed as inorganic phosphorus released from protein at 0.05 uM after 30 min,Other,,
1320,1094666,1,2,,103477782,30323,Active,,,,,Inhibition of Sus scrofa (pig) left ventricle Ca2+-ATPase activity of cardiac myosin assessed as inorganic phosphorus released from protein at > 0.1 uM after 10 min,Other,,
1321,1094667,1,2,,103477782,30323,Unspecified,,,,,Inhibition of Sus scrofa (pig) left ventricle Ca2+-ATPase activity of cardiac myosin assessed as inorganic phosphorus released from protein at 0.2 to 1 uM,Other,,
1322,1094668,1,2,,103477782,30323,Inactive,,,,,Inhibition of Sus scrofa (pig) left ventricle Ca2+-ATPase activity of cardiac myosin assessed as inorganic phosphorus released from protein at 0.4 uM in presence of Mg2+,Other,,
1323,1094669,1,2,,103477782,30323,Active,,,,,Inhibition of Sus scrofa (pig) left ventricle Ca2+-ATPase activity of cardiac myosin assessed as inorganic phosphorus released from protein at 0.2 uM after 1 hr,Other,,
1324,1094670,1,2,,103477782,30323,Unspecified,,,,,Inhibition of Sus scrofa (pig) left ventricle Ca2+-ATPase activity of cardiac myosin assessed as residual activity at 0.8 uM,Other,,
1325,1117298,1,2,,170465048,30323,Inactive,,,7.0795,AC50 (uM),"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus, Screen 2 green channel",Confirmatory,,
1326,1117304,1,2,,170465048,30323,Active,,,5.0119,AC50 (uM),"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus, Screen 2 blue channel",Confirmatory,,
1327,1117305,1,2,,170465048,30323,Active,,,5.0119,AC50 (uM),"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus, Screen 2 ratio channel",Confirmatory,,
1328,1117308,1,1,,170465048,30323,Active,,,2.43155,Ac50,"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen 4, ratio channel",Confirmatory,,
1329,1117309,1,1,,170465048,30323,Inactive,,,2.43155,Ac50,"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen 4, blue channel",Confirmatory,,
1330,1117310,1,1,,170465048,30323,Inactive,,,7.079460000000001,Ac50,"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen 2, green channel",Confirmatory,,
1331,1117312,1,1,,170465048,30323,Active,,,5.01187,Ac50,"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen2, ratio channel",Confirmatory,,
1332,1117314,1,1,,170465048,30323,Inactive,,,5.01187,Ac50,"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen 2, blue channel",Confirmatory,,
1333,1117316,1,1,,170465048,30323,Inactive,,,2.72824,Ac50,"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen 4, green channel",Confirmatory,,
1334,1117322,1,1,,170465048,30323,Active,,,0.11815,IC50,RKO viability from Cell TiterGlo-IC50,Confirmatory,,
1335,1117323,1,1,,170465048,30323,Active,,,0.3376,IC50,SNU-C1 viability from Cell TiterGlo-IC50,Confirmatory,,
1336,1117325,1,1,,170465048,30323,Active,,,0.3691,IC50,nuclear beta catenin stimulation in WNT3A conditioned C2C12 cells-IC50,Confirmatory,,
1337,1117326,1,1,,170465048,30323,Active,,,,,nuclear beta catenin stimulation in WNT3A conditioned C2C12 cells-screen,Screening,,
1338,1117327,1,1,,170465048,30323,Active,,,0.0061,IC50,alkaline phosphatase stimulation in WNT3A conditioned C2C12 cells-IC50,Confirmatory,,
1339,1117328,1,1,,170465048,30323,Inactive,,,,,human p70S6K1 kinase inhibition-screen,Screening,,
1340,1117329,1,1,,170465048,30323,Inactive,,,,,insulin secretion from INS-1E cells in the presence of 5 mM glucose-screen,Screening,,
1341,1117330,1,1,,170465048,30323,Active,,,0.64846,IC50,HT-29 viability from Cell TiterGlo-IC50,Confirmatory,,
1342,1117332,1,1,,170465048,30323,Active,,,0.05086,IC50,HCT116 viability from Cell TiterGlo-IC50,Confirmatory,,
1343,1117334,1,1,,170465048,30323,Inactive,,,9.2476,IC50,Colo320 viability from Cell TiterGlo-IC50,Confirmatory,,
1344,1117336,1,1,,170465048,30323,Active,,,,,GSK3B-pretreated HCT116 viability from Cell TiterGlo-screen,Screening,,
1345,1117338,1,1,,170465048,30323,Active,,,1.4657799999999999,IC50,SW480 viability from Cell TiterGlo-IC50,Confirmatory,,
1346,1117339,1,1,,170465048,30323,Active,,,0.05538,IC50,GSK3B-pretreated HCT116 viability from Cell TiterGlo-IC50,Confirmatory,,
1347,1117340,1,1,,170465048,30323,Active,,,,,VEGF stimulated ADSC/ECFC co-culture CD31-stained tube area decrease-screen,Screening,,
1348,1117341,1,1,,170465048,30323,Inactive,,,,,GLP1 secretion from NCI-H716 cells-screen,Screening,,
1349,1117342,1,1,,170465048,30323,Active,,,,,HCT116 viability from Cell TiterGlo-screen,Screening,,
1350,1117343,1,1,,170465048,30323,Active,,,,,SW480 viability from Cell TiterGlo-screen,Screening,,
1351,1117346,1,1,,170465048,30323,Active,,,,,DLD-1 viability from Cell TiterGlo-screen,Screening,,
1352,1117347,1,1,,170465048,30323,Active,,,0.00805,IC50,Decreased HeLa cell count-IC50,Confirmatory,,
1353,1117348,1,1,,170465048,30323,Inactive,,,9.6046,IC50,Increased HeLa cells in S-phase-IC50,Confirmatory,,
1354,1117349,1,1,,170465048,30323,Active,,,0.010159999999999999,IC50,Increased HeLa cells with 2N DNA content-IC50,Confirmatory,,
1355,1117350,1,1,,170465048,30323,Active,,,0.3738,IC50,Increased chromatin condensation in HeLa cells-IC50,Confirmatory,,
1356,1117351,1,1,,170465048,30323,Active,,,0.04645,IC50,Increased HeLa cells with 4N DNA content-IC50,Confirmatory,,
1357,1117352,1,1,,170465048,30323,Active,,,0.18804,IC50,DLD-1 viability from Cell TiterGlo-IC50,Confirmatory,,
1358,1117353,1,1,,170465048,30323,Inactive,,,,,human KDR kinase inhibition-screen,Screening,,
1359,1117354,1,1,,170465048,30323,Inactive,,,,,human JAK2 kinase inhibition-screen,Screening,,
1360,1117355,1,1,,170465048,30323,Inactive,,,,,human GSK3B kinase inhibition-screen,Screening,,
1361,1117356,1,1,,170465048,30323,Inactive,,,,,human FLT3 kinase inhibition-screen,Screening,,
1362,1123500,1,1,,103477782,30323,Unspecified,,,,,Toxicity in Salmonella typhimurium TA98 assessed as growth inhibition after 1 hr,Other,370390.0,
1363,1123501,1,1,,103477782,30323,Unspecified,,,,,Toxicity in Salmonella typhimurium TA100 assessed as growth inhibition after 1 hr,Other,370390.0,
1364,1123502,1,1,,103477782,30323,Unspecified,,,,,Toxicity in Salmonella typhimurium TA1537 assessed as growth inhibition after 1 hr,Other,370390.0,
1365,1123503,1,1,,103477782,30323,Unspecified,,,,,Mutagenic activity in Salmonella typhimurium TA98 assessed as mutation frequency at 10'4 times D50 after 1 hr,Other,370390.0,
1366,1123504,1,1,,103477782,30323,Unspecified,,,,,Mutagenic activity in Salmonella typhimurium TA100 assessed as mutation frequency at 10'4 times D50 after 1 hr,Other,370390.0,
1367,1123505,1,1,,103477782,30323,Unspecified,,,,,Mutagenic activity in Salmonella typhimurium TA1537 assessed as mutation frequency at 10'4 times D50 after 1 hr,Other,370390.0,
1368,1123727,1,1,,103477782,30323,Active,,,0.66,ED50,Inhibition of DNA synthesis in mouse L1210 cells,Confirmatory,423182.0,
1369,1123728,1,1,,103477782,30323,Active,,,0.33,ED50,Inhibition of RNA synthesis in mouse L1210 cells,Confirmatory,423182.0,
1370,1123755,1,1,,103477782,30323,Unspecified,,,,,Antitumor activity against mouse P388 cells allografted in ip dosed mouse assessed as optimal dose,Other,423191.0,
1371,1123756,1,1,,103477782,30323,Unspecified,,,,,"Antitumor activity against mouse P388 cells allografted in mouse assessed as average survival time at 2.9 mg/kg, ip relative to untreated control",Other,423191.0,
1372,1123760,1,1,,103477782,30323,Unspecified,,,,,"Toxicity in mouse allografted with mouse P388 cells at 2.9 mg/kg, ip",Other,423191.0,
1373,1124694,1,1,,103477782,30323,Unspecified,,,,,"Antitumor activity against mouse P388 cells allografted in CDF1 mouse assessed as tumor inhibition at 32 mg/kg, ip on days 5, 9 and 13 relative to untreated control",Other,571021.0,
1374,1124695,1,1,,103477782,30323,Unspecified,,,,,"Antitumor activity against mouse P388 cells allografted in CDF1 mouse assessed as tumor inhibition at 16 mg/kg, ip on days 5, 9 and 13 relative to untreated control",Other,571021.0,
1375,1124696,1,1,,103477782,30323,Unspecified,,,,,"Antitumor activity against mouse P388 cells allografted in CDF1 mouse assessed as tumor inhibition at 8 mg/kg, ip on days 5, 9 and 13 relative to untreated control",Other,571021.0,
1376,1124697,1,1,,103477782,30323,Unspecified,,,,,"Antitumor activity against mouse P388 cells allografted in CDF1 mouse assessed as tumor inhibition at 4 mg/kg, ip on days 5, 9 and 13 relative to untreated control",Other,571021.0,
1377,1124698,1,1,,103477782,30323,Unspecified,,,,,"Antitumor activity against mouse P388 cells allografted in CDF1 mouse assessed as tumor inhibition at 2 mg/kg, ip on days 5, 9 and 13 relative to untreated control",Other,571021.0,
1378,1124710,1,1,,103477782,30323,Unspecified,,,,,"Antitumor activity against mouse B16 cells allografted in CDF1 mouse assessed as tumor inhibition at 4 mg/kg, ip on day 5 relative to untreated control",Other,571021.0,
1379,1124711,1,1,,103477782,30323,Unspecified,,,,,"Antitumor activity against mouse B16 cells allografted in CDF1 mouse assessed as tumor inhibition at 2 mg/kg, ip on day 5 relative to untreated control",Other,571021.0,
1380,1124712,1,1,,103477782,30323,Unspecified,,,,,"Antitumor activity against mouse B16 cells allografted in CDF1 mouse assessed as tumor inhibition at 1 mg/kg, ip on day 5 relative to untreated control",Other,571021.0,
1381,1124717,1,1,,103477782,30323,Unspecified,,,,,"Toxicity in CDF1 mouse allografted with mouse B16 cells at 16 mg/kg, ip on day 5",Other,571021.0,
1382,1124720,1,1,,103477782,30323,Unspecified,,,,,"Toxicity in CDF1 mouse allografted with mouse P388 cells assessed as survival at 2 to 32 mg/kg, ip on days 5, 9 and 13",Other,571021.0,
1383,1130426,1,1,,103477782,30323,Unspecified,,,,,Selectivity ratio of ED50 for inhibition of DNA synthesis in mouse L1210 cells to ED50 for inhibition of RNA synthesis in mouse L1210 cells,Other,490536.0,
1384,1130427,1,1,,103477782,30323,Active,,,0.66,ED50,Inhibition of DNA synthesis in mouse L1210 cells,Confirmatory,490536.0,
1385,1130428,1,2,,103477782,30323,Unspecified,,,,,Binding affinity to calf thymus DNA assessed as change in melting temperature,Other,490536.0,
1386,1130429,1,1,,103477782,30323,Unspecified,,,,,"Antitumor activity against mouse P388 cells allografted in CDF/BDF mouse assessed as survival time at 0.78 mg/kg, ip administered as qd for 1 to 9 days relative to control",Other,490536.0,
1387,1130430,1,1,,103477782,30323,Active,,,0.33,ED50,Inhibition of RNA synthesis in mouse L1210 cells,Confirmatory,490536.0,
1388,1130441,1,1,,103477782,30323,Unspecified,,,,,"Antitumor activity against mouse P388 cells allografted in CDF/BDF mouse assessed as survival time at 8 mg/kg, ip administered as qd on day 5, 9, 13",Other,490536.0,
1389,1130449,1,1,,103477782,30323,Unspecified,,,,,Cardiotoxicity in rat assessed as minimum cumulative cardiotoxic dose by Zbinden test,Other,490536.0,
1390,1130450,1,1,,103477782,30323,Unspecified,,,,,Mutagenicity in Salmonella typhimurium TA98 assessed as number of revertants by Ames test in presence of microsomal activation,Other,490536.0,
1391,1130452,1,1,,103477782,30323,Unspecified,,,,,Toxicity in Salmonella typhimurium TA98 assessed as concentration required to cause mortality per plate,Other,490536.0,
1392,1130590,1,1,,103477782,30323,Unspecified,,,,,Antitumor activity against mouse P388 cells allografted in ip dosed mouse assessed as minimum effective dose administered as single dose,Other,490545.0,
1393,1130628,1,1,,103477782,30323,Unspecified,,,,,Toxicity in mouse P388 cells allografted ip dosed mouse assessed as maximum tolerated dose administered as single dose,Other,490545.0,
1394,1130630,1,1,,103477782,30323,Unspecified,,,,,Antitumor activity against mouse P388 cells allografted in ip dosed mouse assessed as dose providing 40% increase in life span administered as single dose,Other,490545.0,
1395,1130632,1,1,,103477782,30323,Unspecified,,,,,"Therapeutic index, ratio of MTD for mouse P388 cells allografted ip dosed mouse to MED for mouse P388 cells allografted in ip dosed mouse administered as single dose",Other,490545.0,
1396,1132426,1,2,,103477782,30323,Unspecified,,,,,Binding affinity to calf thymus DNA by spectral analysis,Other,628003.0,
1397,1132427,1,1,,103477782,30323,Unspecified,,,,,Inhibition of DNA synthesis in mouse L1210 cells compound preincubated for 3 hrs followed by [3H]thymidine addition measured after 1 hr by scintillation counting,Other,628003.0,
1398,1132428,1,1,,103477782,30323,Unspecified,,,,,Inhibition of RNA synthesis in mouse L1210 cells compound preincubated for 3 hrs followed by [3H]uridine addition measured after 1 hr by scintillation counting,Other,628003.0,
1399,1132429,1,1,,103477782,30323,Unspecified,,,,,"Antitumor activity against mouse P388 cells allografted in mouse assessed as increase in survival time at 1.56 mg/kg, ip qd administered starting from day 1 to day 9 post challenge relative to control",Other,628003.0,
1400,1132430,1,1,,103477782,30323,Unspecified,,,,,"Antitumor activity against mouse P388 cells allografted in mouse assessed as increase in survival time at 0.78 mg/kg, ip qd administered starting from day 1 to day 9 post challenge relative to control",Other,628003.0,
1401,1132431,1,1,,103477782,30323,Unspecified,,,,,"Antitumor activity against mouse P388 cells allografted in mouse assessed as increase in survival time at 0.39 mg/kg, ip qd administered starting from day 1 to day 9 post challenge relative to control",Other,628003.0,
1402,1132432,1,1,,103477782,30323,Unspecified,,,,,"Antitumor activity against mouse P388 cells allografted in mouse assessed as increase in survival time at 0.20 mg/kg, ip qd administered starting from day 1 to day 9 post challenge relative to control",Other,628003.0,
1403,1132443,1,1,,103477782,30323,Unspecified,,,,,"Antitumor activity against mouse P388 cells allografted in mouse assessed as increase in survival time at 16 mg/kg, ip qd administered starting on day 5,9 and 13 post challenge relative to control",Other,628003.0,
1404,1132444,1,1,,103477782,30323,Unspecified,,,,,"Antitumor activity against mouse P388 cells allografted in mouse assessed as increase in survival time at 8 mg/kg, ip qd administered starting on day 5,9 and 13 post challenge relative to control",Other,628003.0,
1405,1132445,1,1,,103477782,30323,Unspecified,,,,,"Antitumor activity against mouse P388 cells allografted in mouse assessed as increase in survival time at 4 mg/kg, ip qd administered starting on day 5,9 and 13 post challenge relative to control",Other,628003.0,
1406,1132906,1,2,,103477782,30323,Unspecified,,,,,Binding affinity to calf thymus DNA assessed as change in melting temperature at 5 uM by spectrophotometer analysis,Other,690999.0,
1407,1132908,1,1,,103477782,30323,Active,,,0.48,ED50,Inhibition of DNA synthesis in mouse L1210 cells,Confirmatory,690999.0,
1408,1132909,1,1,,103477782,30323,Active,,,0.23,ED50,Inhibition of RNA synthesis in mouse L1210 cells,Confirmatory,690999.0,
1409,1132910,2,1,,103477782,30323,Unspecified,,,,,"Partition coefficient, log P of the compound",Other,690999.0,
1410,1132914,1,1,,103477782,30323,Unspecified,,,,,"In vivo antitumor activity against mouse P388 cells allografted in BDF/CDF mouse assessed as host survival time at 4 mg/kg, ip administered on days 1 to 9 relative to control",Other,690999.0,
1411,1132915,1,1,,103477782,30323,Unspecified,,,,,"In vivo antitumor activity against mouse P388 cells allografted in BDF/CDF mouse assessed as host survival time at 2 mg/kg, ip administered on days 1 to 9 relative to control",Other,690999.0,
1412,1132916,1,1,,103477782,30323,Unspecified,,,,,"In vivo antitumor activity against mouse P388 cells allografted in BDF/CDF mouse assessed as host survival time at 1 mg/kg, ip administered on days 1 to 9 relative to control",Other,690999.0,
1413,1132917,1,1,,103477782,30323,Unspecified,,,,,"In vivo antitumor activity against mouse P388 cells allografted in BDF/CDF mouse assessed as host survival time at 0.5 mg/kg, ip administered on days 1 to 9 relative to control",Other,690999.0,
1414,1132918,1,1,,103477782,30323,Unspecified,,,,,"In vivo antitumor activity against mouse P388 cells allografted in BDF/CDF mouse assessed as host survival time at 0.25 mg/kg, ip administered on days 1 to 9 relative to control",Other,690999.0,
1415,1132920,1,1,,103477782,30323,Unspecified,,,,,Cardiotoxicity in rat EEG model,Other,690999.0,
1416,1132921,1,1,,103477782,30323,Unspecified,,,,,Cardiotoxicity in rat EEG model relative to adriamycin,Other,690999.0,
1417,1145422,1,1,,103477782,30323,Unspecified,,,,,Inhibition of DNA synthesis in mouse L1210 cells assessed as inhibition of [3H]-thymidine incorporation measured per 10'6 cells at 1 uM pretreated for 1 hr followed by radiotracer addition measured after 1 hr by scintillation spectrometric analysis relative to control,Other,1271407.0,
1418,1145423,1,1,,103477782,30323,Unspecified,,,,,Inhibition of DNA synthesis in mouse L1210 cells assessed as inhibition of [3H]-thymidine incorporation measured per 10'6 cells at 3 uM pretreated for 1 hr followed by radiotracer addition measured after 1 hr by scintillation spectrometric analysis relative to control,Other,1271407.0,
1419,1145424,1,1,,103477782,30323,Unspecified,,,,,Inhibition of DNA synthesis in mouse L1210 cells assessed as inhibition of [3H]-thymidine incorporation measured per 10'6 cells at 5 uM pretreated for 1 hr followed by radiotracer addition measured after 1 hr by scintillation spectrometric analysis relative to control,Other,1271407.0,
1420,1145425,1,1,,103477782,30323,Unspecified,,,,,Inhibition of RNA synthesis in mouse L1210 cells assessed as inhibition of [14C]-uridine incorporation measured per 10'6 cells at 1 uM pretreated for 1 hr followed by radiotracer addition measured after 1 hr by scintillation spectrometric analysis relative to control,Other,1271407.0,
1421,1145426,1,1,,103477782,30323,Unspecified,,,,,Inhibition of RNA synthesis in mouse L1210 cells assessed as inhibition of [14C]-uridine incorporation measured per 10'6 cells at 3 uM pretreated for 1 hr followed by radiotracer addition measured after 1 hr by scintillation spectrometric analysis relative to control,Other,1271407.0,
1422,1145427,1,1,,103477782,30323,Unspecified,,,,,Inhibition of RNA synthesis in mouse L1210 cells assessed as inhibition of [14C]-uridine incorporation measured per 10'6 cells at 5 uM pretreated for 1 hr followed by radiotracer addition measured after 1 hr by scintillation spectrometric analysis relative to control,Other,1271407.0,
1423,1145428,1,1,,103477782,30323,Unspecified,,,,,Cellular uptake in mouse L1210 cells assessed per 10'6 cells at 3 uM up to 120 mins,Other,1271407.0,
1424,1145429,1,1,,103477782,30323,Unspecified,,,,,Ratio of inhibition of [3H]-thymidine incorporation into DNA in mouse L1210 cells to cellular uptake in mouse L1210 cells,Other,1271407.0,
1425,1145430,1,1,,103477782,30323,Unspecified,,,,,Ratio of inhibition of [14C]-uridine incorporation into RNA in mouse L1210 cells to cellular uptake in mouse L1210 cells,Other,1271407.0,
1426,1145593,1,1,,103477782,30323,Unspecified,,,,,Cytotoxicity against human HeLa cells assessed as cloning efficiency after 8 hrs,Other,1271420.0,
1427,1145594,1,1,,103477782,30323,Unspecified,,,,,Antiproliferative activity against MEF after 72 hrs,Other,1271420.0,
1428,1145595,1,1,,103477782,30323,Unspecified,,,,,Inhibition of Murine sarcoma virus (Moloney) foci formation in MEF after 72 hrs,Other,1271420.0,
1429,1145597,1,1,,103477782,30323,Unspecified,,,,,"Antitumor activity against mouse Sarcoma 180 cells allografted in mouse assessed as average survival time at 2 mg/kg, ip on day 1 post challenge relative to untreated control",Other,1271420.0,
1430,1145734,1,2,,103477782,30323,Unspecified,,,,,Binding affinity to calf thymus DNA assessed as increase in melting temperature at 2 x 10'-5 M by UV spectrophotometric analysis,Other,176359.0,
1431,1145737,1,1,,103477782,30323,Active,,,0.3,ED50,Inhibition of DNA synthesis in mouse L1210 cells preincubated for 3 hrs followed by [3H]-thymidine addition measured after 1 hr by scintillation spectrometric analysis,Confirmatory,176359.0,
1432,1145738,1,1,,103477782,30323,Active,,,0.3,ED50,Inhibition of RNA synthesis in mouse L1210 cells preincubated for 3 hrs followed by [3H]-uridine addition measured after 1 hr by scintillation spectrometric analysis,Confirmatory,176359.0,
1433,1145741,1,1,,103477782,30323,Unspecified,,,,,"Antitumor activity against mouse P388 cells allografted in mouse assessed as change in survival time at 4 mg/kg, ip qd administered for 9 days relative to control",Other,176359.0,
1434,1145742,1,1,,103477782,30323,Unspecified,,,,,"Antitumor activity against mouse P388 cells allografted in mouse assessed as increase in survival time at 2 mg/kg, ip qd administered for 9 days relative to control",Other,176359.0,
1435,1145743,1,1,,103477782,30323,Unspecified,,,,,"Antitumor activity against mouse P388 cells allografted in mouse assessed as increase in survival time at 1 mg/kg, ip qd administered for 9 days relative to control",Other,176359.0,
1436,1145744,1,1,,103477782,30323,Unspecified,,,,,"Antitumor activity against mouse P388 cells allografted in mouse assessed as increase in survival time at 0.5 mg/kg, ip qd administered for 9 days relative to control",Other,176359.0,
1437,1145745,1,1,,103477782,30323,Unspecified,,,,,"Antitumor activity against mouse P388 cells allografted in mouse assessed as increase in survival time at 0.25 mg/kg, ip qd administered for 9 days relative to control",Other,176359.0,
1438,1145746,1,1,,103477782,30323,Unspecified,,,,,"Antitumor activity against mouse P388 cells allografted in mouse assessed as increase in survival time at 0.12 mg/kg, ip qd administered for 9 days relative to control",Other,176359.0,
1439,1145747,1,1,,103477782,30323,Unspecified,,,,,"Antitumor activity against mouse P388 cells allografted in mouse assessed as increase in survival time at 0.06 mg/kg, ip qd administered for 9 days relative to control",Other,176359.0,
1440,1145755,1,1,,103477782,30323,Unspecified,,,,,"Acute toxicity in mouse allografted with mouse P388 cells assessed as survival less than 5 days at 0.06 to 4 mg/kg, ip qd",Other,176359.0,
1441,1145758,1,2,,103477782,30323,Active,,,,,Binding affinity to calf thymus DNA assessed as bathochromatic shift at 1:1 to 16:1 compound to DNA ratio by UV-visible spectra analysis,Other,176359.0,
1442,1145760,1,2,,103477782,30323,Active,,,,,Binding affinity to calf thymus DNA assessed as decrease in absorptivity of visible maxima of compound at 1:1 to 16:1 compound to DNA ratio by UV-visible spectra analysis,Other,176359.0,
1443,1146806,1,1,,103477782,30323,Active,,,,,Induction of Escherichia coli omega enzyme-mediated relaxation of Escherichia coli (RR1) pBR313 closed circular DNA at 40 X 10'-12 mol preincubated for 10 mins followed by enzyme-addition measured after 30 mins by agarose gel electrophoretic analysis,Other,330857.0,
1444,1150091,1,1,,103477782,30323,Active,,,,,Inhibition of Escherichia coli RNA polymerase assessed as reduction in RNA transcription at compound/DNA molar ratio of 1,Other,926111.0,
1445,1159509,1,1,,170465048,30323,Inconclusive,119626539.0,4790.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the NFkB signaling pathway,Confirmatory,,
1446,1159515,1,1,,170465048,30323,Inconclusive,,,3.7902,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the NFkB signaling pathway - cell viability counter screen,Confirmatory,,
1447,1159516,1,1,,170465048,30323,Inconclusive,119611100.0,22926.0,1.8996,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway,Confirmatory,,
1448,1159517,1,1,,170465048,30323,Active,,,0.9521,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway - cell viability counter screen,Confirmatory,,
1449,1159518,1,1,,170465048,30323,Inactive,119626539.0,4790.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the NFkB signaling pathway: Summary,Summary,,
1450,1159519,1,1,,170465048,30323,Inconclusive,119611100.0,22926.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway: Summary,Summary,,
1451,1159520,1,1,,170465048,30323,Active,,,14.9601,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway - cell viability counter screen,Confirmatory,,
1452,1159521,1,1,,170465048,30323,Inactive,15928672.0,19885.0,10.5909,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway,Confirmatory,,
1453,1159523,1,1,,170465048,30323,Inconclusive,15928672.0,19885.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway: Summary,Summary,,
1454,1159524,1,1,,11114094,30323,Inactive,,,,Potency,High Throughput Screening for Foot and Mouth Disease Virus Antivirals,Confirmatory,,
1455,1159525,1,1,,170465048,30323,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the AP-1 signaling pathway - cell viability counter screen,Confirmatory,,
1456,1159526,1,1,,170465048,30323,Inconclusive,119627033.0,3725.0,0.0107,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the AP-1 signaling pathway,Confirmatory,,
1457,1159527,1,1,,170465048,30323,Inconclusive,325495497.0,6256.0,1.693,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the RXR signaling pathway,Confirmatory,,
1458,1159528,1,1,,170465048,30323,Inconclusive,119627033.0,3725.0,0.010682200000000001,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the AP-1 signaling pathway: Summary,Summary,,
1459,1159529,1,1,,170465048,30323,Inconclusive,,,26.8325,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the RXR signaling pathway - cell viability counter screen,Confirmatory,,
1460,1159531,1,1,,170465048,30323,Inconclusive,325495497.0,6256.0,1.69301,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the RXR signaling pathway: Summary,Summary,,
1461,1159551,1,1,,170465048,30323,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid acid receptor (RAR) signaling pathway - cell viability counter screen,Confirmatory,,
1462,1159552,1,1,,170465048,30323,Active,325495463.0,5914.0,0.0335,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoic acid receptor (RAR) signaling pathway,Confirmatory,,
1463,1159553,2,1,,170465048,30323,Inconclusive,325495463.0,5914.0,1.6785,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the retinoic acid receptor (RAR) signaling pathway,Confirmatory,,
1464,1159555,1,1,,170465048,30323,Active,325495463.0,5914.0,0.334915,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the retinoic acid receptor (RAR) signaling pathway: Summary,Summary,,
1465,1159580,2,1,,268734457,30323,Inactive,,,,,"The chemical genetic matrix (CGM) dataset as reported in Wildenhain et al. (2015) Prediction of Synergism from Chemical-Genetic Interactions by Machine Learning. Cell Systems Volume 1, Issue 6, p383-395",Summary,,
1466,1159607,2,1,,312596602,30323,Inactive,,,,,Screen for inhibitors of RMI FANCM (MM2) intereaction,Other,26962873.0,
1467,1159614,1,2,,170465048,30323,Inactive,22328079.0,2581.0,,Potency,A Novel Cell-Based Assay to Identify Small Molecules for B -Galactocerebrosidase,Confirmatory,,
1468,1175395,1,1,,103477782,30323,Active,,,0.096,IC50,Antiproliferative activity against human H1299 cells by XTT assay,Confirmatory,25467291.0,
1469,1175396,1,1,,103477782,30323,Active,,,0.08,IC50,Antiproliferative activity against human A549 cells by XTT assay,Confirmatory,25467291.0,
1470,1175397,1,1,,103477782,30323,Active,,,0.65,IC50,Antiproliferative activity against human MCF7 cells by XTT assay,Confirmatory,25467291.0,
1471,1175398,1,1,,103477782,30323,Active,,,0.091,IC50,Antiproliferative activity against human MDA-MB-231 cells by XTT assay,Confirmatory,25467291.0,
1472,1175399,1,1,,103477782,30323,Active,,,0.078,IC50,Antiproliferative activity against human MRC5 cells by XTT assay,Confirmatory,25467291.0,
1473,1179426,1,1,,103477782,30323,Unspecified,,,,,Genotoxicity in Salmonella typhimurium TA102 at 3 ug/plate assessed as number of revertants per plate (Rvb = 301 +/- 5.2 no unit),Other,24907144.0,
1474,1201522,1,1,,103477782,30323,Active,,,,,Genotoxicity in DNA (unknown origin) incubated for 24 hrs in dark condition by methyl green displacement assay,Other,25791675.0,
1475,1202305,1,1,,103477782,30323,Active,,,0.1,GI50,Cytotoxicity against human HL60 cells assessed as growth inhibition after 48 hrs by trypan blue staining-based hemocytometric analysis,Confirmatory,25874335.0,
1476,1202306,1,1,,103477782,30323,Inconclusive,,,,AC50,Induction of apoptosis in human HL60 cells after 48 hrs by acridine orange/ethidium bromide staining-based fluorescence microscopic analysis,Confirmatory,25874335.0,
1477,1202307,1,1,,103477782,30323,Active,,,38.0,GI50,Cytotoxicity against human HL60R cells expressing p-glycoprotein assessed as growth inhibition after 48 hrs by trypan blue staining-based hemocytometric analysis,Confirmatory,25874335.0,
1478,1202308,1,1,,103477782,30323,Inconclusive,,,,AC50,Induction of apoptosis in human HL60R cells expressing p-glycoprotein after 48 hrs by acridine orange/ethidium bromide staining-based fluorescence microscopic analysis,Confirmatory,25874335.0,
1479,1202309,1,1,,103477782,30323,Inconclusive,,,,GI50,Cytotoxicity against human K562 cells expressing Bcr-Abl assessed as growth inhibition after 48 hrs by trypan blue staining-based hemocytometric analysis,Confirmatory,25874335.0,
1480,1202310,1,1,,103477782,30323,Inconclusive,,,,AC50,Induction of apoptosis in human K562 cells expressing Bcr-Abl after 48 hrs by acridine orange/ethidium bromide staining-based fluorescence microscopic analysis,Confirmatory,25874335.0,
1481,1202311,1,1,,103477782,30323,Inconclusive,,,,GI50,Cytotoxicity against human HepG2 cells assessed as growth inhibition after 48 hrs by trypan blue staining-based hemocytometric analysis,Confirmatory,25874335.0,
1482,1202312,1,1,,103477782,30323,Inconclusive,,,,AC50,Induction of apoptosis in human HepG2 cells after 48 hrs by acridine orange/ethidium bromide staining-based fluorescence microscopic analysis,Confirmatory,25874335.0,
1483,1207795,1,1,,103477782,30323,Unspecified,,,,,Terminal half-life of daunorubicin following intravenous daunorubicin at 1.2 mg.Kg-1 dose in dog,Other,,
1484,1207797,1,1,,103477782,30323,Unspecified,,,,,Terminal half-life ratio of 13-dihydrometabolite of daunorubicin to daunorubicin following intravenous daunorubicin at 1.2 mg.Kg-1 dose in dog,Other,,
1485,1207806,1,1,,103477782,30323,Unspecified,,,,,Volume of distribution of daunorubicin following intravenous daunorubicin at 1.2 mg.Kg-1 dose in dog,Other,,
1486,1207815,1,1,,103477782,30323,Unspecified,,,,,Plasma clearance of daunorubicin following intravenous daunorubicin at 1.2 mg.Kg-1 dose in dog,Other,,
1487,1207817,1,1,,103477782,30323,Unspecified,,,,,Plasma clearance ratio of 13-dihydrometabolite of daunorubicin to daunorubicin following intravenous daunorubicin at 1.2 mg.Kg-1 dose in dog,Other,,
1488,1207828,1,1,,103477782,30323,Unspecified,,,,,AUC of daunorubicin following intravenous daunorubicin at 1.2 mg.Kg-1 dose in dog,Other,,
1489,1221956,1,1,,103477782,30323,Unspecified,,,,,Apparent permeability from apical to basolateral side of human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis,Other,21051535.0,
1490,1221957,1,1,,103477782,30323,Unspecified,,,,,Apparent permeability from basolateral to apical side of human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis,Other,21051535.0,
1491,1221958,1,1,,103477782,30323,Unspecified,,,,,Efflux ratio of permeability from apical to basolateral side over basolateral to apical side of human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis,Other,21051535.0,
1492,1221960,1,1,,103477782,30323,Unspecified,,,,,Apparent permeability from apical to basolateral side of human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 1 uM of P-gp inhibitor LY335979,Other,21051535.0,
1493,1221961,1,1,,103477782,30323,Unspecified,,,,,Apparent permeability from basolateral to apical side of human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 1 uM of P-gp inhibitor LY335979,Other,21051535.0,
1494,1221962,1,1,,103477782,30323,Unspecified,,,,,Efflux ratio of permeability from apical to basolateral side over basolateral to apical side of human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 1 uM of P-gp inhibitor LY335979,Other,21051535.0,
1495,1221963,1,1,,103477782,30323,Unspecified,,,,,Transporter substrate index ratio of permeability from apical to basolateral side in human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 1 uM of P-gp inhibitor LY335979,Other,21051535.0,
1496,1221964,1,1,,103477782,30323,Unspecified,,,,,Transporter substrate index ratio of permeability from basolateral to apical side in human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 1 uM of P-gp inhibitor LY335979,Other,21051535.0,
1497,1221965,1,1,,103477782,30323,Unspecified,,,,,Transporter substrate index of efflux ratio in human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 1 uM of P-gp inhibitor LY335979,Other,21051535.0,
1498,1221967,1,1,,103477782,30323,Unspecified,,,,,Ratio of intestine AUC in po dosed mdr1 knock out mouse to intestine AUC in po dosed wild type mouse,Other,21051535.0,
1499,1221968,1,1,,103477782,30323,Unspecified,,,,,Apparent permeability from apical to basolateral side of human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 1 uM of BCRP inhibitor Ko143,Other,21051535.0,
1500,1221969,1,1,,103477782,30323,Unspecified,,,,,Apparent permeability from basolateral to apical side of human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 1 uM of BCRP inhibitor Ko143,Other,21051535.0,
1501,1221970,1,1,,103477782,30323,Unspecified,,,,,Efflux ratio of permeability from apical to basolateral side over basolateral to apical side of human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 1 uM of BCRP inhibitor Ko143,Other,21051535.0,
1502,1221971,1,1,,103477782,30323,Unspecified,,,,,Apparent permeability from apical to basolateral side of human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 10 uM of MRP2 inhibitor MK571,Other,21051535.0,
1503,1221972,1,1,,103477782,30323,Unspecified,,,,,Apparent permeability from basolateral to apical side of human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 10 uM of MRP2 inhibitor MK571,Other,21051535.0,
1504,1221973,1,1,,103477782,30323,Unspecified,,,,,Efflux ratio of permeability from apical to basolateral side over basolateral to apical side of human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 10 uM of MRP2 inhibitor MK571,Other,21051535.0,
1505,1221975,1,1,,103477782,30323,Unspecified,,,,,Transporter substrate index ratio of permeability from apical to basolateral side in human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 1 uM of BCRP inhibitor Ko143,Other,21051535.0,
1506,1221976,1,1,,103477782,30323,Unspecified,,,,,Transporter substrate index ratio of permeability from basolateral to apical side in human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 1 uM of BCRP inhibitor Ko143,Other,21051535.0,
1507,1221977,1,1,,103477782,30323,Unspecified,,,,,Transporter substrate index of efflux ratio in human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 1 uM of BCRP inhibitor Ko143,Other,21051535.0,
1508,1221978,1,1,,103477782,30323,Unspecified,,,,,Transporter substrate index ratio of permeability from apical to basolateral side in human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 10 uM of MRP2 inhibitor MK571,Other,21051535.0,
1509,1221979,1,1,,103477782,30323,Unspecified,,,,,Transporter substrate index ratio of permeability from basolateral to apical side in human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 10 uM of MRP2 inhibitor MK571,Other,21051535.0,
1510,1221980,1,1,,103477782,30323,Unspecified,,,,,Transporter substrate index of efflux ratio in human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 10 uM of MRP2 inhibitor MK571,Other,21051535.0,
1511,1221982,1,1,,103477782,30323,Unspecified,,,,,Fraction absorbed in human,Other,21051535.0,
1512,1224834,3,1,,170465048,30323,Active,,,0.4731,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library - cell viability counter screen,Confirmatory,,
1513,1224835,1,1,,170465048,30323,Inactive,160794.0,,,Potency-Replicate_1,qHTS assay to identify small molecule inhibitors of firefly luciferase,Confirmatory,,
1514,1224836,1,1,,170465048,30323,Active,,,1.1883,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway - cell viability counter screen,Confirmatory,,
1515,1224837,1,1,,170465048,30323,Active,,,0.2113,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway - cell viability counter screen,Confirmatory,,
1516,1224838,1,1,,170465048,30323,Active,66775687.0,9970.0,0.0168,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway,Confirmatory,,
1517,1224839,1,1,,170465048,30323,Inactive,66775687.0,9970.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway,Confirmatory,,
1518,1224840,3,1,,170465048,30323,Inconclusive,,,1.8834,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library - cell viability counter screen,Confirmatory,,
1519,1224841,3,1,,170465048,30323,Inactive,325495545.0,2101.0,0.0841,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library,Confirmatory,,
1520,1224842,3,1,,170465048,30323,Inconclusive,325495545.0,2101.0,0.075,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library,Confirmatory,,
1521,1224843,1,1,,170465048,30323,Inactive,119601739.0,7253.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway,Confirmatory,,
1522,1224844,1,1,,170465048,30323,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway - cell viability counter screen,Confirmatory,,
1523,1224845,1,1,,170465048,30323,Active,344243002.0,100757539.0,0.0391,Potency-Replicate_1,qHTS assay to identify small molecule agonists of H2AX,Confirmatory,,
1524,1224846,1,1,,170465048,30323,Inconclusive,11995455.0,3091.0,3.378,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway,Confirmatory,,
1525,1224847,1,1,,170465048,30323,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of H2AX - cell viability counter screen,Confirmatory,,
1526,1224848,3,1,,170465048,30323,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library,Confirmatory,,
1527,1224849,3,1,,170465048,30323,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library,Confirmatory,,
1528,1224857,2,1,,170465048,30323,Inactive,,,11.2202,Potency,qHTS assay for measurement of the activity of small molecule inhibitors on Zika virus induced Caspase-3 activity in human iPSC derived neural progenitor cells (hNPCs),Confirmatory,,
1529,1224859,2,1,,170465048,30323,Inactive,,,,Potency,qHTS assay for measurement of the activity of small molecule inhibitors on Zika virus induced Caspase-3 activity in human astrocytoma cells,Confirmatory,,
1530,1224863,1,1,,176484195,30323,Inactive,90421313.0,1080.0,,IC50,Phenotypic Assay to Identify Small Molecules that Upregulate Production of hCFTR in HeLa Cells,Confirmatory,,
1531,1224863,1,1,,316920218,30323,Inactive,90421313.0,1080.0,,IC50,Phenotypic Assay to Identify Small Molecules that Upregulate Production of hCFTR in HeLa Cells,Confirmatory,,
1532,1224867,1,1,,170465048,30323,Inconclusive,,,0.0601,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 24 hour,Confirmatory,,
1533,1224868,1,1,,170465048,30323,Active,,,0.0034,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 32 hour,Confirmatory,,
1534,1224869,1,1,,170465048,30323,Inconclusive,,,26.8325,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 0 hour,Confirmatory,,
1535,1224870,1,1,,170465048,30323,Inconclusive,,,0.0601,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 40 hour,Confirmatory,,
1536,1224871,1,1,,170465048,30323,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 40 hour,Confirmatory,,
1537,1224872,1,1,,170465048,30323,Active,,,0.1509,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 16 hour,Confirmatory,,
1538,1224873,1,1,,170465048,30323,Inconclusive,,,21.3138,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 8 hour,Confirmatory,,
1539,1224874,1,1,,170465048,30323,Active,,,0.003,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 40 hour,Confirmatory,,
1540,1224875,1,1,,170465048,30323,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 24 hour,Confirmatory,,
1541,1224876,1,1,,170465048,30323,Inconclusive,,,26.8325,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 16 hour,Confirmatory,,
1542,1224877,1,1,,170465048,30323,Inconclusive,,,0.0601,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 32 hour,Confirmatory,,
1543,1224878,1,1,,170465048,30323,Inconclusive,,,26.8325,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 24 hour,Confirmatory,,
1544,1224879,1,1,,170465048,30323,Inconclusive,,,0.0239,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 40 hour,Confirmatory,,
1545,1224880,1,1,,170465048,30323,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 0 hour,Confirmatory,,
1546,1224881,1,1,,170465048,30323,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 32 hour,Confirmatory,,
1547,1224882,1,1,,170465048,30323,Inconclusive,,,26.8325,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 0 hour,Confirmatory,,
1548,1224883,1,1,,170465048,30323,Active,,,0.0301,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 32 hour,Confirmatory,,
1549,1224884,1,1,,170465048,30323,Inconclusive,,,26.8325,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 8 hour,Confirmatory,,
1550,1224885,1,1,,170465048,30323,Active,,,23.9145,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 16 hour,Confirmatory,,
1551,1224886,1,1,,170465048,30323,Active,,,0.0048,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 24 hour,Confirmatory,,
1552,1224887,1,1,,170465048,30323,Active,,,21.3138,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 8 hour,Confirmatory,,
1553,1224888,1,1,,170465048,30323,Inconclusive,,,26.8325,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 16 hour,Confirmatory,,
1554,1224889,1,1,,170465048,30323,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 0 hour,Confirmatory,,
1555,1224890,1,1,,170465048,30323,Inconclusive,,,26.8325,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 8 hour,Confirmatory,,
1556,1224892,1,1,,170465048,30323,Inconclusive,66775687.0,9970.0,,,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway: Summary,Summary,,
1557,1224893,1,1,,170465048,30323,Inconclusive,66775687.0,9970.0,0.10590899999999999,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway: Summary,Summary,,
1558,1224894,1,1,,170465048,30323,Inconclusive,11995455.0,3091.0,4.77156,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway: Summary,Summary,,
1559,1224895,1,1,,170465048,30323,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway: Summary,Summary,,
1560,1224896,1,1,,170465048,30323,Active,344243002.0,100757539.0,0.266223,Ratio Potency (uM),qHTS assay to identify small molecule agonists of H2AX: Summary,Summary,,
1561,1224905,2,1,,92308820,30323,Active,120997.0,25643.0,,,High-throughput screen for inhibitors of the GIV GBA-motif interaction with Galpha-i G protein subunits,Screening,,
1562,1224905,2,1,,92308820,30323,Active,74356043.0,55704.0,,,High-throughput screen for inhibitors of the GIV GBA-motif interaction with Galpha-i G protein subunits,Screening,,
1563,1259241,1,1,,170465048,30323,Active,,,13.3332,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol - cell viability counter screen,Confirmatory,,
1564,1259242,1,1,,170465048,30323,Inconclusive,,,13.3332,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881 - cell viability counter screen,Confirmatory,,
1565,1259243,1,1,,170465048,30323,Active,124375976.0,367.0,0.0266,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881,Confirmatory,,
1566,1259244,1,1,,170465048,30323,Inactive,348019627.0,2099.0,0.0237,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol,Confirmatory,,
1567,1259247,1,1,,170465048,30323,Active,124375976.0,367.0,0.181246,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881: Summary,Summary,,
1568,1259248,1,1,,170465048,30323,Inconclusive,348019627.0,2099.0,0.181246,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol: Summary,Summary,,
1569,1259310,1,1,,332876841,30323,Inactive,,,,,AlphaScreen-based biochemical high throughput primary assay to identify activators of the E3 ligase (FBW7).,Screening,,
1570,1259310,1,1,,333494062,30323,Inactive,,,,,AlphaScreen-based biochemical high throughput primary assay to identify activators of the E3 ligase (FBW7).,Screening,,
1571,1259310,1,1,,333494070,30323,Inactive,,,,,AlphaScreen-based biochemical high throughput primary assay to identify activators of the E3 ligase (FBW7).,Screening,,
1572,1259344,1,1,,144204447,30323,Inactive,,,,Potency,qHTS assay to identify small molecule phospholipidosis (PLD) inducers,Confirmatory,,
1573,1259355,1,1,,144204447,30323,Active,,,1.7783,Potency,qHTS assay to identify small molecule inhibitors of chordoma cells - UCH-1,Confirmatory,,
1574,1259356,1,1,,144204447,30323,Inconclusive,,,1.1577,Potency,qHTS assay to identify small molecule inhibitors of chordoma cells - UCH-2,Confirmatory,,
1575,1259364,1,1,,170465048,30323,Inactive,1013403374.0,9734.0,,Potency-Replicate_1,qHTS assay to identify small molecule HDAC inhibitors,Confirmatory,,
1576,1259365,1,1,,170465048,30323,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule HDAC inhibitors - cell viability counter screen,Confirmatory,,
1577,1259366,1,1,,170465048,30323,Active,,,2.1132,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway - cell viability counter screen,Confirmatory,,
1578,1259367,1,1,,170465048,30323,Active,,,1.8834,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway - cell viability counter screen,Confirmatory,,
1579,1259368,1,1,,170465048,30323,Inactive,109731339.0,2737.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway,Confirmatory,,
1580,1259369,1,1,,170465048,30323,Inconclusive,109731339.0,2737.0,0.0106,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway,Confirmatory,,
1581,1259377,1,1,,170465048,30323,Inconclusive,54288833.0,2100.0,0.9439,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway,Confirmatory,,
1582,1259378,1,1,,170465048,30323,Active,54288833.0,2100.0,4.2163,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway,Confirmatory,,
1583,1259379,1,1,,170465048,30323,Active,,,11.8832,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist - cell viability counter screen,Confirmatory,,
1584,1259380,1,1,,170465048,30323,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway - cell viability counter screen,Confirmatory,,
1585,1259381,1,1,,170465048,30323,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist,Confirmatory,,
1586,1259382,1,1,,170465048,30323,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway - cell viability counter screen,Confirmatory,,
1587,1259383,1,1,,170465048,30323,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist,Confirmatory,,
1588,1259384,1,1,,170465048,30323,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists or antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway - wild type cell line counter screen,Confirmatory,,
1589,1259385,1,1,,170465048,30323,Inconclusive,119601739.0,7253.0,29.8493,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway,Confirmatory,,
1590,1259386,1,1,,170465048,30323,Active,,,21.1317,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist - cell viability counter screen,Confirmatory,,
1591,1259387,1,1,,170465048,30323,Inactive,124375976.0,367.0,,,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist: Summary,Summary,,
1592,1259388,1,1,,170465048,30323,Inactive,1013403374.0,9734.0,,Antagonist Potency (uM),qHTS assay to identify small molecule HDAC inhibitors: Summary,Summary,,
1593,1259390,1,1,,170465048,30323,Inconclusive,109731339.0,2737.0,,,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway: Summary,Summary,,
1594,1259391,1,1,,170465048,30323,Inactive,348019627.0,2099.0,,,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist: Summary,Summary,,
1595,1259392,1,1,,170465048,30323,Active,109731339.0,2737.0,0.0473079,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway: Summary,Summary,,
1596,1259393,1,1,,170465048,30323,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists or antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway - wild type cell line counter screen: Summary,Summary,,
1597,1259394,1,1,,170465048,30323,Active,54288833.0,2100.0,0.841267,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway: Summary,Summary,,
1598,1259395,1,1,,170465048,30323,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway: Summary,Summary,,
1599,1259396,1,1,,170465048,30323,Inconclusive,54288833.0,2100.0,,,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway: Summary,Summary,,
1600,1259400,1,1,,170465048,30323,Inactive,166209887.0,59350.0,,,qHTS Assay for Antagonists of the Relaxin Receptor RXFP1,Screening,,
1601,1259401,1,1,,170465048,30323,Inconclusive,325495545.0,2101.0,0.10590899999999999,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library: Summary,Summary,,
1602,1259402,1,1,,170465048,30323,Active,325495545.0,2101.0,,,qHTS assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library: Summary,Summary,,
1603,1259403,1,1,,170465048,30323,Inactive,325495545.0,2101.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library: Summary,Summary,,
1604,1259404,1,1,,170465048,30323,Inactive,325495545.0,2101.0,,,qHTS assay to identify small molecule agonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library: Summary,Summary,,
1605,1259407,1,1,,363898864,30323,Active,,,,,CCRIS mutagenicity studies,Other,,
1606,1259408,1,1,,363897014,30323,Active,,,,,GENE-TOX mutagenicity studies,Other,,
1607,1259411,1,1,,363898864,30323,Active,,,,,CCRIS carcinogenicity studies,Other,,
1608,1259416,1,2,,340081189,30323,Inactive,56786138.0,3458.0,,,Toxoplasma gondii inhibition HTS in the presence of IFN-y,Screening,,
1609,1259416,1,2,,375174646,30323,Inactive,56786138.0,3458.0,,,Toxoplasma gondii inhibition HTS in the presence of IFN-y,Screening,,
1610,1259416,1,2,,375192654,30323,Active,56786138.0,3458.0,,,Toxoplasma gondii inhibition HTS in the presence of IFN-y,Screening,,
1611,1259421,1,1,,340081189,30323,Inactive,56786138.0,3458.0,,,Toxoplasma gondii HTS in the absence of IFN-y,Screening,,
1612,1259421,1,1,,375174646,30323,Inactive,56786138.0,3458.0,,,Toxoplasma gondii HTS in the absence of IFN-y,Screening,,
1613,1259421,1,1,,375192654,30323,Active,56786138.0,3458.0,,,Toxoplasma gondii HTS in the absence of IFN-y,Screening,,
1614,1259423,1,2,,354909962,30323,Inactive,,,,,Primary cell-based high-throughput screening assay for identification of small molecule agonists of Aedes aegypti NPYLR7 [Small Molecule Inhibitors of Mosquito Biting Behavior],Screening,,
1615,1259423,1,2,,354933147,30323,Inactive,,,,,Primary cell-based high-throughput screening assay for identification of small molecule agonists of Aedes aegypti NPYLR7 [Small Molecule Inhibitors of Mosquito Biting Behavior],Screening,,
